A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
A form of undifferentiated malignant LYMPHOMA usually found in central Africa, but also reported in other parts of the world. It is commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. B-cell antigens are expressed on the immature cells that make up the tumor in virtually all cases of Burkitt lymphoma. The Epstein-Barr virus (HERPESVIRUS 4, HUMAN) has been isolated from Burkitt lymphoma cases in Africa and it is implicated as the causative agent in these cases; however, most non-African cases are EBV-negative.
Lymphoid cells concerned with humoral immunity. They are short-lived cells resembling bursa-derived lymphocytes of birds in their production of immunoglobulin upon appropriate stimulation.
A general term for various neoplastic diseases of the lymphoid tissue.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.
Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.
Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.
Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire mucosa-associated lymphoid tissue (MALT) type as a result of an immunologically mediated disorder.
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).
A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.
B-cell lymphoid tumors that occur in association with AIDS. Patients often present with an advanced stage of disease and highly malignant subtypes including BURKITT LYMPHOMA; IMMUNOBLASTIC LARGE-CELL LYMPHOMA; PRIMARY EFFUSION LYMPHOMA; and DIFFUSE, LARGE B-CELL, LYMPHOMA. The tumors are often disseminated in unusual extranodal sites and chromosomal abnormalities are frequently present. It is likely that polyclonal B-cell lymphoproliferation in AIDS is a complex result of EBV infection, HIV antigenic stimulation, and T-cell-dependent HIV activation.
A classification of B-lymphocytes based on structurally or functionally different populations of cells.
A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.
A systemic, large-cell, non-Hodgkin, malignant lymphoma characterized by cells with pleomorphic appearance and expressing the CD30 ANTIGEN. These so-called "hallmark" cells have lobulated and indented nuclei. This lymphoma is often mistaken for metastatic carcinoma and MALIGNANT HISTIOCYTOSIS.
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.
The activated center of a lymphoid follicle in secondary lymphoid tissue where B-LYMPHOCYTES are stimulated by antigens and helper T cells (T-LYMPHOCYTES, HELPER-INDUCER) are stimulated to generate memory cells.
Malignant lymphoma characterized by the presence of immunoblasts with uniformly round-to-oval nuclei, one or more prominent nucleoli, and abundant cytoplasm. This class may be subdivided into plasmacytoid and clear-cell types based on cytoplasmic characteristics. A third category, pleomorphous, may be analogous to some of the peripheral T-cell lymphomas (LYMPHOMA, T-CELL, PERIPHERAL) recorded in both the United States and Japan.
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
Antibodies obtained from a single clone of cells grown in mice or rats.
The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa.
A class of immunoglobulin bearing mu chains (IMMUNOGLOBULIN MU-CHAINS). IgM can fix COMPLEMENT. The name comes from its high molecular weight and originally being called a macroglobulin.
An encapsulated lymphatic organ through which venous blood filters.
Process of classifying cells of the immune system based on structural and functional differences. The process is commonly used to analyze and sort T-lymphocytes into subsets based on CD antigens by the technique of flow cytometry.
An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.)
The type species of LYMPHOCRYPTOVIRUS, subfamily GAMMAHERPESVIRINAE, infecting B-cells in humans. It is thought to be the causative agent of INFECTIOUS MONONUCLEOSIS and is strongly associated with oral hairy leukoplakia (LEUKOPLAKIA, HAIRY;), BURKITT LYMPHOMA; and other malignancies.
An immunoglobulin which accounts for less than 1% of plasma immunoglobulin. It is found on the membrane of many circulating B LYMPHOCYTES.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
Genes encoding the different subunits of the IMMUNOGLOBULINS, for example the IMMUNOGLOBULIN LIGHT CHAIN GENES and the IMMUNOGLOBULIN HEAVY CHAIN GENES. The heavy and light immunoglobulin genes are present as gene segments in the germline cells. The completed genes are created when the segments are shuffled and assembled (B-LYMPHOCYTE GENE REARRANGEMENT) during B-LYMPHOCYTE maturation. The gene segments of the human light and heavy chain germline genes are symbolized V (variable), J (joining) and C (constant). The heavy chain germline genes have an additional segment D (diversity).
Antibodies produced by a single clone of cells.
Ordered rearrangement of B-lymphocyte variable gene regions coding for the IMMUNOGLOBULIN CHAINS, thereby contributing to antibody diversity. It occurs during the differentiation of the IMMATURE B-LYMPHOCYTES.
A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
Glycoproteins expressed on all mature T-cells, thymocytes, and a subset of mature B-cells. Antibodies specific for CD5 can enhance T-cell receptor-mediated T-cell activation. The B-cell-specific molecule CD72 is a natural ligand for CD5. (From Abbas et al., Cellular and Molecular Immunology, 2d ed, p156)
A type of chromosome aberration characterized by CHROMOSOME BREAKAGE and transfer of the broken-off portion to another location, often to a different chromosome.
A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.
Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation.
They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.
Ordered rearrangement of B-lymphocyte variable gene regions of the IMMUNOGLOBULIN HEAVY CHAINS, thereby contributing to antibody diversity. It occurs during the first stage of differentiation of the IMMATURE B-LYMPHOCYTES.
Differentiation antigens expressed on B-lymphocytes and B-cell precursors. They are involved in regulation of B-cell proliferation.
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
An extranodal neoplasm, usually possessing an NK-cell phenotype and associated with EPSTEIN-BARR VIRUS. These lymphomas exhibit a broad morphologic spectrum, frequent necrosis, angioinvasion, and most commonly present in the midfacial region, but also in other extranodal sites.
That region of the immunoglobulin molecule that varies in its amino acid sequence and composition, and comprises the binding site for a specific antigen. It is located at the N-terminus of the Fab fragment of the immunoglobulin. It includes hypervariable regions (COMPLEMENTARITY DETERMINING REGIONS) and framework regions.
A lectin and cell adhesion molecule found in B-LYMPHOCYTES. It interacts with SIALIC ACIDS and mediates signaling from B-CELL ANTIGEN RECEPTORS.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
Multi-subunit proteins which function in IMMUNITY. They are produced by B LYMPHOCYTES from the IMMUNOGLOBULIN GENES. They are comprised of two heavy (IMMUNOGLOBULIN HEAVY CHAINS) and two light chains (IMMUNOGLOBULIN LIGHT CHAINS) with additional ancillary polypeptide chains depending on their isoforms. The variety of isoforms include monomeric or polymeric forms, and transmembrane forms (B-CELL ANTIGEN RECEPTORS) or secreted forms (ANTIBODIES). They are divided by the amino acid sequence of their heavy chains into five classes (IMMUNOGLOBULIN A; IMMUNOGLOBULIN D; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M) and various subclasses.
A DNA-binding protein that represses GENETIC TRANSCRIPTION of target genes by recruiting HISTONE DEACETYLASES. Aberrant Blc-6 expression is associated with certain types of human B-CELL LYMPHOMA.
A tumor necrosis factor superfamily member that plays a role in the regulation of B-LYMPHOCYTE survival. It occurs as a membrane-bound protein that is cleaved to release an biologically active soluble form with specificity to TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR PROTEIN; B-CELL ACTIVATION FACTOR RECEPTOR; and B-CELL MATURATION ANTIGEN.
A specific pair of GROUP D CHROMOSOMES of the human chromosome classification.
A member of the tumor necrosis factor receptor superfamily with specificity for CD40 LIGAND. It is found on mature B-LYMPHOCYTES and some EPITHELIAL CELLS, lymphoid DENDRITIC CELLS. Evidence suggests that CD40-dependent activation of B-cells is important for generation of memory B-cells within the germinal centers. Mutations of the gene for CD40 antigen result in HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 3. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.
The ordered rearrangement of gene regions by DNA recombination such as that which occurs normally during development.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.
T-cell enhancement of the B-cell response to thymic-dependent antigens.
A member of the tumor necrosis factor receptor superfamily that may play a role in the regulation of NF-KAPPA B and APOPTOSIS. They are found on activated T-LYMPHOCYTES; B-LYMPHOCYTES; NEUTROPHILS; EOSINOPHILS; MAST CELLS and NK CELLS. Overexpression of CD30 antigen in hematopoietic malignancies make the antigen clinically useful as a biological tumor marker. Signaling of the receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Lymphocyte progenitor cells that are restricted in their differentiation potential to the B lymphocyte lineage. The pro-B cell stage of B lymphocyte development precedes the pre-B cell stage.
Membrane antigens associated with maturation stages of B-lymphocytes, often expressed in tumors of B-cell origin.
A component of the B-cell antigen receptor that is involved in B-cell antigen receptor heavy chain transport to the PLASMA MEMBRANE. It is expressed almost exclusively in B-LYMPHOCYTES and serves as a useful marker for B-cell NEOPLASMS.
A specific pair of GROUP E CHROMOSOMES of the human chromosome classification.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
A malignant disease of the B-LYMPHOCYTES in the bone marrow and/or blood.
A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)
Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).
A member of the tumor necrosis factor receptor superfamily that specifically binds B-CELL ACTIVATING FACTOR. It is found on B-LYMPHOCYTES and plays a role in maturation and survival of B-cells. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
Specialized tissues that are components of the lymphatic system. They provide fixed locations within the body where a variety of LYMPHOCYTES can form, mature and multiply. The lymphoid tissues are connected by a network of LYMPHATIC VESSELS.
The altered state of immunologic responsiveness resulting from initial contact with antigen, which enables the individual to produce antibodies more rapidly and in greater quantity in response to secondary antigenic stimulus.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
Large cells, usually multinucleate, whose presence is a common histologic characteristic of classical HODGKIN DISEASE.
Established cell cultures that have the potential to propagate indefinitely.
The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.
The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.
Strains of mice in which certain GENES of their GENOMES have been disrupted, or "knocked-out". To produce knockouts, using RECOMBINANT DNA technology, the normal DNA sequence of the gene being studied is altered to prevent synthesis of a normal gene product. Cloned cells in which this DNA alteration is successful are then injected into mouse EMBRYOS to produce chimeric mice. The chimeric mice are then bred to yield a strain in which all the cells of the mouse contain the disrupted gene. Knockout mice are used as EXPERIMENTAL ANIMAL MODELS for diseases (DISEASE MODELS, ANIMAL) and to clarify the functions of the genes.
Tumors or cancer of the THYMUS GLAND.
Molecular sites on or in B-lymphocytes, follicular dendritic cells, lymphoid cells, and epithelial cells that recognize and combine with COMPLEMENT C3D. Human complement receptor 2 (CR2) serves as a receptor for both C3dg and the gp350/220 glycoprotein of HERPESVIRUS 4, HUMAN, and binds the monoclonal antibody OKB7, which blocks binding of both ligands to the receptor.
The class of heavy chains found in IMMUNOGLOBULIN M. They have a molecular weight of approximately 72 kDa and they contain about 57 amino acid residues arranged in five domains and have more oligosaccharide branches and a higher carbohydrate content than the heavy chains of IMMUNOGLOBULIN G.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
A programmed mutation process whereby changes are introduced to the nucleotide sequence of immunoglobulin gene DNA during development.
Disorders characterized by proliferation of lymphoid tissue, general or unspecified.
One of the types of light chains of the immunoglobulins with a molecular weight of approximately 22 kDa.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Antibodies which react with the individual structural determinants (idiotopes) on the variable region of other antibodies.
Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges.
Membrane proteins encoded by the BCL-2 GENES and serving as potent inhibitors of cell death by APOPTOSIS. The proteins are found on mitochondrial, microsomal, and NUCLEAR MEMBRANE sites within many cell types. Overexpression of bcl-2 proteins, due to a translocation of the gene, is associated with follicular lymphoma.
A member of the tumor necrosis factor receptor superfamily found on most T-LYMPHOCYTES. Activation of the receptor by CD70 ANTIGEN results in the increased proliferation of CD4-POSITIVE T-LYMPHOCYTES and CD8-POSITIVE T-LYMPHOCYTES. Signaling by the activated receptor occurs through its association with TNF RECEPTOR-ASSOCIATED FACTORS.
A transcription factor that is essential for CELL DIFFERENTIATION of B-LYMPHOCYTES. It functions both as a transcriptional activator and repressor to mediate B-cell commitment.
In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.
The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.
A cell line derived from cultured tumor cells.
Polypeptide chains, consisting of 211 to 217 amino acid residues and having a molecular weight of approximately 22 kDa. There are two major types of light chains, kappa and lambda. Two Ig light chains and two Ig heavy chains (IMMUNOGLOBULIN HEAVY CHAINS) make one immunoglobulin molecule.
A group of disorders having a benign course but exhibiting clinical and histological features suggestive of malignant lymphoma. Pseudolymphoma is characterized by a benign infiltration of lymphoid cells or histiocytes which microscopically resembles a malignant lymphoma. (From Dorland, 28th ed & Stedman, 26th ed)
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Ordered rearrangement of B-lymphocyte variable gene regions coding for the kappa or lambda IMMUNOGLOBULIN LIGHT CHAINS, thereby contributing to antibody diversity. It occurs during the second stage of differentiation of the IMMATURE B-LYMPHOCYTES.
A membrane glycoprotein and differentiation antigen expressed on the surface of T-cells that binds to CD40 ANTIGENS on B-LYMPHOCYTES and induces their proliferation. Mutation of the gene for CD40 ligand is a cause of HYPER-IGM IMMUNODEFICIENCY SYNDROME, TYPE 1.
Tumors or cancer of the EYE.
CXCR receptors isolated initially from BURKITT LYMPHOMA cells. CXCR5 receptors are expressed on mature, recirculating B-LYMPHOCYTES and are specific for CHEMOKINE CXCL13.
One of the types of light chain subunits of the immunoglobulins with a molecular weight of approximately 22 kDa.
Leukemia associated with HYPERPLASIA of the lymphoid tissues and increased numbers of circulating malignant LYMPHOCYTES and lymphoblasts.
Substances that inhibit or prevent the proliferation of NEOPLASMS.
Antigenic determinants recognized and bound by the B-cell receptor. Epitopes recognized by the B-cell receptor are located on the surface of the antigen.
A CXC chemokine that is chemotactic for B-LYMPHOCYTES. It has specificity for CXCR5 RECEPTORS.
Non-hematopoietic cells, with extensive dendritic processes, found in the primary and secondary follicles of lymphoid tissue (the B cell zones). They are different from conventional DENDRITIC CELLS associated with T-CELLS. They are derived from MESENCHYMAL STEM CELLS and are negative for class II MHC antigen and do not process or present antigen like the conventional dendritic cells do. Instead, follicular dendritic cells have FC RECEPTORS and C3B RECEPTORS that hold antigen in the form of ANTIGEN-ANTIBODY COMPLEXES on their surfaces for long periods for recognition by B-CELLS.
Therapeutic act or process that initiates a response to a complete or partial remission level.
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected.
Tumors or cancer of the NOSE.
Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.
Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.
Antigens which may directly stimulate B lymphocytes without the cooperation of T lymphocytes.
The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.
Tumors or cancer of the SKIN.
Process whereby the immune system reacts against the body's own tissues. Autoimmunity may produce or be caused by AUTOIMMUNE DISEASES.
White blood cells formed in the body's lymphoid tissue. The nucleus is round or ovoid with coarse, irregularly clumped chromatin while the cytoplasm is typically pale blue with azurophilic (if any) granules. Most lymphocytes can be classified as either T or B (with subpopulations of each), or NATURAL KILLER CELLS.
Antibodies that react with self-antigens (AUTOANTIGENS) of the organism that produced them.
Transplantation of an individual's own tissue from one site to another site.
DNA present in neoplastic tissue.
All of the processes involved in increasing CELL NUMBER including CELL DIVISION.
Family of retrovirus-associated DNA sequences (myc) originally isolated from an avian myelocytomatosis virus. The proto-oncogene myc (c-myc) codes for a nuclear protein which is involved in nucleic acid metabolism and in mediating the cellular response to growth factors. Truncation of the first exon, which appears to regulate c-myc expression, is crucial for tumorigenicity. The human c-myc gene is located at 8q24 on the long arm of chromosome 8.
The B-cell leukemia/lymphoma-2 genes, responsible for blocking apoptosis in normal cells, and associated with follicular lymphoma when overexpressed. Overexpression results from the t(14;18) translocation. The human c-bcl-2 gene is located at 18q24 on the long arm of chromosome 18.
Mice homozygous for the mutant autosomal recessive gene "scid" which is located on the centromeric end of chromosome 16. These mice lack mature, functional lymphocytes and are thus highly susceptible to lethal opportunistic infections if not chronically treated with antibiotics. The lack of B- and T-cell immunity resembles severe combined immunodeficiency (SCID) syndrome in human infants. SCID mice are useful as animal models since they are receptive to implantation of a human immune system producing SCID-human (SCID-hu) hematochimeric mice.
A soluble factor produced by activated T-LYMPHOCYTES that induces the expression of MHC CLASS II GENES and FC RECEPTORS on B-LYMPHOCYTES and causes their proliferation and differentiation. It also acts on T-lymphocytes, MAST CELLS, and several other hematopoietic lineage cells.
Genes and gene segments encoding the IMMUNOGLOBULIN HEAVY CHAINS. Gene segments of the heavy chain genes are symbolized V (variable), D (diversity), J (joining), and C (constant).
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.

Fas-induced B cell apoptosis requires an increase in free cytosolic magnesium as an early event. (1/3054)

Ligation of the Fas molecule expressed on the surface of a cell initiates multiple signaling pathways that result in the apoptotic death of that cell. We have examined Mg2+ mobilization as well as Ca2+ mobilization in B cells undergoing Fas-initiated apoptosis. Our results indicate that cytosolic levels of free (non-complexed) Mg2+ ([Mg2+]i) and Ca2+ ([Ca2+]i) increase in cells undergoing apoptosis. Furthermore, the percentages of cells mobilizing Mg2+, fragmenting DNA, or externalizing phosphatidylserine (PS) increase in parallel as the concentration of anti-Fas monoclonal antibody is raised. Kinetic analysis suggests that Mg2+ mobilization is an early event in apoptosis, clearly preceding DNA fragmentation and probably occurring prior to externalization of PS as well. The source of Mg2+ that produces the increases in [Mg2+]i is intracellular and most likely is the mitochondria. Extended pretreatment of B cells with carbonyl cyanide m-chlorophenylhydrazone, an inhibitor of mitochondrial oxidative phosphorylation, produces proportional decreases in the percentage of cells mobilizing Mg2+, fragmenting DNA, and externalizing PS in response to anti-Fas monoclonal antibody treatment. These observations are consistent with the hypothesis that elevated [Mg2+]i is required for apoptosis. Furthermore, we propose that the increases in [Mg2+]i function not only as cofactors for Mg2+-dependent endonucleases, but also to facilitate the release of cytochrome c from the mitochondria, which drives many of the post-mitochondrial, caspase-mediated events in apoptotic cells.  (+info)

Merkel cell carcinoma and melanoma: etiological similarities and differences. (2/3054)

Merkel cell carcinoma (MCC) of the skin and cutaneous malignant melanoma can now be compared epidemiologically through the use of population-based data not previously available for MCC. The results may provide new clues to etiology. In this study, United States data covered by the Surveillance, Epidemiology, and End Results (SEER) Program were from nine areas of the United States (approximately 10% of the population). In 1986-1994, 425 cases of MCC were registered. The annual age-adjusted incidence per 100,000 of MCC was 0.23 for whites and 0.01 for blacks; among whites, the ratio of melanoma to MCC was approximately 65 to 1. Only 5% of MCC occurred before age 50, unlike the lifelong risk of nodular and superficial spreading melanoma. Regional incidence rates of both cancers increased similarly with increasing sun exposure as measured by the UVB solar index. The most sun-exposed anatomical site, the face, was the location of 36% of MCC but only 14% of melanoma. Both cancers increased in frequency and aggressiveness after immunosuppression and organ transplantation (36 cases from the Cincinnati Transplant Tumor registry and 12 from published case reports) and after B-cell neoplasia (5 cases in this study; 13 from case series in the literature). The SEER data contained reports of six patients with both types of cancer; 5 melanomas before the diagnosis of MCC and 1 after diagnosis. MCC and melanoma are similarly related to sun exposure and immunosuppression, but they differ markedly from one another in their distributions by age, race, and anatomical site, especially the face.  (+info)

Immunoglobulin VH gene expression among extranodal marginal zone B-cell lymphomas of the ocular adnexa. (3/3054)

PURPOSE: Most lymphomas of the ocular adnexa are primary extranodal non-Hodgkin's lymphomas of the B-cell type, with the most common lymphoma subtype being the extranodal marginal-zone B-cell lymphoma (EMZL). Analysis of somatic mutations in the variable (V) region of the Ig heavy (H)-chain gene segment suggests that EMZL development in other locations is dependent on antigen stimulation. The purpose of this study was to analyze the presence of somatic hypermutations in clonally rearranged Ig H-chain V genes of this lymphoma entity in the ocular adnexa and to estimate whether the mutation pattern is compatible with antigen selection. METHODS: Twenty-six cases of EMZL of the ocular adnexa were diagnosed on the basis of morphology, histology, and immunohistology. A nested polymerase chain reaction (PCR) was performed on DNA extracted from paraffin sections. The isolated PCR products were sequenced and compared with published VH germline segments to determine the number of somatic mutations in the complementarity-determining region (CDR) 2 and framework (FW) region 3. RESULTS: The number of somatic mutations in the cases of EMZL varied between 0 and 24: Five cases involved 0 to 3 somatic mutations, and the remaining 21 cases involved 4 to 24 mutations. Based on the ratio of replacement (R) to silent (S) mutations in the CDR2 or FW3 regions, antigen selection seems to have occurred in 60% of ocular adnexal EMZL. The VH3 family was the most commonly expressed germline VH family (54%), followed by VH4 (23%), with biased usage of the latter. Some germline VH1 genes used included DP-8, DP-10, DP-53, DP-63 (VH4.21), and DP-49, which are frequently used by autoantibodies (e.g., rheumatoid factors) and natural autoantibodies. CONCLUSIONS: EMZLs of the ocular adnexa have an Ig H-chain mutation pattern that supports the concept that they represent a clonal expansion of post-germinal-center memory B-cells in most instances. In two thirds of cases, antigen selection may have occurred, and autoantibodies may have a role in their development.  (+info)

Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. (4/3054)

Node biopsies of 30 benign lymphadenopathies and 71 B-cell non-Hodgkin's lymphomas (B-NHLs) were investigated for microvessel and macrophage counts using immunohistochemistry and morphometric analysis. Both counts were significantly higher in B-NHL. Moreover, when these were grouped into low-grade and high-grade lymphomas, according to the Kiel classification and Working Formulation (WF), statistically significant higher counts were found in the high-grade tumours. Immunohistochemistry and electron microscopy revealed a close spatial association between microvessels and macrophages. Overall, the results suggest that, in analogy to what has already been shown in solid tumours, angiogenesis occurring in B-NHLs increases with tumour progression, and that macrophages promote the induction of angiogenesis via the release of their angiogenic factors.  (+info)

Primary mediastinal large B-cell lymphoma: a clinicopathologic study of 43 patients from the Nebraska Lymphoma Study Group. (5/3054)

PURPOSE: To investigate whether primary mediastinal large B-cell lymphoma (PMLBL) is a distinct clinicopathologic entity with a more aggressive course than other diffuse large B-cell lymphomas (DLBL). MATERIALS AND METHODS: All patients with CD20-positive DLBL who presented with a mediastinal mass measuring at least 5.0 cm and were treated with curative intent were identified. A control group of 352 patients with nonmediastinal DLBL was selected for comparison. RESULTS: The 43 patients with PMLBL had a male to female ratio of 20:23 and a median age of 42 years. Stage I/II disease was present in 58% of the patients, with only 9% having bone marrow involvement. A complete remission was achieved in 63% of the patients, and the 5-year overall and failure-free survivals were 46% and 38%, respectively. Among the clinical variables, an elevated serum lactate dehydrogenase level, a low performance score, more than one extranodal site, and an intermediate or high International Prognostic Index score were predictive of poor survival. When compared with the DLBL group, a younger median age was the only clinical feature that was significantly different in the PMLBL group. CONCLUSION: The clinical features of PMLBL do not appear to be significantly different from those of nonmediastinal DLBL. Although the younger age of onset, slight female predominance, mediastinal location, and size of the mass may justify the recognition of PMLBL as a clinical syndrome, additional evidence is needed to define it as a distinct disease entity.  (+info)

Cancer dormancy. VII. A regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state. (6/3054)

Dormant tumor cells resistant to ablative cancer therapy represent a significant clinical obstacle due to later relapse. Experimentally, the murine B cell lymphoma (BCL1) is used as a model of tumor dormancy in mice vaccinated with the BCL1 Ig. Here, we used this model to explore the cellular mechanisms underlying dormancy. Our previous studies have demonstrated that T cell-mediated immunity is an important component in the regulation of tumor dormancy because Id-immune T cells adoptively transferred into passively immunized SCID mice challenged with BCL1 cells significantly increased the incidence and duration of the dormant state. We have extended these observations and demonstrate that CD8+, but not CD4+, T cells are required for the maintenance of dormancy in BCL1 Ig-immunized BALB/c mice. In parallel studies, the transfer of Id-immune CD8+ cells, but not Id-immune CD4+ cells, conferred significant protection to SCID mice passively immunized with nonprotective levels of polyclonal anti-Id and then challenged with BCL1 cells. Furthermore, the ability of CD8+ T cells to induce a state of dormancy in passively immunized SCID mice was completely abrogated by treatment with neutralizing alpha-IFN-gamma mAbs in vivo. In vitro studies demonstrated that IFN-gamma alone or in combination with reagents to cross-link the surface Ig induced both cell cycle arrest and apoptosis in a BCL1 cell line. Collectively, these data demonstrate a role for CD8+ T cells via endogenous production of IFN-gamma in collaboration with humoral immunity to both induce and maintain a state of tumor dormancy.  (+info)

Histopathologic features and expression of Bcl-2 and p53 proteins in primary gastric lymphomas. (7/3054)

The aim of this study is to present a histopathologic and immunohistochemical analysis of primary gastric lymphomas which were reclassified according to the concept of mucosa associated lymphoid tissue (MALT). The resected specimens from 41 patients with primary gastric lymphoma were investigated retrospectively. Immunohistochemical study was done to analyze the immunophenotype and bcl-2 and p53 proteins expression. Twenty three of the cases had tumors mainly located in the antrum. Histologically, 12 were low grade and 20 were high grade B-cell lymphoma of MALT, 9 other B-cell nonHodgkin's lymphomas. Helicobacter pylori was identified in 72% of the cases. According to Musshoff's modification, most of the MALT lymphoma cases had stage I or II disease. There was significant difference between low and high grade cases, in respect to depth of invasion in gastric wall. Immunohistochemically, the neoplastic cells in all MALT lymphomas expressed B-cell phenotype. Bcl-2 protein was found to be expressed in 59% and p53 protein expression was detected in 72% of cases. Among the B-cell lymphoma of MALT, bcl-2 positivity decreased and p53 positivity increased significantly as the histological grade advanced. So, an inverse correlation was observed between the expression of bcl-2 and p53. In conclusion, most primary gastric lymphomas are low or high grade B-cell MALT lymphomas and appear to arise in MALT acquired as a reaction to Helicobacter pylori infection. Expression of bcl-2 and p53 in gastric lymphomas may be associated with transformation from low-grade to high-grade disease.  (+info)

Presentation of antigens internalized through the B cell receptor requires newly synthesized MHC class II molecules. (8/3054)

Exogenous Ags taken up from the fluid phase can be presented by both newly synthesized and recycling MHC class II molecules. However, the presentation of Ags internalized through the B cell receptor (BCR) has not been characterized with respect to whether the class II molecules with which they become associated are newly synthesized or recycling. We show that the presentation of Ag taken up by the BCR requires protein synthesis in splenic B cells and in B lymphoma cells. Using B cells transfected with full-length I-Ak molecules or molecules truncated in cytoplasmic domains of their alpha- or beta-chains, we further show that when an Ag is internalized by the BCR, the cytoplasmic tails of class II molecules differentially control the presentation of antigenic peptides to specific T cells depending upon the importance of proteolytic processing in the production of that peptide. Integrity of the cytoplasmic tail of the I-Ak beta-chain is required for the presentation of the hen egg lysozyme determinant (46-61) following BCR internalization, but that dependence is not seen for the (34-45) determinant derived from the same protein. The tail of the beta-chain is also of importance for the dissociation of invariant chain fragments from class II molecules. Our results demonstrate that Ags internalized through the BCR are targeted to compartments containing newly synthesized class II molecules and that the tails of class II beta-chains control the loading of determinants produced after extensive Ag processing.  (+info)

PURPOSE: Primary cutaneous B-cell lymphomas (PCBCLs) are a distinct group of primary cutaneous lymphomas with few and conflicting data on their prognostic factors. PATIENTS AND METHODS: The study group included 467 patients with PCBCL who were referred, treated, and observed in 11 Italian centers (the Italian Study Group for Cutaneous Lymphomas) during a 24-year period (1980 to 2003). All of the patients were reclassified according to the WHO-European Organisation for Research and Treatment of Cancer (EORTC) classification. RESULTS: Follicle center lymphoma (FCL) accounted for 56.7% of occurrences, followed by marginal-zone B-cell lymphoma (MZL; 31.4%); diffuse large B-cell lymphoma (DLBCL), leg type, was reported in 10.9% of patients. Radiotherapy was the first-line treatment in 52.5% of patients and chemotherapy was the first-line treatment in 24.8% of patients. The complete response rate was 91.9% and the relapse rate was 46.7%. The 5- and 10-year overall survival (OS) rates were 94% and 85%, ...
Principal cutaneous B-cell lymphomas are a heterogeneous group of older B-cells neoplasms with tropism for the epidermis, whose biology and clinical training course differ from the equal nodal lymphomas significantly. huge B-cell lymphomas. Treatment might consist of operative excision, radiotherapy, antibiotics, corticosteroids, interferon, monoclonal chemotherapy and antibodies, depending upon the type of lymphoma and upon the area and type of the epidermis lesions. In subtypes with great treatment is certainly KIAA1516 contraindicated overtreatment and in those linked with a even worse treatment the suggested therapy depends on CHOP-like routines linked with rituximab, helped or not really with regional radiotherapy. We critique the principal cutaneous B-cell lymphomas, knowing how the analysis requirements, differential medical diagnosis, category, and prognostic elements and introducing the obtainable therapies. infections, although the subject is controversy still. 15-21 Cutaneous B-cell ...
One classification system for lymphomas divides the diseases according to the size of the white blood cells that has turned cancerous. The large-cell lymphomas have large cells. A large cell, in this context, has a diameter of 17 to 20 µm. Other groups of lymphomas in this system are the small-cell lymphomas and mixed-cell lymphomas. Diffuse large B-cell lymphoma is the most common of the large-cell lymphomas. MeSH now classifies the phrase large-cell lymphoma under Diffuse large B cell lymphoma. Many other B-cell lymphomas feature large cells: Angiocentric lymphoma Burkitts lymphoma Follicular large-cell lymphoma Immunoblastic lymphoma Intravascular large-cell lymphoma Primary mediastinal B-cell lymphoma T-cell-rich B-cell lymphoma Primary splenic lymphoma (rare) Primary central nervous system lymphomas, which are often diffuse large-B-cell lymphomas Activated B-Cell Diffuse Large B-Cell Lymphoma, or ABC-DLBCL, is believed to be caused by aberrant activation of a critical intracellular ...
TY - JOUR. T1 - Adult high-grade B-cell lymphoma with Burkitt lymphoma signature. T2 - Genomic features and potential therapeutic targets. AU - Bouska, Alyssa. AU - Bi, Chengfeng. AU - Lone, Waseem. AU - Zhang, Weiwei. AU - Kedwaii, Ambreen. AU - Heavican, Tayla. AU - Lachel, Cynthia M.. AU - Yu, Jiayu. AU - Ferro, Roberto. AU - Eldorghamy, Nanees. AU - Greiner, Timothy Charles. AU - Vose, Julie Marie. AU - Weisenburger, Dennis D.. AU - Gascoyne, Randy D.. AU - Rosenwald, Andreas. AU - Ott, German. AU - Campo, Elias. AU - Rimsza, Lisa M.. AU - Jaffe, Elaine S.. AU - Braziel, Rita M.. AU - Siebert, Reiner. AU - Miles, Rodney R.. AU - Dave, Sandeep. AU - Reddy, Anupama. AU - Delabie, Jan. AU - Staudt, Louis M.. AU - Song, Joo Y.. AU - McKeithan, Timothy W.. AU - Fu, Kai. AU - Green, Michael. AU - Chan, Wing C.. AU - Iqbal, Javeed. PY - 2017/10/19. Y1 - 2017/10/19. N2 - The adult high-grade B-cell lymphomas sharing molecular features with Burkitt lymphoma (BL) are highly aggressivelymphomas with ...
TY - JOUR. T1 - Indolent B-Cell lymphomas associated with HCV infection. T2 - Clinical and virological features and role of antiviral therapy. AU - Arcaini, Luca. AU - Merli, Michele. AU - Volpetti, Stefano. AU - Rattotti, Sara. AU - Gotti, Manuel. AU - Zaja, Francesco. PY - 2012. Y1 - 2012. N2 - The association between hepatitis C virus (HCV) infection and B-cell non-Hodgkins lymphomas (NHL) has been demonstrated by epidemiological studies, in particular in highly endemic geographical areas such as Italy, Japan, and southern parts of United States. In these countries, together with diffuse large B-cell lymphomas, marginal zone lymphomas are the histotypes most frequently associated with HCV infection; in Italy around 2030 cases of marginal zone lymphomas are HCV positive. Recently, antiviral treatment with interferon with or without ribavirin has been proved to be effective in the treatment of HCV-positive patients affected by indolent lymphoma, prevalently of marginal zone origin. An ...
Histology: Diagnosis of aggressive CD20+, confirmed by an excisional biopsy of a lymph node or by a sufficiently extensive biopsy of an extranodal involvement if there is no lymph node involvement. It will be possible to treat the following entities in this study as defined by the new WHO classification of 2008: B-NHL, Follicular lymphoma grade IIIb,DLBCL, not otherwise specified (NOS),common morphologic variants: centroblastic,immunoblastic,anaplastic,rare morphologic variants.DLBCL subtypes/entities:T cell/histiocyte rich large B-cell lymphoma, primary cutaneous DLBCL, leg type, EBV-positive DLBCL of the elderly, DLBCL associated with chronic inflammation, primary mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma,ALK-positive large B-cell lymphoma, Plasmoblastic lymphoma, Primary effusion lymphoma, B-cell lymphoma, unclassifiable, with features inter¬mediate between diffuse large B-cell lymphoma and Burkitt lymphoma, B-cell lymphoma, unclassifiable, with features ...
RnRMarketResearch.com adds report B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014 to its store.. B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014. Summary. GlobalDatas clinical trial report, B-Cell Non-Hodgkin Lymphoma Global Clinical Trials Review, H1, 2014″ provides data on the B-Cell Non-Hodgkin Lymphoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on B-Cell Non-Hodgkin Lymphoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating B-Cell Non-Hodgkin Lymphoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis ...
In 2000, Cerroni et al1 first reported primary cutaneous spindle-cell B-cell lymphoma as a rare variant of primary cutaneous B-cell lymphoma characterized by admixed centrocytes and centroblasts with spindle-shaped, elongated nuclei and in some foci a boomerang-like or spermatozoa-like morphology. Subsequently, studies reappraised this entity as a special subtype of primary cutaneous follicle center lymphoma.3,5,6 Ries et al14 reported the only Bcl-6-negative spindle-cell B-cell lymphoma. However, that particular case was not fulfilling the criteria of Cerroni et al.1 The skin is most frequently affected, with 18 cases reported.1-6,8,11,13,14 The liver, vagina, and uterus were also affected in isolated cases.7,9,10 Primary cutaneous spindle-cell B-cell lymphoma shares several clinicopathologic features with primary cutaneous follicle center cell lymphoma. It typically affects elderly people with no apparent sex difference. It usually presents as single or occasionally multiple lesions on the ...
Specify your expertise for the Disease/group of diseases (eg SCT, Molecular diagnosis): Novel agents, immunotherapy, biomarkers, phase I-III clinical trials Diseases: Tumor of hematopoietic and lymphoid tissues Lymphoid hemopathy Post-transplant lymphoproliferative disease Lymphoma Non-Hodgkin lymphoma Acute lymphoblastic leukemia Precursor B-cell acute lymphoblastic leukemia Precursor T-cell acute lymphoblastic leukemia Mature B-cell acute lymphoblastic leukemia B-cell non-Hodgkin lymphoma Indolent B-cell non-Hodgkin lymphoma Follicular lymphoma Waldenström macroglobulinemia Hairy cell leukemia B-cell chronic lymphocytic leukemia Indolent primary cutaneous B-cell lymphoma Primary cutaneous marginal zone B-cell lymphoma Primary cutaneous follicle center lymphoma Hairy cell leukemia variant Marginal zone lymphoma MALT lymphoma Splenic marginal zone lymphoma Nodal marginal zone B-cell lymphoma Splenic diffuse red pulp small B-cell lymphoma Lymphoplasmacytic lymphoma without IgM production ...
TY - JOUR. T1 - Outcomes among North American patients with diffuse large b-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. AU - Tracy, Sean I.. AU - Habermann, Thomas Matthew. AU - Feldman, Andrew L. AU - Maurer, Matthew J.. AU - Dogan, Ahmet. AU - Perepu, Usha S.. AU - Syrbu, Sergei. AU - Ansell, Stephen Maxted. AU - Thompson, Carrie A. AU - Weiner, George J.. AU - Nowakowski, Grzegorz S. AU - Allmer, Cristine. AU - Slager, Susan L. AU - Witzig, Thomas Elmer. AU - Cerhan, James R. AU - Link, Brian K.. PY - 2018/1/31. Y1 - 2018/1/31. N2 - The prevalence, presenting clinical and pathological characteristics, and outcomes for patients with diffuse large B-cell lymphoma that is Epstein-Barr virus positive remain uncertain as does the impact of congenital or iatrogenic immunosuppression. Patients with newly diagnosed diffuse large B-cell lymphoma with available tissue arrays were identified from the University of Iowa/Mayo Clinic Molecular Epidemiology ...
What types of high-grade B-cell lymphomas are difficult to classify? There are lots of different types of lymphoma. The tests you have when you are diagnosed help your medical team find out which type of lymphoma you have. This is called classifying your lymphoma.
TY - JOUR. T1 - A Case of cutaneous large B-cell lymphoma during treatment of multiple sclerosis with fingolimod. AU - Stitt, Derek W.. AU - Boes, Christopher J.. AU - Flanagan, Eoin. AU - Howard, Matthew T.. AU - Colgan, Joseph P.. PY - 2018/1/1. Y1 - 2018/1/1. N2 - The authors report a case of a 69-year-old woman with multiple sclerosis treated with fingolimod for duration of over one year who subsequently developed cutaneous large B cell lymphoma. There are few reported cases of lymphoma associated with fingolimod treatment for multiple sclerosis, but rates are higher than expected in the general population. The authors hope to promote awareness of the potential risk of this medication so that more diligent disease surveillance can be performed by both prescribing practitioners of fingolimod and their patients who receive it.. AB - The authors report a case of a 69-year-old woman with multiple sclerosis treated with fingolimod for duration of over one year who subsequently developed cutaneous ...
In situ follicular neoplasia (ISFN) is the earliest morphologically identifiable precursor of follicular lymphoma (FL). Although it is genetically less complex than FL and has low risk for progression, ISFN already harbors secondary genetic alterations, in addition to the defining t(14;18)(q32;q21) translocation. FL, in turn, frequently progresses to diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). By BCL2 staining of available reactive lymphoid tissue obtained at any time point in patients with aggressive B-cell lymphoma (BCL), we identified 10 paired cases of ISFN and DLBCL/HGBL, including 6 de novo tumors and 4 transformed from FL as intermediate step, and investigated their clonal evolution using microdissection and next generation sequencing. A clonal relationship between ISFN and aggressive BCL was established by immunoglobulin and/or BCL2 rearrangements and/or the demonstration of shared somatic mutations for all 10 cases. Targeted sequencing revealed CREBBP, ...
Sborník Background. Diffuse large B-cell lymphoma (DLBCL), a heterogeneous clinicopathologic entity, accounts for up to 40% of non-Hodgkins lymphomas. Gene expression profiling confirmed the presence of three molecular prognostic subgroups - germinal center B-cell-like (GCB), activated B-cell-like (ABC) and primary mediastinal B-cell lymphoma (PMBL). Nevertheless, there is a need to...
BACKGROUND: An association between Borrelia burgdorferi and cutaneous B-cell lymphoma (CBCL) has been made in several European countries. The evidence in favor of such an association has recently been based on more definitive tests for the pathogenetic role of B. burgdorferi in CBCL, including positive cultures or polymerase chain reaction (PCR) amplification of borrelial DNA from lesional skin. However, there is only one report of B. burgdorferi in four North American cases of B-cell lymphoma. METHODS: We retrieved 38 cases of primary and secondary CBCL from different geographic regions of the United States. Two separate techniques were used to detect borrelial DNA by PCR, a nested PCR method to amplify a B. burgdorferi-specific gene as well as a borrelial chromosomal Ly-1 clone amplification method. Southern blot hybridization was used for confirmation of the PCR results. RESULTS: No B. burgdorferi-specific DNA was detected in any of the 38 CBCL cases, whereas detectable PCR products were obtained
Background Although chemo-immunotherapy has led to an improved overall survival for most B-cell lymphoma types, relapsed and refractory disease remains a challenge. The malaria drug artesunate has previously been identified as a growth suppressor in some cancer types and was tested as a new treatment option in B-cell lymphoma. Methods We included artesunate in a cancer sensitivity drug screen in B lymphoma cell lines. The preclinical properties of artesunate was tested as single agent in vitro in 18 B-cell lymphoma cell lines representing different histologies and in vivo in an aggressive B-cell lymphoma xenograft model, using NSG mice. Artesunate-treated B lymphoma cell lines were analyzed by functional assays, gene expression profiling, and protein expression to identify the mechanism of action. Results Drug screening identified artesunate as a highly potent anti-lymphoma drug.Artesunate induced potent growth suppression in most B lymphoma cells with an IC50 comparable to concentrations ...
Diffuse large B-cell lymphoma (DLCBL) is the most frequent form of lymphoid cancer, accounting for 30% to 35% of all nodal lymphomas.1 Based on gene expression profiling (GEP), 3 distinct subtypes of DLBCL have been identified, namely the germinal center (GC) B-cell (GCB), activated B-cell (ABC), and primary mediastinal B-cell lymphoma subtypes.2 The ABC subtype of DLBCL is characterized by adverse prognosis and constitutive activation of the transcription factor nuclear factor-κB (NF-κB).3 This is thought to be the consequence of somatic mutations in the genes encoding the B-cell receptor (BCR)-associated CD79A and CD79B chains,4 or the BCR signal transducer caspase recruitment domain-containing membrane-associated guanylate kinase-1 (CARMA1) (also known as CARD11),5 and polymorphisms in RNF31 (also known as HOIP),6 which result in constitutive BCR signaling. These can be present alone or in combination with activating mutations in genes encoding the Toll-like receptor (TLR) downstream ...
COPYRIGHT (C) 2016 KISTI. ALL RIGHTS RESERVED.. 대전광역시 유성구 대학로 245 한국과학기술정보연구원TEL : 042.869.1234 서울시 동대문구 회기로 66NDSL고객센터 : 080.969.4114E-mail : [email protected] ...
MONDAY, Dec. 11, 2017 (HealthDay News) - Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy and autologous T cells that express a CD19-directed CAR (CTL019) are effective for refractory B-cell lymphomas, according to two studies published online Dec. 10 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Hematology, held from Dec. 9 to 12 in Atlanta.. Sattva S. Neelapu, M.D., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues enrolled 111 patients with diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, or transformed follicular lymphoma with refractory disease despite receiving prior therapy. A target dose of 2×106 anti-CD19 CAR T cells/kg body weight was administered to 101 patients. The researchers found that the objective and complete response rates were 82 and 54 percent, respectively. Overall, 42 percent of the patients continued to have a ...
The B-cell lymphomas are types of lymphoma affecting B cells. Lymphomas are blood cancers in the lymph nodes. They develop more frequently in older adults and in immunocompromised individuals. B-cell lymphomas include both Hodgkins lymphomas and most non-Hodgkin lymphomas. They are typically divided into low and high grade, typically corresponding to indolent (slow-growing) lymphomas and aggressive lymphomas, respectively. As a generalisation, indolent lymphomas respond to treatment and are kept under control (in remission) with long-term survival of many years, but are not cured. Aggressive lymphomas usually require intensive treatments, with some having a good prospect for a permanent cure. Prognosis and treatment depends on the specific type of lymphoma as well as the stage and grade. Treatment includes radiation and chemotherapy. Early-stage indolent B-cell lymphomas can often be treated with radiation alone, with long-term non-recurrence. Early-stage aggressive disease is treated with ...
What is it? Also known as … Cutaneous B-cell Lymphoma What is Primary Ctaneous B-cell Lymphoma (PCBCL)? Tumours of the lymph nodes and lymphatic system are called lymphomas. B-cell lymphomas are caused by an excess of B-cell lymphocytes, a type of white blood cell. Primary cutaneous B-cell lymphomas (PCBCL) are a group of B-cell lymphomas […]. ...
TY - JOUR. T1 - Ratios of Four STAT3 Splice Variants in Human Eosinophils and Diffuse Large B Cell Lymphoma Cells.. AU - Turton, Keren. AU - Mosher, Deane. AU - Annis, Douglas. AU - Rui, Lixin. AU - Esnault, Stephane. PY - 2015/5/18. Y1 - 2015/5/18. N2 - Signal transducer and activator of transcription 3 (STAT3) is a key mediator of leukocyte differentiation and proliferation. The 3 end of STAT3 transcripts is subject to two alternative splicing events. One results in either full-length STAT3α or in STAT3β, which lacks part of the C-terminal transactivation domain. The other is at a tandem donor (5) splice site and results in the codon for Ser-701 being included (S) or excluded (ΔS). Despite the proximity of Ser-701 to the site of activating phosphorylation at Tyr-705, ΔS/S splicing has barely been studied. Sequencing of cDNA from purified eosinophils revealed the presence of four transcripts (S-α, ΔS-α, S-β, and ΔS-β) rather than the three reported in publically available databases ...
Dermoscopy is a non invasive diagnostic method. Dermoscopedia is the online resource for dermoscopy and is provided by the international dermoscopy society. This is page „Cutaneous B-cell lymphoma
Primary cutaneous follicle center lymphoma, marginal zone lymphoma, and diffuse large b-cell lymphoma, were 3 subgroups assessed in a 2021 update.
Extranodal presentation of B-cell lymphoma is uncommon. Isolated primary epiglottic B-cell lymphoma is even rarer. To our knowledge, there has been only one description of isolated B-cell lymphoma presenting as a large epiglottic mass. We report an unusual type of B-cell lymphoma of the epiglottis, as it could not be subtyped based on routine staining and hybridization. The lymphoma presented as a large isolated globular mass pedicled to the epiglottis, occupying most of the oropharynx, but did not have any ball-valving effect or increased respiratory efforts. Initial radiographic findings were nonspecific. The diagnosis of B-cell lymphoma was determined by transoral incisional biopsy under local anesthesia. The condition was treated successfully with chemoradiation. The current standard of treatment for high grade B-cell lymphoma is concurrent chemoradiotherapy, with excellent prognosis. Although rare, B-cell lymphoma should be considered when investigating pedunculated hypopharyngeal masses.
Chimeric antigen receptor T-cells are a novel class of anti-cancer therapy in which autologous or allogeneic T-cells are engineered to express a chimeric antigen receptor targeting a membrane antigen. In Europe, Tisagenlecleucel (KymriahTM) is approved for the treatment of refractory/relapsed Acute Lymphoblastic Leukaemia in children and young adults as well as relapsed/refractory Diffuse Large B-cell Lymphoma; Axicabtagene ciloleucel (YescartaTM) is approved for the treatment of relapsed/refractory high-grade B-cell Lymphoma and Primary Mediastinal B-cell Lymphoma. Both agents are genetically engineered autologous T-cells targeting CD19. These practical recommendations, prepared under the auspices of the European Society of Blood and Marrow Transplantation, relate to patient care and supply chain management under the following headings: patient eligibility, screening laboratory tests and imaging and work-up prior to leukapheresis, how to perform leukapheresis, bridging therapy, lymphodepleting ...
Zhang, Y, et al. (2012) LNA-mediated anti-miR-155 silencing in low-grade B-cell lymphomas. Blood. 2012 Aug 23; 120(8):1678-86. PM ID: ...
Researchers affiliated with the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) have reported that conventional chemoimmunotherapy was superior to sequential high-dose chemotherapy with autologous stem cell support for the treatment of high-risk patients with aggressive B-cell lymphoma. The details of this randomized study were presented at the 2011 meeting of the American Society of Clinical Oncology.. Non-Hodgkins lymphoma (NHL) is a form of cancer that begins in the cells of the lymph system. The lymph system includes the spleen, thymus, tonsils, bone marrow, lymph nodes, and circulating immune cells. The main cells in the lymph system are lymphocytes, of which there are two types: B- and T-cells. Each cell type has a specific function in helping the body fight infection.. Non-Hodgkins lymphoma is characterized by the excessive accumulation of atypical (cancerous) lymphocytes. These lymphocytes can crowd the lymph system and suppress the formation and function of other immune ...
OUTLINE: This is a multicenter study.. Blood and tissue samples collected at the time of diagnosis are analyzed for serum free light chain and clonal immunoglobulin (Ig) DNA rearrangements and circulating clonotypic B-cells via PCR.. PROJECTED ACCRUAL: A total of 50 patients (25 with diffuse large B-cell/immunoblastic histologies, 15 with Burkitt lymphoma, and 10 with Hodgkin lymphoma) will be accrued for this study. ...
Fingerprint Dive into the research topics of High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: The role of flow cytometry versus cytology. Together they form a unique fingerprint. ...
The most frequent mature aggressive B-cell lymphomas are diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). Patients suffering from molecularly defined BL (mBL) but treated with a regimen developed for DLBCL show an unfavorable outcome compared to mBL treated with chemotherapy regimens for BL. Distinguishing BL from DLBCL by conventional histopathology is challenging in lymphomas that have features common to both diseases (aggressive B-cell lymphoma unclassifiable with features of DLBCL and BL [intermediates]). Moreover, DLBCL are a heterogeneous group of lymphomas comprising distinct molecular subtypes: the activated B-cell (ABC)-like, the germinal center B-cell-like (GCB) and the unclassifyable subtype as defined by gene expression profiling (GEP). Attempts to replace GEP with techniques applicable to formalin-fixed paraffin-embedded (FFPE) tissue led to algorithms for immunohistochemical stainings (IHS). Disappointingly, the algorithms yielded conflicting results with respect to ...
Species: Human Category: Cancer Tissue of Origin: B-cell / Plasma Cell Cancer Type: B-cell Non-Hodgkin Lymphoma Description SK-LY-18 is a human lymphoma cell line. Source This cell line was established from a B-cell in a person with lymphoma
Ricerca Primary cutaneous B-cell lymphomas (PCBCLs) comprise a group of extranodal B-cell non-Hodgkin lymphomas B-cell derived, which primarily involve the skin without evidence of extracutaneous disease at the time of diagnosis.... Leggi tutto ...
We present an extensive characterization of 10 B-cell lymphomas with a t(9;14)(p13;q32). The presence of the PAX5/IGH gene rearrangement was demonstrated by fluorescence in situ hybridization (FISH) using a validated probe set, whereas complex karyotypic changes were reassessed by multiplex-FISH (M-FISH). Pathologic and clinical review revealed the presence of this rearrangement in 4 histiocyte-rich, T-cell-rich B-cell lymphomas (HRTR-BCLs) and 2 posttransplantation diffuse large B-cell lymphomas (PTLD-DLBCLs). In contrast to initial observations describing this translocation in lymphoplasmacytic lymphoma (LPL) and LPL-derived large B-cell lymphoma, our data showed a wide morphologic and clinical spectrum associated with the PAX5/IGH rearrangement, pointing to an association between this aberration and a subset of de novo DLBCLs presenting with advanced disease and adverse prognosis. In addition, the recurrent incidence of this rearrangement in both HRTR-BCL (4 cases) and PTLD-DLBCL (2 cases) ...
The incidences of type 2 diabetes mellitus and many cancers are rapidly increasing worldwide. Diabetes is a strong risk factor for some cancers (including lymphomas) and is also associated with adverse cancer outcomes. After gastrointestinal tract, the skin is the second most frequent extranodal site involved by non-Hodgkin lymphomas and the cutaneous B-cell lymphomas (CBCLs) range from 25% to 30% of all primary cutaneous lymphomas. The primary cutaneous diffuse large B-cell lymphoma (PCDLBCL) is an aggressive lymphoma with a poor prognosis, representing roughly 20% of all primary CBCLs. Classically, the cutaneous manifestation of this lymphoma is a red or violaceous tumors arising on a leg. To date, despite the large body of evidence suggesting that diabetes is strongly associated with an increased risk of some cancers, very little information is available regarding a possible association between type 2 diabetes and primary cutaneous diffuse large B-cell lymphoma. In this report, we will ...
The incidences of type 2 diabetes mellitus and many cancers are rapidly increasing worldwide. Diabetes is a strong risk factor for some cancers (including lymphomas) and is also associated with adverse cancer outcomes. After gastrointestinal tract, the skin is the second most frequent extranodal site involved by non-Hodgkin lymphomas and the cutaneous B-cell lymphomas (CBCLs) range from 25% to 30% of all primary cutaneous lymphomas. The primary cutaneous diffuse large B-cell lymphoma (PCDLBCL) is an aggressive lymphoma with a poor prognosis, representing roughly 20% of all primary CBCLs. Classically, the cutaneous manifestation of this lymphoma is a red or violaceous tumors arising on a leg. To date, despite the large body of evidence suggesting that diabetes is strongly associated with an increased risk of some cancers, very little information is available regarding a possible association between type 2 diabetes and primary cutaneous diffuse large B-cell lymphoma. In this report, we will ...
Read Epstein-Barr virus-mediated protection against etoposide-induced apoptosis in BJA-B B cell lymphoma cells: role of Bcl-2 and caspase proteins, Archives of Virology on DeepDyve, the largest online rental service for scholarly research with thousands of academic publications available at your fingertips.
Daniel C. McFarland, DO; Joshua Brody, MD; Joseph Tripodi, MsS; Issa Leonard, BS; Vesna Najfeld, PhD. Mechanism of Action/Pathway Profiles. Remission in aggressive B-cell lymphomas is increasingly linked to complex karyotypes and gene rearrangements that often portend aggressive behavior and resistance to standard therapy. An understanding of lymphoma cytogenetics has lagged behind that of leukemia, in which pretreatment karyotype constitutes an independent prognostic determinant for attainment of complete remission. In 2008, the World Health Organization added the category B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma (BCLu-DLBCL/BL), which incorporates aggressive lymphomas with variable morphology. However, this category is nonspecific and does not elevate cytogenetic criteria to a diagnostic status based on chromosomal abnormalities as seen in acute leukemia. In part, this could be because cytogenetic analyses or ...
Based on the assumption that molecular mechanisms involved in cancerogenesis are characterized by groups of coordinately expressed genes, we developed and validated a novel method for analyzing transcriptional data called Correlated Gene Set Analysis (CGSA). Using 50 extracted gene sets we identified three different profiles of tumors in a cohort of 364 Diffuse large B-cell (DLBCL) and related mature aggressive B-cell lymphomas other than Burkitt lymphoma. The first profile had high level of expression of genes related to proliferation whereas the second profile exhibited a stromal and immune response phenotype. These two profiles were characterized by a large scale gene activation affecting genes which were recently shown to be epigenetically regulated, and which were enriched in oxidative phosphorylation, energy metabolism and nucleoside biosynthesis. The third and novel profile showed only low global gene activation similar to that found in normal B cells but not cell lines. Our study ...
Lanier, L L.; Lynes, M; Haughton, G; and Wettstein, P J., Noval type of murine b-cell lymphoma. (1978). Subject Strain Bibliography 1978. 1670 ...
Signs of B-cell lymphomas including medical signs and symptoms of B-cell lymphomas, symptoms, misdiagnosis, tests, common medical issues, duration, and the correct diagnosis for B-cell lymphomas signs or B-cell lymphomas symptoms.
Double-hit lymphomas and double-expressor lymphomas are some of the most difficult non-Hodgkin lymphomas to treat. Patients with these types of lymphomas, which are subtypes of diffuse large B-cell lymphoma, dont respond as well to chemotherapy treatment as other lymphoma patients do.. An estimated 22,000 patients nationwide are diagnosed with diffuse large B-cell lymphoma each year. About 5 to 10 percent have double-hit lymphoma (or cancer cells that contain chromosomal rearrangements of the MYC, BCL2 and/or BCL6 genes) and about 20 to 30 percent have double-expressor lymphoma (containing the MYC and BCL2 genes).. Which is why Alex F. Herrera, M.D., an assistant professor in City of Hopes Department of Hematology and Hematopoietic Cell Transplantation, and a team of doctors at City of Hope and the Dana-Farber Cancer Institute examined how well patients whose double-hit and/or double-expressor lymphoma had recurred, or was resistant to initial treatment, fared after they had received high-dose ...
【市場調査資料】CAR-T r/r B-cell NHLの世界市場予測 | 発行日:2017年8月 | 商品コード:VACZ712009 | 発行/リサーチ会社:VacZine Analytics | CAR-T r/r B-cell NHL global market forecast | キーワード:グローバル、製薬、 [世界の市場(産業/企業/技術/製品/サービス)調査・情報ならグローバルリサーチ]
Primary mediastinal B-cell lymphoma (PMBL) is characterized by aberrant activation of JAK/STAT-signaling resulting in constitutive presence of phosphorylated STAT6 (pSTAT6). identified five STAT-binding-sites in the promoter. We confirmed STAT6 binding to the promoter and by band shift / super shift assays and chromatin immunoprecipitationsUsing luciferase reporter assays, depletion of STAT6 by siRNA, and ectopic overexpression of a constitutive active STAT6 mutant, we proved that pSTAT6 is sufficient to transcriptionally KLF5 repress BCL6. Recently developed small molecule inhibitors 79-6 and TG101348 that increases BCL6 target gene expression and decreases pSTAT6 levels, respectively, demonstrate that a combined targeting results in additive efficacy regarding their negative effect on cell viability. The delineated pSTAT6-mediated molecular repression mechanism links JAK/STAT to BCL6-signaling in PMBL and may carry therapeutic potential. amplifications that established PMBL as a genetically ...
Primary Mediastinal B-Cell Lymphoma (or PMBCL for short), is a very rare form of cancer. At this point, I think I have found and read every article or scientific study written about PMBCL. There are not that many in fact, as it was only designated as its own entity in 2008 (prior to this it…
TY - JOUR. T1 - C-Myc immunohistochemistry in diffuse large B cell lymphoma. AU - Gocke, Christopher D.. PY - 2014/12/10. Y1 - 2014/12/10. N2 - Diffuse large B cell lymphoma is a collection of different biologic entities with a common appearance but different clinical behaviors. The MYC oncogene is mutated in a subset of diffuse large B cell lymphoma and is also mutated in related entities such as Burkitt lymphoma. Recently, an antibody to the c-Myc oncoprotein has become available for immunohistochemistry, raising the possibility of a rapid, reproducible and inexpensive measure of MYC abnormality. Initial retrospective studies of these lymphomas suggest that the c-Myc status is clinically important for diagnosis and prognosis, particularly when used in conjunction with BCL2 immunohistochemistry. It is possible that therapy will be modified based in part on c-Myc status, once the appropriate prospective studies have been performed.. AB - Diffuse large B cell lymphoma is a collection of different ...
While NFKBIE deletions were relatively rare in patients diagnosed with follicular lymphoma (3/225 [1.3%]), splenic marginal zone lymphoma (3/175 [1.7%]), and T-cell acute lymphoblastic leukemia (1/94 [1.1%]), slightly higher frequencies were detected among DLBCL (18/520 [3.5%]), mantle cell lymphoma (8/189 [4.2%]), primary central nervous system lymphoma (1/34 [2.9%]), and small lymphocytic lymphoma (1/9 [11.1%]). In contrast, PMBL patients showed a marked enrichment, with 46 of 203 cases harboring a NFKBIE deletion (22.7% vs 2.9% [38/1257 in other entities]; P , .001; Figure 1A). Notably, the prevalence of NFKBIE-deleted PMBL cases was independent of contributing center (supplemental Table 3).. In an ongoing exome sequencing analysis of microdissected HRS cells in cHL, we obtained indication for NFKBIE mutations in 4 out of 11 cases. From these 4 cases, we isolated HRS cells and confirmed somatic NFKBIE aberrations (1 deletion and 2 missense mutations) in 3 out of 4 cases by Sanger sequencing ...
A dose-adjusted, infusion approach to aggressive chemotherapy with Rituxan® (rituximab) may allow patients with primary mediastinal B-cell lymphoma to skip radiation, according to the results of a study published in the New England Journal of Medicine.. Non-Hodgkins lymphoma (NHL) refers to a group of cancers that originate in different cells of the immune system. Diffuse large B-cell NHL (DLBCL) is a common type of NHL that affects immune cells called B-cells; it is considered an aggressive type of NHL. Primary mediastinal B-cell lymphoma is a distinct subtype of DLBCL that is closely related to nodular sclerosing Hodgkins lymphoma. Patients are usually young and present with large mediastinal masses. There is no standard treatment-and because immunochemotherapy alone has proven inadequate, some patients are treated with consolodiation with radiation, which has potentially serious late effects.. In an attempt to improve cure rates and prevent the need for radiation in this population, ...
TY - JOUR. T1 - Constitutive activation of extracellular signal-regulated kinase predisposes diffuse large B-cell lymphoma cell lines to CD40-mediated cell death.. AU - Hollmann, C Annette. AU - Owens, Trevor. AU - Nalbantoglu, Josephine. AU - Hudson, Thomas J. AU - Sladek, Robert. PY - 2006/4/1. Y1 - 2006/4/1. N2 - CD40 promotes survival, proliferation, and differentiation of normal B cells but can cause activation-induced cell death in malignant B lymphocytes. CD40 ligand and anti-CD40 antibodies have been used successfully to induce apoptosis in lymphoma lines both in vitro and in xenograft tumor models. Although this makes CD40 an attractive target for antitumor therapies, the response of malignant B cells to CD40 signaling is variable, and CD40 stimulation can enhance proliferation and can increase chemoresistance in some cell lines. It would therefore be useful to identify markers that predict whether a specific cell line or tumor will undergo apoptosis when stimulated with CD40 and to ...
A collection of disease information resources and questions answered by our Genetic and Rare Diseases Information Specialists for Primary cutaneous follicle center lymphoma
TY - JOUR. T1 - Cutaneous lymphoid hyperplasia and marginal zone B-cell lymphoma following vaccination. AU - May, Steve A.. AU - Netto, George. AU - Domiati-Saad, Rana. AU - Kasper, Candace. PY - 2005/9. Y1 - 2005/9. N2 - Atypical lymphoid infiltrations arose within the influenza inoculation sites of two adult female patients. One patient developed a low-grade cutaneous marginal zone B-cell lymphoma (MZL) that was responsive to local excision and radiation therapy despite spread to a distant cutaneous site. The second patients clinical course was characterized by a locally aggressive, histologically reactive inflammatory reaction responsive only to radiation therapy after multiple failed attempts at surgical resection.. AB - Atypical lymphoid infiltrations arose within the influenza inoculation sites of two adult female patients. One patient developed a low-grade cutaneous marginal zone B-cell lymphoma (MZL) that was responsive to local excision and radiation therapy despite spread to a distant ...
In diffuse large B-cell lymphoma, first-line treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; salvage with cisplatin-based regimens for relapsing patients; and autologous stem cell therapy are standards of care. Treatment approaches are less clear for patients who are refractory or who are not candidates for autologous stem cell therapy. Options may include palliative regimens or clinical trial enrollment. One therapy under investigation in diffuse large B-cell lymphoma is lenalidomide, an immunomodulatory agent with antiangiogenic activity. We present the case of a 55-year-old Caucasian male patient diagnosed with diffuse large B-cell lymphoma who had an early relapse after treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. He then had a subsequent early relapse after cisplatin-based salvage consolidated with autologous stem cell therapy. The efficacy of gemcitabine-cisplatin-rituximab was limited to five months, followed by
1 of 2 NCCN QUICK GUIDE tm Diffuse Large B-cell Lymphoma, 2017 This NCCNQUICK GUIDE tm sheet summarizes key points from the complet e NCCN Guidelines for Patients ® : Diffuse Large B-cell Lymphoma . T hese guidelines explain which tests and treatments are recommended by experts in cancer. To view and download the guidelines, visit NCC N.or g/patients or, to order printed copies, visit Amazon.com What is diffuse large B-cell lymphoma (DLBCL)? Lymphoma is a cancer of white blood cells called lymphocytes that are within the lymphatic system. This system transports fluids to the bloodstream and fights germs. DLBCL is a cancer of B-cells that are from within or have been released by germinal centers of lymphatic organs. 9 How is DLBCL diagnosed? Tissue from the tumor will likely be removed with an incisional or excisional biopsy. A doctor will test the tissue to look for a pattern of proteins on the cells surface that is common to DLBCL. 10 What health care is needed before treatment? A report of ...
FOSTER CITY, Calif. & SANTA MONICA, Calif.-(BUSINESS WIRE)-Kite, a Gilead Company, (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted regular approval to Yescarta™ (axicabtagene ciloleucel), the first chimeric antigen receptor T cell (CAR T) therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma (PMBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma, or TFL). Yescarta is not indicated for the treatment of patients with primary central nervous system lymphoma.. CAR T therapy is a breakthrough in hematologic cancer treatment in which a patients own T cells are engineered to seek and destroy cancer cells. CAR T therapy is manufactured specifically for each individual patient.. The FDA approval of ...
TY - JOUR. T1 - Germinal center and activated B-cell profiles separate Burkitt lymphoma and diffuse large B-cell lymphoma in AIDS and non-AIDS cases. AU - Gormley, Robert P.. AU - Madan, Rashna. AU - Dulau, Alina E.. AU - Xu, Dongsheng. AU - Tamas, Ecaterina F.. AU - Bhattacharyya, Pritish K.. AU - LeValley, Aaron. AU - Xue, Xiaonan. AU - Kumar, Pankaj. AU - Sparano, Joseph. AU - Ramesh, K. H.. AU - Pulijaal, Venkat. AU - Cannizzaro, Linda. AU - Walsh, Daniel. AU - Ioachim, Harry L.. AU - Ratech, Howard. PY - 2005/11. Y1 - 2005/11. N2 - Morphologic features of Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL) overlap. No single phenotypic marker or molecular abnormality is pathognomonic. We tested a panel of 8 germinal center (GC) and activated B-cell (ABC) markers for their ability to separate BL and DLBCL. We diagnosed 16 BL and 39 DLBCL cases from 21 patients with AIDS and 34 without AIDS based on traditional morphologic criteria, Ki-67 proliferative index, and c-myc ...
MalaCards based summary : Splenic Diffuse Red Pulp Small B-Cell Lymphoma, also known as splenic diffuse red pulp lymphoma, is related to b-cell lymphoma and hairy cell leukemia. An important gene associated with Splenic Diffuse Red Pulp Small B-Cell Lymphoma is BCOR (BCL6 Corepressor), and among its related pathways/superpathways are GPCR Pathway and PI3K-Akt signaling pathway. Affiliated tissues include b cells, bone and t cells, and related phenotypes are cardiovascular system and embryo ...
Yogi Berra offered the comment Its déjà vu all over again when he witnessed Mickey Mantle and Roger Maris repeatedly hitting back-to-back home runs in the early 1960s. His pithy remark neatly summarizes my reaction when I read the article, Dose-Adjusted EPOCH-Rituximab Therapy in Primary Mediastinal B-Cell Lymphoma, by Drs. Dunleavy, Wilson, and colleagues in The New England Journal of Medicine.1. The report nicely caps more than a decade of clinical investigation carried out by Dr. Wilsons group at the National Cancer Institute, focused on the use of infusional immunochemotherapy to treat various aggressive non-Hodgkin lymphomas (see a summary of the report in this issue of The ASCO Post). Briefly, this group demonstrated that when they used dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab [Rituxan]) to treat primary mediastinal large B-cell lymphoma in 51 patients, almost all of the patients appeared to have been cured. ...
TY - JOUR. T1 - A case of rectal squamous cell carcinoma with metachronous diffuse large B cell lymphoma in an HIV-infected patient. AU - Choi, Heun. AU - Lee, Hye Won. AU - Ann, Hea Won. AU - Kim, Jae Kyung. AU - Kang, Hua Pyong. AU - Kim, Sun Wook. AU - Ku, Nam Su. AU - Han, Sang Hoon. AU - Kim, June Myung. AU - Choi, Jun Yong. N1 - Publisher Copyright: © 2014 by The Korean Society of Infectious Diseases,Korean Society for Chemotherapy.. PY - 2014. Y1 - 2014. N2 - Diffuse large B cell lymphoma (DLBCL) is one of the most common acquired immune deficiency syndrome (AIDS)-defining malignancies among human immunodeficiency virus -infected patients, and rectal cancer has recently emerged as a prevalent non-AIDS-defining malignancy. We report a case of rectal squamous cell carcinoma that was metachronous with DLBCL in an HIV-infected patient who was receiving highly active antiretroviral therapy. The patient was diagnosed with DLBCL and showed complete remission after chemotherapy. Follow-up ...
NICE has published final guidance which recommends tisagenlecleucel (Kymriah) therapy for use within the Cancer Drugs Fund as an option for treating relapsed or refractory diffuse large B-cell lymphoma in adults after two or more systemic therapies, only if the conditions in the managed access agreement are followed. There is no standard treatment for relapsed or refractory diffuse large B-cell lymphoma after two or more systemic therapies. Salvage chemotherapy (that is, chemotherapy to control the disease) is the most common treatment option. Evidence from a single-arm study with short follow-up and a small observational study suggests that people having tisagenlecleucel may live for longer or have more time before their disease relapses. But longer follow-up from the study is needed and there are no data directly comparing tisagenlecleucel with salvage chemotherapy. To assess the comparative effectiveness of tisagenlecleucel and salvage chemotherapy, data from the first CORAL extension study ...
1. Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50:74-87 2. Kubuschok B, Held G, Pfreundschuh M. Management of diffuse large B-cell lymphoma (DLBCL). Cancer treatment and research. 2015;165:271-88 3. Flowers CR, Sinha R, Vose JM. Improving outcomes for patients with diffuse large B-cell lymphoma. CA: a cancer journal for clinicians. 2010;60:393-408 4. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. The New England journal of medicine. 2002;346:1937-47 5. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-11 6. Wight JC, Chong G, Grigg AP, Hawkes EA. Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI. Blood reviews. 2018;32:400-15 7. Wang XJ, Medeiros LJ, Bueso-Ramos CE, ...
Researchers from the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, have discovered a new potential therapeutic target for Diffuse Large B-Cell Lymphoma (DLBCL), the most aggressive and common type of lymphoma in adults. The new study, published in the November 23 issue of Nature, reveals the underlying molecular mechanism contributing to the development of lymphomagenesis. We have discovered that the protein FBXO11 is a novel tumor suppressor in B-cells, said senior study author Michele Pagano, MD, the May Ellen and Gerald Jay Ritter Professor of Oncology and Professor of Pathology at NYU Langone Medical Center and a Howard Hughes Medical Institute Investigator. Our new research findings show deletion or mutation of the FBXO11 gene in B-cells may lead to the formation of Diffuse Large B-Cell Lymphoma. Lymphoma is a blood cancer that affects the lymphatic system, the bodys infection and disease-fighting network. DLBCL is the most common type of adult ...
AIMS: To assess the value of flow cytometry (FCM) in the diagnosis and classification of reactive lymphoid hyperplasia and malignant lymphoma by fine needle aspiration (FNA) cytology. METHODS: Forty six fine needle aspirates of lymphoproliferative disorders were examined by FCM as well as routine cytological assessment. An immunoglobulin light chain ratio (LCR) was calculated for clonality analysis. Additional immunophenotyping was performed in 15 cases. RESULTS: All 25 cases of reactive lymphoid hyperplasia were polyclonal by FCM (LCR , 2/1); 17 of 20 cases of B cell non-Hodgkins lymphoma were monoclonal (LCR , 3/1). Analysis of cells based on size facilitated detection of small populations of clonal neoplastic cells. Analysis of CD5, CD10, and CD23 expression by FCM facilitated subclassification of mantle cell lymphoma, small lymphocytic lymphoma, and some lymphomas of follicle centre cell origin. One case of T cell non-Hodgkins lymphoma was correctly classified by FCM. CONCLUSIONS: FNA ...
BACKGROUND: Germinal center-derived B cell lymphomas are tumors of the lymphoid tissues representing one of the most heterogeneous malignancies. Here we characterize the variety of transcriptomic … phenotypes of this disease based on 873 biopsy specimens collected in the German Cancer Aid MMML (Molecular Mechanisms in Malignant Lymphoma) consortium. They include diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), Burkitts lymphoma, mixed FL/DLBCL lymphomas, primary mediastinal large B cell lymphoma, multiple myeloma, IRF4-rearranged large cell lymphoma, MYC-negative Burkitt-like lymphoma with chr. 11q aberration and mantle cell lymphoma. METHODS: We apply self-organizing map (SOM) machine learning to microarray-derived expression data to generate a holistic view on the transcriptome landscape of lymphomas, to describe the multidimensional nature of gene regulation and to pursue a modular view on co-expression. Expression data were complemented by pathological, genetic and ...
In this study we assessed the prognostic significance of absolute monocyte count and elected the best cut-off value at diagnosis, in a large cohort of patients with diffuse large B-cell lymphoma. Data were retrieved for therapy-naive patients with diffuse large B-cell lymphoma followed in Israel and Italy during1993-2010. A final cohort of 1017 patients was analyzed with a median follow up of 48 months and a 5 year overall survival rate of 68%. The best absolute monocyte count cut-off level was, 630/mm3and the 5 years overall survival for these patients was 71% and 59% for those with ,630mm3 (p=0.0002). Of the 1017 patients, 521 (51%) were treated with chemo-immunotherapy, and in this cohort, using multivariate analysis, elevated monocyte counte retained a negative prognostic value even when adjusted for IPI (HR 1.54, P=0.009). This large study shows that a simple parameter like absolute monocyte count (,630 /mm3) can easily be used routinely in the evaluation of newly diagnosed diffuse large ...
Cladribine is a purine nucleoside analog used to treat B-cell chronic lymphocytic leukemia and hairy cell leukemia, also functions as an inhibitor of DNA synthesis to block the repair of the damaged DNA. The therapeutic role of cladribine against diffuse large B-cell lymphoma cells (DLBCL) is still undefined. In the present study, we demonstrated that cladribine inhibited cell proliferation and induced G1 phase arrest in human DLBCL cells. Furthermore, we showed that cladribine induced apoptosis by decreasing the expression of c-FLIPL and increasing the expression of DR4 and the cleaved form of caspase8. Cladribine also upregulated the expression of Bax, and downregulated the expression of Mcl-1 and Bcl-2 in a dose-dependent manner. It also activated endoplasmic reticulum (ER) stress, and ATF4 expression was required for cladribine induced apoptosis. Also, we showed that suberoylanilide hydroxamic acid (SAHA) enhanced the pro-apoptotic role of cladribine. Collectively, cladribine activated ...
We recently demonstrated that the prognosis for de novo CD5-positive (CD5+) diffuse large-B-cell lymphoma (DLBCL) is markedly worse than that for CD5-negative (CD5-) DLBCL. Our findings also suggested that on the basis of its clinical features CD5+ DLBCL may constitute a unique disease category. How …
Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2015 Summary Global Markets Direct s, Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2015, provides...
Site: Primary cardiac lymphoma typically involves the right atrium, as a mass and is often associated with pericardial effusion. Involvement of the other chambers is less common. Most patients have pericardial involvement, but extension into the valves is rare. Reporting of Cardiac Tumours Type of Primary cardiac lymphomas : Non Hodgkins Type: (mostly of B-cell nature) - Low ; Intermediate ; High grade Microscopic diagnosis is based on the same criteria as applied in lymphomas in general. Case Link (NEJM) Cardiac lymphomas demonstrate a wide range of histologic types, including well-differentiated B-cell lymphomas, follicular center cell lymphomas, diffuse large cell lymphomas, and undifferentiated Burkitt-like lymphomas.. The tumour usually infiltrate the surrounding muscle and epicardial fat . In some cases it may infiltrate the adventitia of the coronary arteries.. Reporting of Endomyocardial Biopsy Diagnosis of lymphoma after cardiac transplantation should be done carefully, as there are ...
Radioimmunotherapy treatment with Zevalin® (ibritumomab tiuxetan) is safe and effective in high-risk elderly patients with diffuse large B-cell lymphoma, according to the results of a study published in Clinical Cancer Research. Non-Hodgkins lymphoma (NHL) refers to a group of cancers that originate in different cells of the immune system. Diffuse large B-cell NHL is a common type of NHL that affects immune cells called B-cells; it is considered an aggressive type of NHL.. Standard treatment for DLBCL typically includes R-CHOP, which refers to treatment with the monoclonal antibody Rituxan® (rituxamab) plus cyclophosphamide/Adriamycin/vincristine/prednisone (CHOP). Although this regimen has led to improved outcomes, there is a group of poor-risk patients who need an alternative treatment strategy.. Zevalin is a type of radioimmunotherapy treatment (RIT) that combines the monoclonal antibody Rituxan with Zevalin, which is comprised of an anti-CD20 monoclonal antibody and Yttrium-90, a ...
Mantle cell lymphoma is a mature lymphoid neoplasm characterized by the t(11;14)(q13;q32) and cyclin D1 overexpression. SOX11 is a transcription factor commonly overexpressed in these tumors but absent in most other mature B-cell lymphomas whose function is not well understood. Experimental studies have shown that silencing of SOX11 in mantle cell lymphoma cells promotes the shift from a mature B cell into an early plasmacytic differentiation phenotype, suggesting that SOX11 may contribute to tumor development by blocking the B-cell differentiation program. The relationship between SOX11 expression and terminal B-cell differentiation in primary mantle cell lymphoma and its relationship to the plasmacytic differentiation observed in occasional cases is not known. In this study we have investigated the terminal B-cell differentiation phenotype in 60 mantle cell lymphomas, 41 SOX11-positive and 19 SOX11-negative. Monotypic plasma cells and lymphoid cells with plasmacytic differentiation expressing ...
Introduction: Diffuse large B-cell lymphoma (DLBCL), not otherwise specified, is a large B-cell lymphoma with a diffuse growth pattern and aggressive clinical course. It is divided in subgroups according to its morphology, immunophenotype, and primary site. Dissemination to bone marrow occurs in 11% to 35% of cases and can be of concordant or discordant morphology. Objective: To examine the association, the type of bone marrow involvement in relation to the primary site, morphology, immunohistochemistry of DLBCLs and to determine the cases of Epstein-Barr virus positive DLBCLs. Materials and Methods: We reviewed lymph node and extranodal biopsies as well as the respective bone marrow biopsies in all cases of DLBCL diagnosed in the Hospital General de México during the period from 2002 to 2010. We used immunohystochemistry for immunophenotype identification (Hanss algorithm) and an in-situ hybridization technique to detect presence of Epstein Barr encoded RNA (EBER). Results: We included 108 patients
Addition of rituximab (R) to CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) chemotherapy improved outcome for diffuse large B-cell lymphoma (DLBCL) patients. Approximately 40% of patients who receive R-CHOP still succumb to disease due to intrinsic resistance or relapse. A potential negative regulator of DLBCL treatment outcome is the CD47 dont eat me immune checkpoint. To delineate the impact of CD47, we used a clinically and molecularly well-annotated cohort of 939 DLBCL patients, comprising both germinal center B-cell (GCB) and non-GCB DLBCL subtypes, treated with either CHOP or R-CHOP. High (above median) CD47 mRNA expression correlated with a detrimental effect on overall survival (OS) when DLBCL patients received R-CHOP therapy (P = 0.001), but not CHOP therapy (P = 0.645). Accordingly, patients with low CD47 expression benefited most from the addition of rituximab to CHOP [HR, 0.32; confidence interval (CI), 0.21-0.50; P ,0.001]. This negative impact of high CD47 ...
Global Markets Directs, Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2014, provides an overview of the Diffuse Large B-Cell Lymphomas therapeutic pipeline. This report provides
Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2016SummaryGlobal Markets Directs, Diffuse Large B-Cell Lymphoma - Pipeline Review, H1 2016, provides ...
Kite Pharma has created engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T-cell receptor (TCR), based on the type of cancer.. The companys primary CAR T therapy candidate, axicabtagene ciloleucel (axi-cel), is expected to be the first available treatment for refractory aggressive non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL).. Kite Pharma president, chairman and CEO Dr Arie Belldegrun said: CAR T has the potential to become one of the most powerful anti-cancer agents for hematologic cancers.. Axicabtagene ciloleucel is currently under priority review by the US Food and Drug Administration (FDA).. A marketing authorisation application (MAA) has also been filed with the European Medicines Agency (EMA) for axi-cel for the treatment of relapsed / refractory DLBCL, TFL and PMBCL.. The approval in Europe is expected in 2018.. ...
Arber DA, Simpson JF, Weiss LM, et al. Non-Hodgkins lymphoma involving the breast. Am J Surg Pathol 1994;18:288-95. Jeanneret-Sozzi W, Taghian A, Epelbaum R, et al. Primary breast lymphoma: Patient pro le, outcome and prognostic factors. A multicentre rare cancer network study. BMC Cancer 2008;8:86. Wiseman C, Liao KT. Primary lymphoma of the breast. Cancer 1972;29:1705-12. Brustein S, Filippa DA, Kimmel M, et al. Malignant lymphoma of the breast. A study of 53 patients. Ann Surg 1987;205:144-50. Ganjoo K, Advani R, Mariappan MR, et al. Non-Hodgkin lymphoma of the breast. Cancer 2007;110:25-30. Ryan G, Martinelli G, Kuper-Hommel M, et al. Primary diffuse large B-cell lymphoma of the breast: Prognostic factors and outcomes of a study by the international extranodal lymphoma study group. Ann Oncol 2008;19:233-41. Dawn B, Perry MC. Bilateral non-Hodgkins lymphoma of the breast mimicking mastitis. South Med J 1997;90:328-9. Fukuhara S, Watanabe T, Munakata W, et al. Bulky disease has an impact on ...
TY - JOUR. T1 - IL-25 dampens the growth of human germinal center-derived B-cell non Hodgkin Lymphoma by curtailing neoangiogenesis. AU - Ferretti, Elisa. AU - Di Carlo, Emma. AU - Ognio, Emanuela. AU - Fraternali-Orcioni, Giulio. AU - Corcione, Anna. AU - Belmonte, Beatrice. AU - Ravetti, Jean Louis. AU - Tripodo, Claudio. AU - Ribatti, Domenico. AU - Pistoia, Vito. PY - 2017. Y1 - 2017. N2 - Interleukin (IL)-25, a member of the IL-17 cytokine superfamily, is produced by immune and non-immune cells and exerts type 2 pro-inflammatory effectsin vitroandin vivo. The IL-25 receptor(R) is composed of the IL-17RA/IL-17RB subunits. Previous work showed that germinal centre (GC)-derived B-cell non Hodgkin lymphomas (B-NHL) expressed IL-17AR, formed by IL-17RA and IL-17RC subunits, and IL-17A/IL-17AR axis promoted B-NHL growth by stimulating neoangiogenesis. Here, we have investigated expression and function of IL-25/IL-25R axis in lymph nodes from human GC-derived B-NHL, i.e. Follicular Lymphoma (FL,10 ...
In 27% of diffuse large B cell lymphoma (DLBCL) cases, bone marrow (BM), assessed by BM biopsy, is involved. BM involvement, an extranodal site …
Diffuse large B-cell lymphoma (DLBCL) shows a higher incidence in males versus females. Epidemiological studies have shown that female gender is a favorable prognostic factor, which may be explained by estrogens. Here we show that when grafting human DLBCL cells to immunocompromised mice, tumor growth in males is faster. When treating mice grafted with either germinal center or activated B-cell like DLBCL cells with the selective estrogen receptor β (ERβ) agonist diarylpropionitrile, tumor growth was significantly inhibited. Furthermore, nuclear ERβ1 expression analysis in primary DLBCLs by immunohistochemistry revealed expression in 89% of the cases. Nuclear ERβ1 expression was in a univariate and multivariate analysis, an independent prognostic factor for adverse progression-free survival in Rituximab-chemotherapy treated DLBCL (p = 0.02 and p = 0.04, respectively). These results suggest that estrogen signaling through ERβ1 is an interesting future therapeutic target for treatment of ...
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma and displays heterogeneous clinical and molecular characteristics. In this study, high throughput gene expression profiling of DLBCL tumor samples was used to design a 12-gene expression-based risk score (GERS) predictive for patients overall survival. GERS allowed identifying a high-risk group comprising 46,4% of the DLBCL patients in two independent cohorts (n=414 and n=69). GERS was shown to be an independent predictor of survival when compared to the previously published prognostic factors, including the International Prognostic Index (IPI). GERS displayed a prognostic value in germinal-center B-cell-like subgroup (GCB) and activated B cell-like (ABC) molecular subgroups of patients as well as in DLBCL patients treated with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or Rituximab-CHOP (R-CHOP) regimens. Combination of GERS and IPI lead to a potent prognostic classification of DLBCL patients.
The activated B cell (ABC-like) subtype of diffuse large B cell lymphoma (DLBCL) is characterized by chronic activation of signaling initiated by immunoglobulin μ (IgM). By analyzing the DNA copy number profiles of 1000 DLBCL tumors, we identified gains of 18q21.2 as the most frequent genetic alteration in ABC-like DLBCL. Using integrative analysis of matched gene expression profiling data, we found that the TCF4 (E2-2) transcription factor gene was the target of these alterations. Overexpression of TCF4 in ABC-like DLBCL cell lines led to its occupancy on immunoglobulin (IGHM) and MYC gene enhancers and increased expression of these genes at the transcript and protein levels. Inhibition of TCF4 activity with dominant-negative constructs was synthetically lethal to ABC-like DLBCL cell lines harboring TCF4 DNA copy gains, highlighting these gains as an attractive potential therapeutic target. Furthermore, the TCF4 gene was one of the top BRD4-regulated genes in DLBCL cell lines. BET ...
Non-Hodgkin's lymphoma. Cyclophosphamide, doxorubicin, vincristine, prednisolone. CHOP. Germ cell tumor. Bleomycin, etoposide, ... The most common medications affect mainly the fast-dividing cells of the body, such as blood cells and the cells lining the ... M - mitosis; where the cell divides to produce two daughter cells that continue the cell cycle. ... cells that produce white and red blood cells) are destroyed, meaning allogenic or autologous bone marrow cell transplants are ...
Mantle cell lymphoma Kite Pharma selpercatinib[15] RET fusion-positive non-small cell lung cancer Eli Lilly ... MET exon 14 skipping mutated non-small cell lung cancer Novartis KTE-X19[15] ...
... expansion may be seen in benign, such as Castleman disease, and malignancy, i.e., Mantle cell lymphoma. Tcl-1 is ...
cutaneous T-cell lymphoma (CTCL) Diphtheria toxin engineered protein combining Interleukin-2 and Diphtheria toxin Interleukin-2 ... mammalian cell lines (see cell culture) and plant cell cultures (see plant tissue culture) and moss plants in bioreactors of ... somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy. Biologics can ... banks for reproductive cells are much more widespread and available due to the ease of which spermatozoa and egg cells are able ...
Baron ED, Stevens SR (2003). "Phototherapy for cutaneous T-cell lymphoma". Nih.gov. 16 (4): 303-10. PMID 14686973.. ... cutaneous T-cell lymphoma[15] and lichen planus. Narrowband UVB lamps, 311-313 nanometer is the most common treatment.[16] ... When they sense UV light the cells manufacture the pigment in order to protect the body from the harming UV light. Treatment is ... Photo therapy is an effective treatment because the skin cells manufacture the pigment when they sense UV light. ...
"Diffuse large B-cell lymphoma in Dilma". O Globo (in Portuguese). 25 April 2009. Retrieved 1 November 2010.. ... It was diagnosed as a diffuse large B-cell lymphoma, an intermediate grade type, but her chances of being cured were up to 90 ... There were many people from Minas Gerais in the Rio de Janeiro cell of Colina (including now-former Belo Horizonte mayor ... Rousseff revealed that she was undergoing treatment to remove an early-stage axillar lymphoma, a cancer in the lymphatic system ...
"Mismatch repair gene expression in malignant lymphoproliferative disorders of B-cell origin". Leuk. Lymphoma. 43 (2): 393-9. ... Cell. Biol. 24 (14): 6430-44. doi:10.1128/MCB.24.14.6430-6444.2004. PMC 434232. PMID 15226443. Okada T, Noji S, Goto Y, Iwata T ... Cell Genet. 88 (3-4): 200-1. doi:10.1159/000015546. PMID 10828585. S2CID 84779733. Kondo E, Horii A, Fukushige S (2001). "The ...
"Notch signaling induces cell cycle arrest in small cell lung cancer cells". Cancer Res. 61 (7): 3200-5. PMID 11306509. Shimizu ... Lymphoma. 46 (2): 157-65. doi:10.1080/10428190400010742. PMID 15621797. S2CID 36863790. Stifani S, Blaumueller CM, Redhead NJ, ... Cell. Biol. 20 (18): 6913-22. doi:10.1128/MCB.20.18.6913-6922.2000. PMC 88767. PMID 10958687. Wu L, Aster JC, Blacklow SC, Lake ... Cell. Biol. 18 (4): 2324-33. doi:10.1128/mcb.18.4.2324. PMC 121486. PMID 9528802. Berezovska O, Xia MQ, Hyman BT (1998). "Notch ...
Cell. Biol. 19 (3): 1810-20. doi:10.1128/MCB.19.3.1810. PMC 83974. PMID 10022868. Li W, Nagineni CN, Hooks JJ, Chepelinsky AB, ... Lymphoma. 35 (5-6): 507-11. doi:10.1080/10428199909169615. PMID 10609788. Staal A, Enserink JM, Stein JL, Stein GS, van Wijnen ... Cell. Biol. 19 (3): 1810-20. doi:10.1128/MCB.19.3.1810. PMC 83974. PMID 10022868. Harada H, Taniguchi T, Tanaka N (1999). "The ... Cell. Biol. 14 (2): 1500-9. doi:10.1128/MCB.14.2.1500. PMC 358505. PMID 7507207. Adams MD, Kerlavage AR, Fleischmann RD, ...
Avraham S, Avraham H (1997). "Characterization of the novel focal adhesion kinase RAFTK in hematopoietic cells". Leuk. Lymphoma ... cell adhesion, and osteoclast motility". J. Cell Biol. 152 (1): 181-95. doi:10.1083/jcb.152.1.181. PMC 2193648. PMID 11149930. ... Cell. Biol. 19 (3): 2338-50. doi:10.1128/MCB.19.3.2338. PMC 84026. PMID 10022920. Seabold GK, Burette A, Lim IA, Weinberg RJ, ... Cell. Biol. 19 (3): 2278-88. doi:10.1128/mcb.19.3.2278. PMC 84020. PMID 10022914. Chauhan D, Pandey P, Hideshima T, Treon S, ...
Oldenborg PA (2004). "Role of CD47 in erythroid cells and in autoimmunity". Leuk. Lymphoma. 45 (7): 1319-27. doi:10.1080/ ... SIRPα recognizes CD47, an anti-phagocytic signal that distinguishes live cells from dying cells. CD47 has a single Ig-like ... This interaction negatively controls effector function of innate immune cells such as host cell phagocytosis. SIRPα diffuses ... Oldenborg PA (2013). "CD47: A Cell Surface Glycoprotein Which Regulates Multiple Functions of Hematopoietic Cells in Health and ...
Signalling of FLT3 is important for the normal development of haematopoietic stem cells and progenitor cells. The FLT3 gene is ... Lymphoma. 44 (1): 1-7. doi:10.1080/1042819021000040233. PMID 12691136. S2CID 28533250. Kottaridis PD, Gale RE, Linch DC (2003 ... CD135 is important for lymphocyte (B cell and T cell) development. Two cytokines that down modulate FLT3 activity (& block FLT3 ... used to identify the cell type, stage of differentiation and activity of a cell. In mice, CD135 is expressed on several ...
... homology to other integrins and a possible cell-cell adhesion function". EMBO J. 8 (5): 1361-8. doi:10.1002/j.1460-2075.1989. ... Lymphoma. 24 (5-6): 423-35. doi:10.3109/10428199709055581. PMID 9086434. Porter JC, Hogg N (1999). "Integrins take partners: ... "Galectin-8 binding to integrins inhibits cell adhesion and induces apoptosis". J. Cell Sci. 113 (Pt 13): 2385-97. PMID 10852818 ... Comparison of alpha 4 beta 1 (VLA-4) and alpha 4 beta 7 on the human B cell line JY". J. Biol. Chem. 267 (12): 8366-70. PMID ...
Most immune cells (or leukocytes) secrete TGF-β1. Some T cells (e.g. regulatory T cells) release TGF-β1 to inhibit the actions ... Lymphoma. 43 (1): 51-7. doi:10.1080/10428190210195. PMID 11908736. S2CID 28490341. Schnaper HW, Hayashida T, Hubchak SC, ... It is a secreted protein that performs many cellular functions, including the control of cell growth, cell proliferation, cell ... However, as with other cell types, TGF-β1 can also have the opposite effect on cells of myeloid origin. For example, TGF-β1 ...
"Neutrophil gelatinase B and chemokines in leukocytosis and stem cell mobilization". Leuk. Lymphoma. 43 (2): 233-41. doi:10.1080 ... airway smooth muscle cells and endothelial cells. Endothelial cells store IL-8 in their storage vesicles, the Weibel-Palade ... there are a relatively wide range of cells (endothelial cells, macrophages, mast cells, and keratinocytes) that respond to this ... and thus are the first cells to release IL-8 to recruit other cells. Both monomer and homodimer forms of IL-8 have been ...
Hori Y, Gu X, Xie X, Kim SK (2005). "Differentiation of insulin-producing cells from human neural progenitor cells". PLOS Med. ... Lymphoma. 31 (5-6): 599-608. doi:10.3109/10428199809057620. PMID 9922051. Prévôt D, Voeltzel T, Birot AM, Morel AP, Rostan MC, ... Cell Genet. 73 (1-2): 114-5. doi:10.1159/000134320. PMID 8646877. Ohnishi K, Tobita T, Sinjo K, Takeshita A, Ohno R (1998). " ... Cell. Biol. 21 (21): 7509-22. doi:10.1128/MCB.21.21.7509-7522.2001. PMC 99922. PMID 11585930. Kosaki K, Kosaki R, Suzuki T, ...
Various types of CD30-positive T cell lymphomas[11]. *CD30-positive cases of the NK cell lymphoma, extranodal NK/T-cell ... "Identification of Hodgkin and Sternberg-reed cells as a unique cell type derived from a newly-detected small-cell population". ... "T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor ... CD30 is associated with anaplastic large cell lymphoma. It is expressed in embryonal carcinoma but not in seminoma and is thus ...
... translocation in a patient with diffuse large B-cell lymphoma". Blood. 95 (8): 2719-21. doi:10.1182/blood.V95.8.2719. PMID ... IKZF1 is upregulated in granulocytes, B cells, CD4 and CD8 T cells, and NK cells, and downregulated in erythroblasts, ... In Ikaros knockout mice, T cells but not B cells are generated late in mouse development due to late compensatory expression of ... The dysfunction affects expression in B cells that can lead to deregulation of the BCR signaling during B cell development and ...
"Neutrophil gelatinase B and chemokines in leukocytosis and stem cell mobilization". Leukemia & Lymphoma. 43 (2): 233-41. doi: ... "Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand". Cell. 109 ( ... For example, its increased expression was seen in a metastatic mammary cancer cell line. Gelatinase B plays a central role in ... Lastly, there is significant evidence that Gelatinase B is required for the recruitment of endothelial stem cells, a critical ...
Bruchova-Votavova H, Yoon D, Prchal JT (2010). "miR-451 enhances erythroid differentiation in K562 cells". Leuk Lymphoma. 51 (4 ... "MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells". Mol Cell. 37 (5): 620- ... Godlewski J, Bronisz A, Nowicki MO, Chiocca EA, Lawler S (2010). "microRNA-451: A conditional switch controlling glioma cell ... Cell Biology. 42 (8): 1282-1290. doi:10.1016/j.biocel.2010.01.014. PMID 20083225. Courts, C; Madea, B (Aug 9, 2011). "Specific ...
T-cell leukemia homeobox protein 1 is a protein that in humans is encoded by the TLX1 gene, which was initially named HOX11. ... Lymphoma. 39 (3-4): 241-56. doi:10.3109/10428190009065824. PMID 11342305. S2CID 27407074. Lu M, Zhang N, Ho AD (Jul 1992). " ... Lu M, Gong ZY, Shen WF, Ho AD (Oct 1991). "The tcl-3 proto-oncogene altered by chromosomal translocation in T-cell leukemia ... "Entrez Gene: TLX1 T-cell leukemia homeobox 1". Kennedy MA, Gonzalez-Sarmiento R, Kees UR, Lampert F, Dear N, Boehm T, Rabbitts ...
DNA sequencing of miR-17-92 cluster at chromosome 13q31-q32 in mantel cell lymphoma cell lines]". Zhongguo Shi Yan Xue Ye Xue ... amplification in human mantle cell lymphoma". Leuk Lymphoma. 48 (2): 410-2. doi:10.1080/10428190601059738. PMID 17325905. ... amplification in human mantle cell lymphoma". Leuk Lymphoma. 48 (2): 410-2. doi:10.1080/10428190601059738. PMID 17325905. ... "Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma". Mod ...
Johnston, JB (June 2011). "Mechanism of action of pentostatin and cladribine in hairy cell leukemia". Leukemia & Lymphoma. 52 ... cladribine targets B cells more than T cells. Both HCL and B-cell chronic lymphocytic leukaemia are types of B cell blood ... which causes it to accumulate in cells and interfere with the cell's ability to process DNA. Cladribine is taken up by cells ... the cells with the highest ratios are B cells, especially germinal centre and naive B cells. This again helps to explain which ...
Cell. 128 (2): 257-67. doi:10.1016/j.cell.2006.11.046. PMID 17254965. Yan B, Zemskova M, Holder S, Chin V, Kraft A, Koskinen PJ ... "Increased expression of the hPim-2 gene in human chronic lymphocytic leukemia and non-Hodgkin lymphoma". Leuk. Lymphoma. 45 (5 ... "Increased Expression of the hPim-2 Gene In Human Chronic lymphocytic Leukemia and Non-Hodgkin Lymphoma". Leukemia & Lymphoma. ... PIM2 is expressed with high levels in the brain and lymphoid cells. PIM1-3 compound knockout mice that survived the perinatal ...
... is most frequently found on plasma B cells, followed by natural killer cells, followed by B cells and T cells, and then ... Sidiqi MH, Gertz MA (February 2019). "Daratumumab for the treatment of AL amyloidosis". Leukemia & Lymphoma. 60 (2): 295-301. ... CD31 on endothelial cells binds to the CD38 receptor on natural killer cells for those cells to attach to the endothelium. CD38 ... In 1992 it was additionally described as a surface marker on B cells, monocytes, and natural killer cells (NK cells). About the ...
Allen TD, Zhu YX, Hawley TS, Hawley RG (Oct 2000). "TALE homeoproteins as HOX11-interacting partners in T-cell leukemia". ... Leukemia & Lymphoma. 39 (3-4): 241-56. doi:10.3109/10428190009065824. PMID 11342305. S2CID 27407074. Bonaldo MF, Lennon G, ... "HOXA9 forms triple complexes with PBX2 and MEIS1 in myeloid cells". Molecular and Cellular Biology. 19 (4): 3051-61. doi: ... "HOXA9 forms triple complexes with PBX2 and MEIS1 in myeloid cells". Molecular and Cellular Biology. 19 (4): 3051-61. doi: ...
September 2003). "Interleukin-6, CD45 and the src-kinases in myeloma cell proliferation". Leukemia & Lymphoma. 44 (9): 1477-81 ... B cell isoform of 220 kDa). B220 expression is not restricted to B cells and can also be expressed on activated T cells, on a ... It is the longest protein and migrates at 200 kDa when isolated from T cells. B cells also express CD45R with heavier ... except erythrocytes and plasma cells). CD45 has been shown to be an essential regulator of T- and B-cell antigen receptor ...
CX-5461 activates p53 via nuclear stress and induces apoptosis of leukemia and lymphoma cells while leaving normal cells ... The promise of these drugs is that they leave healthy cell DNA unharmed and specifically target the fact that cancer cells rely ... It has been said that ribosome biogenesis is the "Achilles heel in cancer cells." Nakhoul H, Ke J, Zhou X, et al. (2014). " ... Zhou X, Liao WJ, Liao JM, Liao P, Lu H (2015). "Ribosomal proteins: functions beyond the ribosome". J Mol Cell Biol. 7 (2): 92- ...
"Overexpression of c-Maf contributes to T-cell lymphoma in both mice and human". Cancer Research. 66 (2): 812-9. doi:10.1158/ ... Olbrot M, Rud J, Moss LG, Sharma A (May 2002). "Identification of beta-cell-specific insulin gene transcription factor RIPE3b1 ... DePianto DJ, Blankenship TN, Hess JF, FitzGerald PG (Jun 2003). "Analysis of non-crystallin lens fiber cell gene expression in ... Cousins DJ, Lee TH, Staynov DZ (Sep 2002). "Cytokine coexpression during human Th1/Th2 cell differentiation: direct evidence ...
Sun L, Kerawalla H, Wu X, Lehnert MS, Uckun FM (Apr 2002). "Expression of a unique helios isoform in human leukemia cells". ... Leukemia & Lymphoma. 43 (4): 841-9. doi:10.1080/10428190290016980. PMID 12153174. S2CID 8170745. Durand C, Kerfourn F, ... Immunology and Cell Biology. 81 (3): 171-5. doi:10.1046/j.1440-1711.2003.01159.x. PMID 12752680. S2CID 43733744. Sridharan R, ... a T cell-restricted Ikaros family member that quantitatively associates with Ikaros at centromeric heterochromatin". Genes & ...
The Lymphomas (PDF). The Leukemia & Lymphoma Society: 2. May 2006 [2008-04-07]. (原始内容 (PDF)存档于2008-07-06).. 已忽略未知参数. ,url- ... T Cells to protect tumour cells. Nature Communications. March 2018, 9 (1): 948. PMC 5838096. PMID 29507342. doi:10.1038/s41467- ... 细胞毒性T细胞(CTLs, killer T cells)负责杀伤被病毒感染的细胞和癌细胞,在对器官移植的免疫排斥中也有参与。其特点在于细胞表面的CD8蛋白质。
"Blood Cells Mol. Dis. 39 (3): 336-9. doi:10.1016/j.bcmd.2007.06.009. PMC 2387274. PMID 17698380.. ... Lymphoma. 50 (6): 1043-6. doi:10.1080/10428190902913591. PMID 19391034.. *. Meester-Smoor MA, Janssen MJ, Grosveld GC, et al. ( ... Cell. Proteomics. 7 (3): 499-508. doi:10.1074/mcp.M700325-MCP200. PMID 18029348.. ... 2009). "Meningioma 1 gene is differentially expressed in CD34 positive cells from bone marrow of patients with myelodysplastic ...
B. C. Giovanella u. a.: Development of invasive tumors in the nude mouse after injection of cultured human melanoma cells. In: ... C. O. Povlsen, J. Rygaard: Effects of Cyclophosphamide (Endoxan R) on a Burkitt´s Lymphoma serially grown in nude mice. In: ... L. Miers u. a.: Implantation of different malignant human cell lines in an athymic mouse does not alter success and growth ... T. Devos u. a.: Occurrence of autoimmunity after xenothymus transplantation in T-cell-deficient mice depends on the thymus ...
... particularly in Hodgkin's lymphoma, non-Hodgkin lymphoma, and lung cancer.[citation needed] ... This tracer is a glucose analog that is taken up by glucose-using cells and phosphorylated by hexokinase (whose mitochondrial ... This means that FDG is trapped in any cell that takes it up until it decays, since phosphorylated sugars, due to their ionic ... PET in the management of patients with non-small-cell lung cancer (NSCLC). Journal of Experimental & Clinical Cancer Research ...
... is superior to CHOP alone in the treatment of diffuse large B-cell lymphoma and many other B-cell lymphomas.[44] In 2010 it was ... cells in destroying these B cells. When an NK cell latched onto the cap, it had an 80% success rate at killing the cell. In ... The antibody binds to the cell surface protein CD20. CD20 is widely expressed on B cells, from early pre-B cells to later in ... Rituximab is used to treat cancers of the white blood system such as leukemias and lymphomas, including non-Hodgkin's lymphoma ...
... treated with stem cell transplants include sickle-cell disease, myelodysplastic syndrome, neuroblastoma, lymphoma, Ewing's ... Peripheral blood stem cells[26] are now the most common source of stem cells for HSCT. They are collected from the blood ... Sources and storage of cells[edit]. To limit the risks of transplanted stem cell rejection or of severe graft-versus-host ... Hematopoietic stem cell transplantation (HSCT) is the transplantation of multipotent hematopoietic stem cells, usually derived ...
It has received regulatory approval for use as a treatment for non-small cell lung cancer,[6][4][7][8] although there is ... Leukemia/lymphoma. *lymphoid: CD20 (Ibritumomab. *Obinutuzumab. *Ofatumumab. *Rituximab. *Tositumomab), CD30 (Brentuximab), ... Afatinib, sold under the brand name Gilotrif among others, is a medication used to treat non-small cell lung carcinoma (NSCLC). ... May 2012). "Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of ...
Lymphoma 43 (7): 1367-73. PMID 12389615. doi:10.1080/10428190290033297. *Zhou T, Zhang J, Carter R, Kimberly R (2003). "BLyS ... Brink R (2007). "Regulation of B cell self-tolerance by BAFF.". Semin. Immunol. 18 (5): 276-83. PMID 16916609. doi:10.1016/j. ... Mackay F, Leung H (2007). "The role of the BAFF/APRIL system on T cell function.". Semin. Immunol. 18 (5): 284-9. PMID 16931039 ... Tangye SG, Bryant VL, Cuss AK, Good KL (2007). "BAFF, APRIL and human B cell disorders.". Semin. Immunol. 18 (5): 305-17. PMID ...
Primary central nervous system lymphoma, Sphenoid wing meningioma, Subependymal giant cell astrocytoma, Subependymoma, ... Anaplastic cells have lost total control of their normal functions and many have deteriorated cell structures. Anaplastic cells ... Necrotic cells send the wrong chemical signals which prevent phagocytes from disposing of the dead cells, leading to a buildup ... Glial cells such as Schwann cells in the periphery or, within the cord itself, oligodendrocytes, wrap themselves around the ...
... or tumors such as lymphoma or squamous cell carcinoma. A tonsillolith (also known as a "tonsil stone") is material that ... These M cells then alert the underlying B cells and T cells in the tonsil that a pathogen is present and an immune response is ... The tonsils have on their surface specialized antigen capture cells called M cells that allow for the uptake of antigens ... "Tonsils Make T-Cells, Too, Ohio State Study Shows". Ohio State University. Ohio State University, Comprehensive Cancer Center. ...
Cells, circulating tumor cells (CTCs), or formalin-fixed paraffin-embedded (FFPE) or frozen tissue sections are fixed, then ... such as translocations and inversions which are hallmark aberrations seen in many types of leukemia and lymphoma. ... FISH can also be used to detect diseased cells more easily than standard Cytogenetic methods, which require dividing cells and ... "Defining the sister rat mammary tumor cell lines HH-16 cl.2/1 and HH-16.cl.4 as an in vitro cell model for Erbb2". PLOS ONE. 7 ...
"Molecular Cell. 68 (1): 130-143.e5. doi:10.1016/j.molcel.2017.08.016. PMC 5632562. PMID 28918903.. ... "Letter: Chemotherapy of advanced histocytic lymphomas". Lancet. 1 (7916): 6300-3. doi:10.1016/s0140-6736(75)92521-0. PMC 49488 ... In specific cell types or on specific promoters TBP can be replaced by one of several TBP-related factors (TRF1 in Drosophila, ... Compounds that trap the protein-DNA intermediate could result in it being toxic to the cell once they encounter a DNA ...
"Cell. 171 (3): 522-539.e20. doi:10.1016/j.cell.2017.08.032. ISSN 0092-8674.. ... Principal cancer types under study: breast, prostate, blood (leukemia, lymphoma); melanoma; liver; ovarian and cervical; lung; ... Plant genome sequencing; epigenetics and stem cell fate; stem cell signaling; plant-environment interactions; using genetic ... Cell biology and genomics. RNA interference (RNAi) and small-RNA biology; DNA replication; RNA splicing; signal transduction; ...
Hodgkin's lymphoma. Follicular dendritic cell sarcoma. Extranodal NK/T-cell lymphoma, nasal type. MCPyV Merkel-cell carcinoma. ... For example, JCV has been found to infect the granule cell layer of the cerebellum, while sparing purkinje fibers, ultimately ... Immunohistochemical detection of JC virus protein (stained brown) in a brain biopsy (glial cells demonstrating progressive ... and can also infect the tubular epithelial cells in the kidneys,[7] where it continues to reproduce, shedding virus particles ...
Lymphoma. M. *Macmillan Cancer Support. *Male breast cancer. *Melanoma. *Merkel-cell carcinoma ...
B-cell lymphoma - B cells - B lymphocytes (B cells) - bactericidal - bacteriostatic - bacterium - baculovirus - baseline - ... T suppressor cells - T4 cell - T4 cells (T-helper cells) - T8 cells - Tanner staging - TAT - TB - template - TeachAIDS - ... cells - CDC National Prevention Information Network (CDC-NPIN) - cell lines - cell-mediated immunity (CMI) - cellular immunity ... NK cell - NLM - NNRTI - non-Hodgkin's lymphoma (NHL) - non-nucleoside reverse transcriptase inhibitors (NNRTI) - non-steroidal ...
Of the various tumors of the blood and lymph, cancers of WBCs can be broadly classified as leukemias and lymphomas, although ... T cells: *CD4+ helper T cells: T cells displaying co-receptor CD4 are known as CD4+ T cells. These cells have T-cell receptors ... B cells: releases antibodies and assists activation of T cells. *T cells: *CD4+ Th (T helper) cells: activate and regulate T ... Natural killer cells: virus-infected and tumor cells.. Deeply staining, eccentric. NK-cells and cytotoxic (CD8+) T-cells. Years ...
cell volume homeostasis. • nucleocytoplasmic transport. • protein localization. • positive regulation of cell proliferation. • ... 2007). «Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias.». Haematologica. 92 (4 ... J Cell Biol. 183 (4): 589-95. PMC 2582899. . PMID 19015314. doi:10.1083/jcb.200807185. !CS1 manut: Uso explícito de et al. ( ... Cell. Biol. 11 (5): 2567-75. PMC 360026. . PMID 2017166. !CS1 manut: Uso explícito de et al. (link) !CS1 manut: Nomes múltiplos ...
... cell responses to mitogens and allogeneic cells, cytokine production by cells Tests for B cell function: antibodies to routine ... such as lymphoma). The nature of the infections, as well as the additional features, may provide clues as to the exact nature ... natural killer cells and monocytes (CD15+), as well as activation markers (HLA-DR, CD25, CD80 (B cells). Tests for T cell ... Normal numbers of B cells with decreased IgG and IgA and increased IgM: Hyper-IgM syndromes Normal numbers of B cells with ...
It is widely used in PUVA (psoralen + UVA) treatment for psoriasis, eczema, vitiligo, and cutaneous T-cell lymphoma; these ... Escherichia coli cells deficient in HRR are highly sensitive to PUVA compared to wild-type cells.[22] HRR appears to be ... "Cell. 165 (5): 1267-1279. doi:10.1016/j.cell.2016.04.028. PMC 5029792. PMID 27180905.. ... In E. coli, even though one or two unrepaired crosslinks are sufficient to inactivate a cell, a wild-type cell can repair and ...
"Post-chemotherapy cognitive impairment in patients with B-cell non-Hodgkin lymphoma: a first comprehensive approach to ... cell-cell signaling. • positive regulation of brain-derived neurotrophic factor receptor signaling pathway. • collateral ... regulation of protein localization to cell surface. • regulation of receptor activity. • activation of phospholipase C activity ... BDNF binds at least two receptors on the surface of cells that are capable of responding to this growth factor, TrkB ( ...
Mendenhall WM, Olivier KR, Lynch JW, Mendenhall NP (April 2006). "Lethal midline granuloma-nasal natural killer/T-cell lymphoma ... a type of white blood cell) are associated with GPA.[11] Involvement of the ears, nose, and throat is more common in ... and many giant cells.[16] Bacterial colonization with Staphylococcus aureus has been hypothesized as an initiating factor of ... and decreases the incidence of abnormally low white blood cell counts by one-third.[8] However, pulsed intravenous ...
"Apoptotic cells in allogeneic hematopoietic stem cell transplantations: "turning trash into gold"". Leukemia & Lymphoma. 53 (11 ... be rejected by the body and biological functions such as cell adhesion and growth will be enhanced through cell-cell and cell- ... "CD46 on glial cells can function as a receptor for viral glycoprotein-mediated cell-cell fusion". Glia. 52 (3): 252-8. doi: ... Olfactory ensheathing cells (OECs), also known as olfactory ensheathing glia or olfactory ensheathing glial cells, are a type ...
2003). "Neutrophil gelatinase B and chemokines in leukocytosis and stem cell mobilization". Leuk. Lymphoma 43 (2): 233-41. PMID ... Yuan A, Chen JJ, Yao PL, Yang PC (2006). "The role of interleukin-8 in cancer cells and microenvironment interaction". Front. ... human venular endothelial cells store interleukin 8 in Weibel-Palade bodies". J. Exp. Med. 188 (9): 1757-62. PMC 2212526. PMID ... "Rapid secretion of prestored interleukin 8 from Weibel-Palade bodies of microvascular endothelial cells". J. Exp. Med. 188 (9 ...
Mantle cell lymphoma/Multiple myeloma t(11 CCND1:14 IGH). *Anaplastic large-cell lymphoma t(2 ALK;5 NPM1) ... The 46/47 annotation indicates that the XY cells have the normal number of 46 total chromosomes, and the XXY cells have a total ... After further rounds of replication, this cell would result in a patch, or "clone" of cells mutant for the allele being studied ... they can be used to determine the tissue or cell type in which a given gene is required and to determine whether a gene is cell ...
Lymphoma 43 (3): 635-9. PMID 12002771. doi:10.1080/10428190290012182. *Marie PJ, Debiais F, Haÿ E (2003). "Regulation of human ... anat (c/f/k/f, u, t/p, l)/phys/devp/cell ... protein receptor complexes on the surface of live cells: a new ... Kawamura C, Kizaki M, Ikeda Y (2003). "Bone morphogenetic protein (BMP)-2 induces apoptosis in human myeloma cells.". Leuk. ... Cell 11 (3): 1023-35. PMC 14828. PMID 10712517. doi:10.1091/mbc.11.3.1023. ...
Iijima S, Teraoka H, Date T, Tsukada K (1992). "DNA-activated protein kinase in Raji Burkitt's lymphoma cells. Phosphorylation ... Cell Genet. 57 (2-3): 109-11. PMID 1914517. doi:10.1159/000133124. CS1 održavanje: Eksplicitna upotreba et al. (link) ... Dang CV, O'donnell KA, Juopperi T (2005). "The great MYC escape in tumorigenesis". Cancer Cell 8 (3): 177-8. PMID 16169462. doi ... 2002). "EBV regulates c-MYC, apoptosis, and tumorigenicity in Burkitt's lymphoma". Curr. Top. Microbiol. Immunol. 258: 153-60. ...
... looks for the presence of red blood cells, white blood cells, or bacteria. Urine culture is deemed positive if it shows a ... Multiple white cells seen in the urine of a person with a urinary tract infection using a microscopy. ... Multiple bacilli (rod-shaped bacteria, here shown as black and bean-shaped) shown between white blood cells in urinary ... In those who have bacteria or white blood cells in their urine but have no symptoms, antibiotics are generally not needed,[14] ...
Schenkein D (June 2002). "Proteasome inhibitors in the treatment of B-cell malignancies". Clinical Lymphoma. 3 (1): 49-55. doi: ... "Cell. 137 (1): 133-45. doi:10.1016/j.cell.2009.01.041. PMC 2668214. PMID 19345192.. ... Cell cycle controlEdit. Cell cycle progression is controlled by ordered action of cyclin-dependent kinases (CDKs), activated by ... Apoptosis is mediated through disrupting the regulated degradation of pro-growth cell cycle proteins.[88] However, some cell ...
Anaplastic large-cell lymphoma is an example of a large-cell lymphoma that involves T cells. Of the large-cell T-cell lymphomas ... B cell[edit]. Diffuse large B-cell lymphoma is the most common of the large-cell lymphomas. MeSH now classifies the phrase " ... which are often diffuse large-B-cell lymphomas. Activated B-Cell Diffuse Large B-Cell Lymphoma, or ABC-DLBCL, is believed to be ... Other groups of lymphomas in this system are the small-cell lymphomas and mixed-cell lymphomas. ...
Anaplastic large-cell lymphoma (ALCL) is a form of cancer. It is a type of non-Hodgkin lymphoma involving aberrant T cells or ... The cells are also typically positive for a subset of markers of T-cell lineage. However, as with other T-cell lymphomas, they ... It has been suggested that ALK-negative anaplastic large-cell lymphomas derive from other T-cell lymphomas that are morphologic ... Other mimics include CD30 positive B-cell lymphomas with anaplastic cells (including Hodgkin lymphomas). These are identified ...
... is a form of non-Hodgkins lymphoma. The prognosis of MCL is poor because patients are typically diagnosed in stage IV. Read ... Mantle cell lymphoma (MCL) is a relatively rare type of cancer of the lymphoid cells; it is termed mantle cell lymphoma because ... home/cancer health center/cancer a-z list/mantle cell lymphoma mcl center /mantle cell lymphoma (mcl) article ... Mantle cell lymphoma (MCL) is a relatively rare cancer of the lymphoid cells that arises from the outer rim or mantle lymphoid ...
it gets its name because the cancer cells spread out (diffuse) all over the lymph node. ... diffuse b-cell lymphoma is a type of non-hodgkins lymphoma. ... "Types of B-Cell Lymphoma," "Types of T-Cell Lymphoma," "What is ... "Adult T-Cell Lymphoma," "Anaplastic Large Cell Lymphoma," "Diffuse Large B-Cell Lymphoma," "Follicular Lymphoma," "Mantle Cell ... "Adult T-Cell Lymphoma," "Anaplastic Large Cell Lymphoma," "Diffuse Large B-Cell Lymphoma," "Follicular Lymphoma," "Mantle Cell ...
If you have mantle cell lymphoma, youll likely see a variety of specialists like hematologists, oncologists, and social ... American Society of Hematology Clinical News: "Understanding Mantle Cell Lymphoma.". Joshua Brody, MD, director, lymphoma ... A hematologist may also be the specialist who does stem cell therapy for mantle cell lymphoma. ... After you get a diagnosis of mantle cell lymphoma, youll likely need a few imaging tests, such as a chest X-ray, body CT scan ...
Relapsed mantle cell lymphoma patients may benefit from CAR T-cell therapy A one-year follow-up study led by The University of ... Tumor cell-based vaccine may prevent relapse of mantle cell lymphoma A phase I/II clinical trial by researchers at Stanford ... First CAR T-cell therapy for mantle cell lymphoma receives FDA approval Todays Food and Drug Administration approval of the ... Majority of patients with mantle cell lymphoma may benefit from CAR T-cell therapy KTE-X19 A one-year follow-up study led by ...
Most (ie, 80-90%) NHLs are of B-cell origin. ... Non-Hodgkin lymphoma (NHL) is a collective term for a ... encoded search term (B-Cell Lymphoma) and B-Cell Lymphoma What to Read Next on Medscape. Related Conditions and Diseases. * ... Diffuse large B-cell non-Hodgkin lymphoma. Large cells with abundant cytoplasm and large round-ovoid nuclei with thick nuclear ... Mantle cell lymphoma. Small lymphoid cells with oval to slightly irregular nuclei and clumped chromatin and rare admixed pink ...
... ,ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory ... Leukemia/Lymphoma Phenotyping (Comprehensive-Bone Marrow). 2. Leukemia/Lymphoma Phenotyping (Comprehensive - Miscellaneous). 3 ...
... large B-cell lymphoma Primary mediastinal (thymic) large B-cell lymphoma (PMLBCL) is a diffuse large B-cell lymphoma (DLBCL) of ... Primary mediastinal (thymic) large B-cell lymphoma (PMLBCL) is a diffuse large B-cell lymphoma (DLBCL) of putative thymic ... Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell ... Olteanu H. (2018) B-Cell Lymphoma, Mediastinal, Diffuse, and Large. In: Allen T.C., Suster S. (eds) Pathology of the Pleura and ...
The proteins are markers that may help diagnose leukemia or lymphoma. ... B-cell leukemia/lymphoma panel is a blood test that looks for certain proteins on the surface of white blood cells called B- ... B-cell leukemia/lymphoma panel is a blood test that looks for certain proteins on the surface of white blood cells called B- ... In some cases, white blood cells are removed during a bone marrow biopsy. The sample may also be taken during a lymph node ...
... and symptoms of breast implant-associated anaplastic large cell lyphoma (ALCL). The U.S. FDA recently reported that theres an ... The cancer, known as anaplastic large cell lymphoma (or ALCL), is a rare type of non-Hodgkins lymphoma (cancer of the cells ... What is anaplastic large cell lymphoma (ALCL)?. A rare type of cancer has been reported in people with breast implants. ... Breast Implant-Associated Anaplastic Large Cell Lymphoma (ALCL). *Medical Author: Melissa Conrad Stöppler, MD ...
... pathophysiology and management of primary central nervous system lymphoma, an aggressive non-Hodgkin lymphoma. ... Risk of Anaplastic Large-Cell Lymphoma (ALCL) in Cases of Late Seroma Formation After Breast Implant Insertion ... Background: Primary central nervous system lymphoma is a rare, malignant non-Hodgkin lymphoma that can arise in the brain, ... To the best of our knowledge, this is the first reported case of a patient with primary central nervous system lymphoma ...
... pathophysiology and management of primary central nervous system lymphoma, an aggressive non-Hodgkin lymphoma. ... Background: Primary central nervous system lymphoma is a rare, malignant non-Hodgkin lymphoma that can arise in the brain, ... To the best of our knowledge, this is the first reported case of a patient with primary central nervous system lymphoma ... Primary central nervous system lymphoma is rare, accounting for 2-6% of all primary brain neoplasms and 1-2% of all non-Hodgkin ...
For lymphomas in general, the skin is actually the second most common extranodal... ... Cutaneous T-cell lymphoma is a term that was created in 1979 at an international workshop sponsored by the National Cancer ... encoded search term (Cutaneous T-Cell Lymphoma) and Cutaneous T-Cell Lymphoma What to Read Next on Medscape. Related Conditions ... Cutaneous T-cell lymphomas are T-cell proliferative disorders. Primary cutaneous lymphomas require distinction from ...
H. D. Foss, I. Anagnostopoulos, I. Araujo et al., "Anaplastic large-cell lymphomas of T-cell and null-cell phenotype express ... "Anaplastic large cell lymphoma: one or more entities among T-cell lymphoma?" Hematological Oncology, vol. 27, no. 4, pp. 161- ... "Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor ... "Cytotoxic cell antigen expression in anaplastic large cell lymphomas of T- and null-cell type and Hodgkins disease: evidence ...
Cutaneous B-cell lymphoma. Cutaneous B-cell lymphoma is a rare type of skin cancer that may form as a nodule that appears the ...
... page provides information about a possible association between breast implants and the development of anaplastic large cell ... lymphoma (ALCL), a rare type of non-Hodgkins lymphoma. ... Anaplastic Large Cell Lymphoma (ALCL) In Women with Breast ... designated breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) as a T-cell lymphoma that can develop following ... Review data from the Patient Registry and Outcomes for Breast Implants and Anaplastic Large Cell Lymphoma (ALCL) Etiology and ...
Cutaneous T cell lymphoma (CTCL) is a non-Hodgkin lymphoma of skin-homing T lymphocytes. We performed exome and whole-genome ... Genomic landscape of cutaneous T cell lymphoma.. Choi J1,2, Goh G3,4, Walradt T1, Hong BS1, Bunick CG1, Chen K1, Bjornson RD5, ... g) IL-2 production from Jurkat cells transduced with WT CD28 or CD28 (p.Phe51Val). Jurkat cells were stimulated with phorbol ... e-f) Binding of CD86-Fc to 293T cells stably transduced with human wild-type (WT) CD28, (e) CD28 (p.Phe51Val), or (f) CD28 (p. ...
... is a subtype of peripheral T-cell lymphoma with a poor prognosis: the 5-year survival rate is approximately 30%. Somatic driver ... Angioimmunoblastic T-cell lymphoma (AITL) is a subtype of peripheral T-cell lymphoma with a poor prognosis: the 5-year survival ... of another peripheral T-cell lymphoma, adult T-cell lymphoma. If validated, our findings would provide new insight into the ... present in T cells or B cells shows differential effects on hemophagocytic symptoms associated with outcome in T-cell lymphomas ...
... is a group of lymphomas that affect the skin. Learn about the symptoms of the different types and treatments for CTCL. ... Cutaneous T-cell lymphoma. Cutaneous T-cell lymphoma (CTCL) is an uncommon type of non-Hodgkin lymphoma (NHL). CTCL is a cancer ... Types of cutaneous T-cell lymphoma. CTCL is not one disease. It is a group of different T-cell lymphomas that affect the skin. ... Cancer information / Cancer types / Non-Hodgkin lymphoma / Non-Hodgkin lymphoma / More types of NHL / Cutaneous T-cell lymphoma ...
NCCN Guidelines for Patients® , Mantle Cell Lymphoma. 52 NCCN Guidelines for Patients ® : Mantle Cell Lymphoma, 2017 5 Making ... At support groups, you can ask questions and hear about the experiences of other people with lymphoma. Find a support group at ...
Mantle Cell Lymphoma. 45 NCCN Guidelines for Patients ® : Mantle Cell Lymphoma, 2017 Review Treatment options for mantle cell ... If your body can endure severe side effects, you may receive immunochemotherapy followed by a stem cell transplant. During and ... lymphoma are based on the cancer stage and your health. For stage I and limited stage II cancers, options for first-line ...
Hepatosplenic T-cell lymphoma (HSTL, or HSTCL) is very rare. Sometimes it develops in people whose immune system isnt working ... Hepatosplenic T-cell lymphoma. Hepatosplenic T-cell lymphoma (HSTL, or HSTCL) is a very rare T-cell lymphoma. It may also be ... Cancer information / Cancer types / Non-Hodgkin lymphoma / Non-Hodgkin lymphoma / More types of NHL / Hepatosplenic T-cell ... Stem cell transplant. Some people with HSTL may be offered a stem cell transplant after chemotherapy. ...
The first step in treating mantle cell lymphoma is usually chemotherapy. After chemo, your doctor may recommend additional ... How is mantle cell lymphoma usually treated?. If you have mantle cell lymphoma (MCL) thats growing quickly or causing symptoms ... If you have a mantle cell lymphoma diagnosis, you might wonder what makes it different from other types of lymphoma. Learn the ... Many people with mantle cell lymphoma respond to treatment and go into remission, but the condition has high rates of relapse. ...
The Emerging Role of Immunotherapy in the Treatment of Lymphoma. *Life with Graft vs. Host Disease (GVHD) Post Allogeneic Stem ... Attending Physician, Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Professor of Clinical ... Progress in the Treatment of Non-Hodgkin Lymphoma (NHL). * ... Update on Diffuse Large B-Cell Lymphoma. *Update on Diffuse ...
... a cancer that is a type of non-Hodgkins lymphoma, affects the white blood cells, which are cells that respond to infections in ... What Is the Prognosis for Mantle Cell Lymphoma?. A: With mantle cell lymphoma, which is a type of non-Hodgkin lymphoma, 69 ... Mantle cell lymphoma, a cancer that is a type of non-Hodgkins lymphoma, affects the white blood cells, which are cells that ... a protein which controls the growth of cells. This increase causes mantle cell lymphoma by making a particular type of B-cell ...
Its important to weigh the risks and benefits of stem cell transplantation with your doctor as you consider your treatment ... Allogeneic Stem Cell Transplantation. *Download or order The Leukemia & Lymphoma Societys free booklet, Blood and Marrow Stem ... Allogeneic stem cell transplantation (infusion of donor stem cells into a patient) is the best-documented curative treatment ... The Leukemia & Lymphoma Society is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest ...
mantle cell lymphoma. Posted by alexandra_k on April 25, 2021, at 0:15:33 ... Re: mantle cell lymphoma alexandra_k 4/25/21. *Re: mantle cell lymphoma alexandra_k 4/26/21 ...
Patient also has a hx of non-Hodgkins lymphoma. I appreciate any ideas how t ... invasive B-cell lymphoma of L4-L5 spine. ... large B-cell lymphoma (C85.2-). mature T/NK-cell lymphomas (C84 ... Code Name: ICD-10 Code for Diffuse large B-cell lymphoma, unspecified site. Block: Diffuse large B-cell lymphoma, unspecified ... Patient also has a hx of non-Hodgkins lymphoma.. I appreciate any ideas how to code invasive B-cell lymphoma of L4-L5 spine.. ...
Low Grade B Cell Lymphoma: What Does It Mean? The diagnosis of a low grade B cell lymphoma is both a specific and a non- ... B-Cell Lymphoma Types: In-Depth List of Lymphoma Classifications A B cell is a type of lymphocyte that produces antibodies to ... Renal Lymphoma: Treatment and Prognosis This entry looks renal lymphoma, also known as primary renal lymphoma (PRL), one of the ... Reprogramming Lymphoma Cells to Respond to Therapy In a phase I clinical trial, researchers say they were able to reprogram ...
  • Mantle cell lymphoma (MCL) is a relatively rare cancer of the lymphoid cells that arises from the outer rim or mantle lymphoid follicle. (medicinenet.com)
  • What is mantle cell lymphoma (MCL)? (medicinenet.com)
  • it is termed mantle cell lymphoma because the cancer cells (lymphoma cells) arise from the outer rim or mantle of lymphoid cells that surround a lymphoid follicle. (medicinenet.com)
  • What causes mantle cell lymphoma? (medicinenet.com)
  • What are risk factors for mantle cell lymphoma? (medicinenet.com)
  • What are signs and symptoms of mantle cell lymphoma? (medicinenet.com)
  • Leukaemia Foundation: "Adult T-Cell Lymphoma," "Anaplastic Large Cell Lymphoma," "Diffuse Large B-Cell Lymphoma," "Follicular Lymphoma," "Mantle Cell Lymphoma," "Non-Hodgkin Lymphoma," "Peripheral T-cell Lymphoma. (webmd.com)
  • If you have mantle cell lymphoma, you'll likely see a variety of experts who will figure out the stage of your cancer, come up with a treatment plan, and help you manage side effects. (webmd.com)
  • A hematologist-oncologist is an expert in treating blood cancers, including mantle cell lymphoma. (webmd.com)
  • A hematologist may also be the specialist who does stem cell therapy for mantle cell lymphoma. (webmd.com)
  • This specialist will likely be the one who helps diagnose your mantle cell lymphoma by doing a lymph node biopsy -- a procedure that removes a small piece of one of these organs to check for cancer cells. (webmd.com)
  • If you've had a biopsy, they're likely the one who will look at the sample under a microscope to check for signs of mantle cell lymphoma. (webmd.com)
  • After you get a diagnosis of mantle cell lymphoma, you'll likely need a few imaging tests, such as a chest X-ray, body CT scan, PET scan, bone scan, MRI, or ultrasound. (webmd.com)
  • The U.S. Food and Drug Administration granted accelerated approval for brexucabtagene autoleucel (TECARTUS™, formerly KTE-X19) as the first and only CAR T-cell therapy for patients with mantle cell lymphoma (MCL) relapsed or refractory to prior treatments. (news-medical.net)
  • Today's Food and Drug Administration approval of the first CAR T-cell therapy for mantle cell lymphoma represents a key advance for patients with relapsed or treatment-resistant forms of the disease, say Dana-Farber Cancer Institute investigators who helped conduct the decisive clinical trial of the therapy. (news-medical.net)
  • A phase I/II clinical trial by researchers at Stanford University suggests that vaccines prepared from a patient's own tumor cells may prevent the incurable blood cancer mantle cell lymphoma (MCL) from returning after treatment. (news-medical.net)
  • A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric antigen receptor (CAR) T-cell therapy. (news-medical.net)
  • A study at The University of Texas MD Anderson Cancer Center demonstrated how a small molecule drug discovered at the institution may help overcome resistance to treatment with ibrutinib in patients with mantle cell lymphoma. (news-medical.net)
  • A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. (medscape.com)
  • 52 NCCN Guidelines for Patients ® : Mantle Cell Lymphoma, 2017 5 Making treatment decisions Deciding between options Deciding between options Deciding which option is best can be hard. (nccn.org)
  • 45 NCCN Guidelines for Patients ® : Mantle Cell Lymphoma, 2017 Review Treatment options for mantle cell lymphoma are based on the cancer stage and your health. (nccn.org)
  • What's After Chemo for Mantle Cell Lymphoma? (healthline.com)
  • How is mantle cell lymphoma usually treated? (healthline.com)
  • If you have mantle cell lymphoma (MCL) that's growing quickly or causing symptoms, your doctor will likely prescribe chemotherapy medications to treat it. (healthline.com)
  • Mantle cell lymphoma, a cancer that is a type of non-Hodgkin's lymphoma, affects the white blood cells, which are cells that respond to infections in the body, according to WebMD. (reference.com)
  • Mantle cell lymphoma is specific to the type of white blood cells called lymphocytes. (reference.com)
  • When some of the lymphocytes known as "B-cell" lymphocytes become cancerous and begin to grow uncontrollably, this is called mantle cell lymphoma. (reference.com)
  • In many cases, this happens before someone is even diagnosed with mantle cell lymphoma. (reference.com)
  • The exact cause of mantle cell lymphoma is unknown as of 2015, but it is thought that most people who contract this condition have a genetic mutation that affects the B-cell lymphocytes by triggering the release of a surplus of cyclin D1, a protein which controls the growth of cells. (reference.com)
  • This increase causes mantle cell lymphoma by making a particular type of B-cell grow uncontrollably. (reference.com)
  • What Is the Prognosis for Mantle Cell Lymphoma? (reference.com)
  • Mantle cell lymphoma (MCL) is a rare form of blood cancer belonging to the disease group classified as non-Hodgkin's lymphoma. (mdanderson.org)
  • Only 3-6% of all non-Hodgkin's lymphoma cases in the United States are mantle cell lymphoma, which forms in the lymph node region known as the mantle zone. (mdanderson.org)
  • The FDA approved zanubrutinib to treat patients with mantle cell lymphoma, an aggressive type of non-Hodgkin lymphoma. (aacr.org)
  • The U.S. Food and Drug Administration (FDA) recently approved the molecularly targeted therapeutic zanubrutinib (Brukinsa) for the treatment of adult patients who have mantle cell lymphoma that has progressed despite at least one prior treatment. (aacr.org)
  • Mantle cell lymphoma is a rare and aggressive form of non-Hodgkin lymphoma . (aacr.org)
  • July 24, 2020 - The U.S. Food and Drug Administration (FDA) approved the use of the chimeric antigen receptor (CAR) T cell therapy brexucabtagene autoleucel (Tecartus) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). (lymphoma.org)
  • November 14, 2019 - The U.S. Food and Drug Administration (FDA) announced it has approved the use of zanubrutinib (BRUKINSA, BeiGene, Ltd.) for adult patients with mantle cell lymphoma (MCL) who have received at least on prior therapy. (lymphoma.org)
  • October 31, 2017 - The U.S. Food and Drug Administration (FDA) approved acalabrutinib (Calquence) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy. (lymphoma.org)
  • October 10, 2014 - The U.S. Food and Drug Administration (FDA) approved bortezomib (Velcade) for previously untreated patients with mantle cell lymphoma. (lymphoma.org)
  • November 13, 2013 - The U.S. Food and Drug Administration (FDA) granted accelerated approval to Ibrutinib (Imbruvica) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. (lymphoma.org)
  • June 5, 2013 - The U.S. Food and Drug Administration (FDA) approved lenalidomide (Revlimid) for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies. (lymphoma.org)
  • Lenalidomide currently represents the first and only oral therapy for mantle cell lymphoma, which is a rare, B-cell non-Hodgkin lymphoma. (lymphoma.org)
  • Mantle cell lymphoma comprises about five percent of all non-Hodgkin lymphomas and is usually diagnosed as a late-stage disease that has typically spread to the gastrointestinal tract and bone marrow. (lymphoma.org)
  • January 23, 2012 - The U.S. Food and Drug Administration (FDA) approved a supplemental new drug application for bortezomib (Velcade), which updates the existing label to include the subcutaneous method of administration for the treatment of mantle cell lymphoma (MCL) patients who have received at least one prior therapy. (lymphoma.org)
  • Mantle cell lymphoma (MCL) is just one of 50-60 known B-cell subtypes of. (lymphomainfo.net)
  • HOUSTON - In a major international study led by researchers at The University of Texas MD Anderson Cancer Center, the targeted therapy ibrutinib continues to show remarkable promise for the treatment of relapsed or refractory mantle cell lymphoma (MCL). (eurekalert.org)
  • This oral inhibitor of the Bruton's tyrosine kinase in the B-cell receptor pathway is the most important breakthrough to date in the treatment of mantle cell lymphoma," said Michael Wang, M.D., associate professor in MD Anderson's Departments of Lymphoma and Myeloma and Stem Cell Transplantation and Cellular Therapy. (eurekalert.org)
  • Mantle cell lymphoma is a particularly aggressive cancer," said Richard Pazdur, M.D., director of the FDA's Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research. (fda.gov)
  • By the time mantle cell lymphoma is diagnosed, it usually has spread to the lymph nodes, bone marrow and other organs. (fda.gov)
  • Today's approval of Calquence was based on data from a single-arm trial that included 124 patients with mantle cell lymphoma who had received at least one prior treatment. (fda.gov)
  • The purpose of this study is to assess the safety, tolerability and activity of the combination of bendamustine and rituximab in patients with relapsed/refractory mantle cell lymphoma who are not eligible for high dose chemotherapy and autologous/allogeneic stem cell transplantation. (pfizer.com)
  • All registrations for the Mantle Cell Lymphoma Workshop will be reviewed and approved by the MCL Consortium Executive Committee. (lymphoma.org)
  • LRF's Mantle Cell Lymphoma Scientific Workshop, held regularly since 2003, is the Foundation's longest running scientific program, encouraging collaboration and the sharing of research developments between the world's leading MCL researchers, including LRF MCL Consortium members, MCL grantees, and scientists from the United States, Canada, and Europe. (lymphoma.org)
  • The 12th Mantle Cell Lymphoma Scientific Workshop will provide a unique forum to share scientific and clinical findings, exchange ideas, and plan new collaborations. (lymphoma.org)
  • With mantle cell lymphoma, which is a type of non-Hodgkin lymphoma, 69 percent of patients can expect to be alive five years after their diagnoses, and 59 percent are likely to be alive 10 years after their diagnoses, according to the American Cancer Society. (reference.com)
  • A micrograph of mantle cell lymphoma cells in the small intestine. (cancer.gov)
  • On October 31, the Food and Drug Administration (FDA) granted accelerated approval to acalabrutinib (Calquence®) for the treatment of adults with mantle cell lymphoma whose cancer has progressed after receiving at least one prior therapy. (cancer.gov)
  • Mantle cell lymphoma is a rare type of non-Hodgkin lymphoma that arises in B cells, a type of white blood cell. (cancer.gov)
  • Most people with mantle cell lymphoma are diagnosed with aggressive, widespread disease. (cancer.gov)
  • Unlike some other types of aggressive lymphomas, however, mantle cell lymphoma is rarely curable with current therapies. (cancer.gov)
  • In 2013, FDA approved the first BTK inhibitor, ibrutinib (Imbruvica®), for patients with relapsed or refractory (treatment-resistant) mantle cell lymphoma. (cancer.gov)
  • In other words, acalabrutinib does not appear to inhibit other tyrosine kinases that don't seem to be necessary for its action against mantle cell lymphoma. (cancer.gov)
  • FDA based its approval on data from a single-arm clinical trial of 124 patients with mantle cell lymphoma whose cancer had progressed or returned after at least one prior treatment regimen. (cancer.gov)
  • In recent years, new treatments for mantle cell lymphoma (MCL) have helped improve life expectancy and quality of life in many people with this disease. (healthline.com)
  • Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma, which has classically been considered an aggressive and incurable lymphoma. (lww.com)
  • SANTA MONICA, Calif.- Kite Pharma , a subsidiary of Gilead Sciences, Inc ., announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tecartus (brexucabtagene autoleucel), reportedly the first approved chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL). (drugdiscoverynews.com)
  • MCL is a rare form of non-Hodgkin lymphoma that arises from cells originating in the "mantle zone" of the lymph node. (drugdiscoverynews.com)
  • This approval marks the first CAR T cell therapy approved for mantle cell lymphoma patients and represents a new frontier in the treatment of this disease. (drugdiscoverynews.com)
  • In the past decade, researchers have made significant progress in our understanding of this disease and we have seen an increase in clinical trials for patients, which we hope will continue to improve treatment strategies and the options available to people with mantle cell lymphoma," noted Meghan Gutierrez, chief executive officer at the Lymphoma Research Foundation. (drugdiscoverynews.com)
  • Today's news builds upon this progress and provides hope to mantle cell patients and their loved ones. (drugdiscoverynews.com)
  • Our study demonstrated significant and durable clinical benefit for patients with relapsed or refractory mantle cell lymphoma for which there are no curative treatment options. (news-medical.net)
  • ZUMA-2 is the first multi-center, Phase II study of CAR T-cell therapy for relapsed/refractory mantle cell lymphoma, and these interim efficacy and safety results are encouraging," said Wang. (news-medical.net)
  • Although this study continues, our reported results, including a manageable safety profile, point to this therapy as an effective and viable option for patients with relapsed or refractory mantle cell lymphoma. (news-medical.net)
  • In a mouse model of blastoid variant mantle cell lymphoma, treatment of tumor-bearing mice with a potent NKT cell agonist, α-galactosylceramide (α-GalCer), resulted in a significant decrease in disease pathology. (mdpi.com)
  • These data demonstrate an important role for NKT cells in the immune response to an aggressive hematologic malignancy like mantle cell lymphoma. (mdpi.com)
  • CHICAGO-Temsirolimus (Torisel) prolongs progression-free survival in patients with relapsed and/or refractory mantle cell lymphoma when compared with commonly used conventional therapies, finds an international phase III trial. (cancernetwork.com)
  • At the molecular level, mantle cell lymphoma is characterized by the translocation t(11;14) that results in the over-expression of cyclin D1, and the translation of cyclin D1 mRNA is regulated by the mTOR kinase," Georg Hess, MD, PhD, said at ASCO 2008 (abstract 8513). (cancernetwork.com)
  • Patients in the trial had relapsed and/or refractory mantle cell lymphoma and had received two to seven therapies for the disease, which may have included stem cell transplantation and must have included rituximab (Rituxan), an anthracycline, and an alkylating agent, said Dr. Hess, a hematologist-oncologist at the Johannes-Gutenberg University, Mainz, Germany. (cancernetwork.com)
  • This first randomized phase III trial in mantle cell lymphoma established the concept of using this drug in this entity," Dr. Hess commented. (cancernetwork.com)
  • Chromosomal translocations involving the immunoglobulin heavy locus is a classic cytogenetic abnormality for many B-cell lymphomas, including follicular lymphoma, mantle cell lymphoma and Burkitt's lymphoma. (wikipedia.org)
  • citation needed] In Burkitt's lymphoma and mantle cell lymphoma, the other protein in the fusion is c-myc (on chromosome 8) and cyclin D1 (on chromosome 11), respectively, which gives the fusion protein pro-proliferative ability. (wikipedia.org)
  • Four forms of anaplastic large cell lymphoma are recognized: primary systemic anaplastic lymphoma kinase (ALK)-positive ALCL, primary systemic ALK-negative ALCL, primary cutaneous ALCL, and breast implant-associated ALCL. (wikipedia.org)
  • In particular, two different entities are recognized as systemic forms, the ALK + and ALK − ALCL [ 1 , 2 , 6 ], on genetic and clinical features, the first one being characterized by the deregulated expression of chimeric proteins expressing the intracytoplasmic domain of the anaplastic lymphoma kinase ( ALK ) gene. (hindawi.com)
  • Recently, the discovery was made that ALCL is actually a combination of two different diseases and even though they look the same under the microscope, what separates the two groups is the expression of another protein called anaplastic lymphoma kinase (ALK). (lymphoma.org)
  • At least three entities of ALCL exist, with similar cellular morphology but varying clinical courses and pathology: systemic ALCL, anaplastic lymphoma kinase (ALK)-positive, systemic ALCL ALK− and primary cutaneous ALCL. (intechopen.com)
  • This was further refined in 1994 on cloning of the t(2;5)(p23;q35) translocation breakpoint product, identified as a fusion protein of Nucleophosmin 1 (NPM) and anaplastic lymphoma kinase (ALK), the latter a previously uncharacterized protein named after the disease from which it was cloned [ 6 ]. (intechopen.com)
  • This is where the lymphoma cells have a protein called anaplastic lymphoma kinase (ALK). (macmillan.org.uk)
  • This chromosomal translocation induces the formation of the chimeric protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), which possesses significant oncogenic potential resulting from the constitutive activation of the tyrosine kinase ALK. (bloodjournal.org)
  • 6 ⇓ - 8 In 1994, 2 independent groups cloned the genes involved in this translocation and illustrated the fusion of the nucleophosmin ( NPM ) gene on chromosome 5q35 to the previously unidentified gene anaplastic lymphoma kinase ( ALK ) gene on 2p23. (bloodjournal.org)
  • Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. (medscape.com)
  • Follicular lymphoma international prognostic index. (medscape.com)
  • What Are the Symptoms of Grade 1 Follicular Lymphoma? (reference.com)
  • CAR T cell therapy is commonly used to treat large B-cell lymphoma and follicular lymphoma, which are types of non-Hodgkin lymphomas, and ongoing research focuses on minimizing toxicities and improving effectiveness, leading to better therapeutic outcomes for patients. (mdanderson.org)
  • Data from the Phase I ALPHA clinical trial found that conditioning with ALLO-647, an anti-CD52 monoclonal antibody, followed by treatment with ALLO-501, an allogeneic anti-CD19 CAR T cell product, is safe and potentially effective against relapsed or refractory large B-cell lymphoma and follicular lymphoma. (mdanderson.org)
  • In follicular lymphoma, the fused protein is Bcl-2 (on chromosome 18), which gives the fusion protein anti-apoptotic abilities. (wikipedia.org)
  • 2011). Primary mediastinal B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: results of the Mabthera International Trial Group Study. (springer.com)
  • Although doctors treat most lymphomas with chemotherapy without surgery, in the rare case of BIA-ALCL lymphoma, surgical removal of the implants and surrounding tissues is the most important for treatment and cure. (medicinenet.com)
  • Some people with HSTL may be offered a stem cell transplant after chemotherapy. (cancer.ca)
  • If you achieve remission after chemotherapy, your doctor might recommend a stem cell transplant, maintenance therapy, or both to help keep you in remission for longer. (healthline.com)
  • If you're young and fit, your doctor might recommend a stem cell transplant (SCT) after chemotherapy. (healthline.com)
  • If you undergo autologous SCT, your healthcare team will remove and freeze some of your stem cells before chemotherapy. (healthline.com)
  • After you finish chemotherapy, they'll thaw and transplant the stem cells back into your body. (healthline.com)
  • Stem cell transplants (SCTs) are sometimes used for hard-to-treat Hodgkin lymphoma , such as disease that doesn't go away completely after chemotherapy (chemo) and/or radiation or lymphoma that comes back after treatment. (cancer.org)
  • Allogeneic stem cell transplantation involves transferring the stem cells from a healthy person (the donor) to your body after high-intensity chemotherapy or radiation. (lls.org)
  • The high-conditioning regimens are meant to severely or completely impair your ability to make stem cells and you will likely experience side effects during the days you receive high-dose conditioning radiation or chemotherapy. (lls.org)
  • Chemotherapy - Medications are delivered intravenously or orally to destroy cancer cells. (moffitt.org)
  • January 27, 2015 - The U.S. Food and Drug Administration (FDA) approved a same-day delivery device for pegfilgrastim (Neulasta) for non-Hodgkin lymphoma patients who do not need to return to the clinic the day after chemotherapy. (lymphoma.org)
  • Blastic NK cell lymphoma is resistant to chemotherapy and radiotherapy. (lymphomainfo.net)
  • Most received chemotherapy (57 percent) and radiation therapy (48 percent), and 11 percent received stem cell transplants. (rand.org)
  • Steroids are drugs that are often given with chemotherapy to treat lymphomas. (macmillan.org.uk)
  • If the DLBCL doesn't respond to the initial treatment or comes back, doctors may suggest high-dose chemotherapy followed by a stem cell transplant or CAR T-cell treatment , a new immunotherapy. (healthcentral.com)
  • Chemotherapy is an important treatment for ALCL and can often get the lymphoma into remission. (macmillan.org.uk)
  • Some people have radiotherapy after chemotherapy to treat an area of lymphoma. (macmillan.org.uk)
  • The study focuses on patients with aggressive non-Hodgkin lymphoma that does not respond to chemotherapy or recurs after autologous stem cell transplant. (eurekalert.org)
  • The Seattle-based biotech company said its experimental drug for non-Hodgkin's lymphoma, pixantrone, was able to completely wipe out tumors for one-fifth of patients in a clinical trial, compared with about 6 percent who did that well on standard chemotherapy. (xconomy.com)
  • The traditional first-line therapy for aggressive non-Hodgkin's lymphoma is a combination of four chemotherapy drugs. (newswise.com)
  • But many patients relapse and go on to get an autologous stem cell transplant after second-line chemotherapy. (newswise.com)
  • After initial chemotherapy, those who responded were randomly assigned to receive an autologous stem cell transplant (125 patients) or to a control group of 128 patients who received three additional cycles of the R-CHOP regimen. (newswise.com)
  • An autologous stem cell transplant enables a patient to tolerate very high doses of chemotherapy and/or radiation. (newswise.com)
  • After the chemotherapy and/or radiation, these stem cells are infused back into the patient. (newswise.com)
  • Previous studies have found that patients who undergo stem cell transplants have a slightly higher risk of developing secondary cancers caused by the chemotherapy and/or radiation. (newswise.com)
  • But even if the T cell lymphoma were totally unrelated to his HIV, he still needs PCP prophylxis merely on the basis of receiving combination chemotherapy, which is itself a risk for PCP. (thebody.com)
  • Combination chemotherapy, such as CHOP, followed by stem cell transplantation. (lymphomation.org)
  • A randomized phase 2 trial of brentuximab vedotin (SGN35, NSC# 749710), or crizotinib (NSC#749005, commercially labeled) in combination with chemotherapy for newly diagnosed patients with anaplastic large cell lymphoma (ALCL) IND#117117. (rush.edu)
  • DIAGNOSIS.T-Cell Non Hodgkin"s Lymphoma- with a background of coeliac disease- Stage 4B with bone marrow infiltration, treated with 8 cycles of CHOP Chemotherapy from August 2010 to January 2011 ,plus 4 cycles of Intrathecal Chemotherapy. (hubpages.com)
  • The disease is generally treated with a combination of chemotherapy and immunotherapy, often accompanied by a hematopoietic stem cell transplant to restore the body's ability to form normal, healthy blood cells. (newswise.com)
  • Often a stem cell transplant procedure is used as a treatment choice when lymphoma still remains after chemotherapy or returns after treatment. (uhhospitals.org)
  • This type of treatment means our team can give higher doses of chemotherapy to fight the diseased cells because new cells will be transplanted to replace them. (uhhospitals.org)
  • Chemotherapy is often suggested for Hodgkin lymphoma treatment . (uhhospitals.org)
  • However, if the cancer does not respond to chemotherapy or returns after an initial response to therapy, a stem cell transplant may be recommended. (uhhospitals.org)
  • In most cases, treatment will involve chemotherapy for non-Hodgkin lymphoma could be accompanied by radiation therapy and/or immunotherapy. (uhhospitals.org)
  • Curcumin may improve outcome in chemotherapy-refractory Natural killer/T-cell lymphoma (NKTL). (greenmedinfo.com)
  • Also required in the diagnosis is immunophenotypic evidence that cells are T lymphocytes , such as the expression of immunologic markers CD3 or CD4 , but CD30 expression must be present in all neoplastic cells. (wikipedia.org)
  • Mayo Clinic: "Non-Hodgkin's lymphoma: Diagnosis & treatment. (webmd.com)
  • The highly aggressive nature of primary central nervous system lymphoma necessitates timely diagnosis and intervention. (medscape.com)
  • [ 73 ] Other conditions to consider in the differential diagnosis of cutaneous t-cell lymphoma include nonlymphomatous erythroderma and erythema neurolyticum migrans. (medscape.com)
  • Usefulness of flow cytometry for differential diagnosis of precursor and peripheral T-cell and NK-cell lymphomas: analysis of 490 cases. (medscape.com)
  • Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma," Journal of Experimental Medicine , vol. 198, no. 6, pp. 851-862, 2003. (hindawi.com)
  • At Moffitt Cancer Center, we take a comprehensive and multispecialty approach to the diagnosis and treatment of cutaneous T-cell lymphoma. (moffitt.org)
  • Information about Cutaneous T Cell Lymphoma, its diagnosis and treatment. (oncolink.org)
  • Anaplastic large cell lymphoma belongs to the T-cell lymphoma group meaning that it arises from the T-cell type lymphocytes and is considered to be an aggressive lymphoma, so treatment is required upon diagnosis. (lymphoma.org)
  • These lymphomas usually presents at diagnosis in stage III or IV, and often has an aggressive clinical course requiring prompt treatment. (lymphomation.org)
  • Diagnosis requires analysis of tissue sample using a variety of tests to identify the cell type. (lymphomation.org)
  • Each lymphoma is unique and the prognosis can depend on many clinical factors, including the unique molecular and biological characteristics of the tumor, the patient's age, general health and immune status, areas of involvement, how widespread the disease is at diagnosis (stage), and if so-called b-symptoms are present. (lymphomation.org)
  • For many B-cell lymphomas, reproducible immunophenotypic patterns and cytogenetic features allow for an algorithmic approach to diagnosis. (lymphomation.org)
  • The distal duodenal and resection was sent for Histology which revealed enteropathy-associated T-Cell Non Hodgkin"s Lymphoma prior to the diagnosis. (hubpages.com)
  • The final histopathologic diagnosis was that of a CD30-positive lymphoproliferative disorder according to the WHO classification, the differential including anaplastic large cell lymphoma (ALCL) and LyP. (thefreedictionary.com)
  • With the experience and expertise of an entire team of University Hospitals Seidman Cancer Center lymphoma specialists, we are able to determine optimal treatment for your lymphoma diagnosis. (uhhospitals.org)
  • Most importantly, as a comprehensive cancer center, we have the experience with the most complex forms of lymphoma and the management of every step of care from diagnosis through treatment and on to recovery. (uhhospitals.org)
  • Angioimmunoblastic T-cell lymphoma (AITL) is a rare form of non-Hodgkin lymphoma, which is a group of related malignancies (cancers) that affect the lymphatic system (lymphomas). (rarediseases.org)
  • We report on a 60-year-old man, having angioimmunoblastic T-cell lymphoma (AITL) with aberrant expression of CD20. (nii.ac.jp)
  • Anaplastic large-cell lymphoma ( ALCL ) is a form of cancer. (wikipedia.org)
  • The term anaplastic large-cell lymphoma (ALCL) encompasses at least four different clinical entities with the same name, which on histological examination share the presence of large pleomorphic cells that express CD30 and T-cell markers. (wikipedia.org)
  • Two types of ALCL present as systemic disease and are considered as aggressive lymphomas , while two types present as localized disease and may progress locally. (wikipedia.org)
  • Two of the ALCL subtypes are systemic lymphomas, in that they usually present with enlarged lymph nodes in multiple regions of the body, or with tumors outside the lymph nodes (extranodal) such as bone, intestine, muscle, liver, or spleen. (wikipedia.org)
  • This is known as breast implant associated anaplastic large cell lymphoma, or BIA-ALCL. (wikipedia.org)
  • What is anaplastic large cell lymphoma (ALCL)? (medicinenet.com)
  • The cancer , known as anaplastic large cell lymphoma (or ALCL), is a rare type of non-Hodgkin's lymphoma ( cancer of the cells that make up the immune system). (medicinenet.com)
  • The cancer is called breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). (medicinenet.com)
  • ALCL is a cancer of the T lymphocytes of the immune system, whereas most lymphomas that arise in the breast in people without implants are of the B lymphocyte type. (medicinenet.com)
  • Breast Implants: Update - Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). (medicinenet.com)
  • The authors revise the concept of anaplastic large cell lymphoma (ALCL) in the light of the recently updated WHO classification of Tumors of Hematopoietic and Lymphoid Tissues both on biological and clinical grounds. (hindawi.com)
  • Anaplastic large cell lymphoma (ALCL) is a peripheral T-cell-derived malignancy, representing around 2%-3% of all lymphoid neoplasms, according to the World Health Organization (WHO) estimates [ 1 , 2 ]. (hindawi.com)
  • According to the WHO classification, ALCL is not sustained by a unique histotype but actually includes five morphologic variants (common, giant cell-rich, lympho-histiocytic, small-cell type, and Hodgkin-like) [ 1 , 2 , 13 , 14 ]. (hindawi.com)
  • Individuals with breast implants have a risk of developing breast implant-associated anaplastic large cell lymphoma, or BIA-ALCL. (fda.gov)
  • BIA-ALCL is not breast cancer-it is a type of non-Hodgkin's lymphoma (cancer of the immune system). (fda.gov)
  • In 2011, the FDA identified a possible association between breast implants and the development of anaplastic large cell lymphoma (ALCL). (fda.gov)
  • designated breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) as a T-cell lymphoma that can develop following breast implants. (fda.gov)
  • recognized breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) as a unique form of ALCL that can develop following breast implant, implantation. (fda.gov)
  • Primary cutaneous anaplastic large cell lymphoma (ALCL) is slow growing (indolent). (cancer.ca)
  • BACKGROUND: There is substantial evidence that a type of anaplastic large cell lymphoma (ALCL) is associated with breast implants. (rand.org)
  • Anaplastic large cell lymphoma (ALCL) is a rare aggressive T-cell lymphoma comprising only about 3 percent of all lymphomas in adults and between 10 percent and 30 percent of all lymphomas in children and can present in either the systemic or cutaneous form. (lymphoma.org)
  • Anaplastic large cell lymphoma (ALCL) is a rare type of aggressive T-cell lymphoma that is characterized by a unique appearance under the microscope. (lymphoma.org)
  • Generally, ALCL presents with symptoms typical for aggressive lymphomas, or what we call B symptoms or constitutional symptoms, that include weight loss, significant sweats at nighttime and unexplained fevers. (lymphoma.org)
  • Anaplastic large cell lymphoma (ALCL) describes a distinct group of T cell lymphomas characterised by cell surface expression of CD30. (intechopen.com)
  • Anaplastic large cell lymphoma (ALCL) was first described in 1985 as a CD30-positive (or ki-1+) histiocytic lymphoma, later re-classified as a distinct clinical entity, ALCL [ 1 ]. (intechopen.com)
  • As well as systemic forms of the disease, there exists a cutaneous type belonging to the class of primary cutaneous CD30-positive T cell lymphoproliferative disorders-primary cutaneous (pc) ALCL [ 7 ]. (intechopen.com)
  • Anaplastic large cell lymphoma (ALCL) is a rare type of fast-growing non-Hodgkin lymphoma (NHL) . (macmillan.org.uk)
  • ALCL is a high-grade lymphoma. (macmillan.org.uk)
  • Stem cell transplants are sometimes used if there are still signs of ALCL or it comes back after other treatments. (macmillan.org.uk)
  • Anaplastic large-cell lymphoma (ALCL) was initially recognized on the basis of morphologic features and the consistent expression of CD30. (bloodjournal.org)
  • Anaplastic large-cell lymphoma (ALCL) is a relatively uncommon tumor. (bloodjournal.org)
  • 2 Subsequent immunophenotyping and gene rearrangement studies showed that the vast majority of ALCL tumors are derived from lymphoid cells of T or null immunophenotype. (bloodjournal.org)
  • Systemic ALCL comprises 2% to 8% of non-Hodgkin lymphomas in adults and 10% to 15% of these lymphomas in children. (bloodjournal.org)
  • 5 The frequency of ALCL increases to 30% to 40% of non-Hodgkin lymphomas in children when only cases with large-cell morphology are included. (bloodjournal.org)
  • Six of the British women developed breast implant-associated anaplastic large cell lymphoma , (BIA-ALCL), a rare blood cancerthat has been linked to textured implants. (thefreedictionary.com)
  • Breast implantation surgery increases the probability of being diagnosed with anaplastic large cell lymphoma (ALCL). (thefreedictionary.com)
  • At first, the study was designed to investigate the incidence of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). (thefreedictionary.com)
  • The most significantly enriched variants, causing p.Lys469Ter in a splice variant of POLK and p.Pro588His in PRKCB , are intriguing candidates as Polk deficient mice display a spontaneous mutator phenotype, whereas PRKCB was recently shown to be somatically mutated in 33% of another peripheral T-cell lymphoma, adult T-cell lymphoma. (springer.com)
  • What is adult T-cell lymphoma (ATLL)? (leukaemia.org.au)
  • Adult T-cell lymphoma (ATLL) is rare in countries such as Australia and North America. (leukaemia.org.au)
  • How does adult T-cell lymphoma affect the body? (leukaemia.org.au)
  • Who does adult T-cell lymphoma commonly affect? (leukaemia.org.au)
  • Do we know what causes adult T-cell lymphoma? (leukaemia.org.au)
  • How is adult T-cell lymphoma treated? (leukaemia.org.au)
  • Activated B-Cell Diffuse Large B-Cell Lymphoma, or ABC-DLBCL, is believed to be caused by aberrant activation of a critical intracellular pathway. (wikipedia.org)
  • Primary mediastinal (thymic) large B-cell lymphoma (PMLBCL) is a diffuse large B-cell lymphoma (DLBCL) of putative thymic origin, arising in the anterior mediastinum and showing distinct clinical and pathologic features (Cazals-Hatem et al. (springer.com)
  • Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of cancer that affects the B lymphocytes, white blood cells that make antibodies to fight infection. (healthcentral.com)
  • DLBCL occurs in both men and women although it is slightly more prevalent in men, according to the Lymphoma Research Foundation . (healthcentral.com)
  • Breyanzi, a chimeric antigen receptor (CAR) T cell therapy, is the third gene therapy approved by the FDA for certain types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL). (prnewswire.com)
  • DLBCL is the most common type of non-Hodgkin lymphoma in adults. (prnewswire.com)
  • Approximately 77,000 new cases of non-Hodgkin lymphoma are diagnosed in the U.S. each year and DLBCL represents approximately one in three newly diagnosed cases. (prnewswire.com)
  • The new findings report positive results from a pre-specified interim analysis of 51 patients with diffuse large B-cell lymphoma (DLBCL), a common and aggressive form of non-Hodgkin lymphoma. (eurekalert.org)
  • Loss of CD37 on neoplastic cells in patients with diffuse large B cell lymphoma (DLBCL) directly correlated with activation of the IL-6 signaling pathway and with worse progression-free and overall survival. (jci.org)
  • NEW YORK (GenomeWeb) - A team from the US and Germany has uncovered new diffuse large B cell lymphoma (DLBCL) subtypes through a multi-omic analysis of hundreds of primary DLBCL tumors, including subtypes with apparent ties to DLBCL development and outcomes. (genomeweb.com)
  • A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomas. (lymphomation.org)
  • What is diffuse large B-cell lymphoma (DLBCL)? (leukaemia.org.au)
  • Diffuse large B-cell lymphoma (DLBCL) is an aggressive type of non-Hodgkin lymphoma that develops from the B-cells in the lymphatic system. (leukaemia.org.au)
  • DLBCL is the most common subtype of non-Hodgkin lymphoma accounting for 30%-40% of all cases. (leukaemia.org.au)
  • This type of DLBCL has all three types of cells present- T-cells, histiocytes and large B-cells, when viewing a biopsy specimen under the microscope.Symptoms include swollen lymph nodes, fever and swelling of the liver or spleen. (leukaemia.org.au)
  • DLBCL can also be found in many other areas including the salivary glands, nasal sinuses, liver, lungs, testes, skin, brain or eye with symptoms being directly related to the amount of pressure the lymphoma is putting on the particular body part that is affected. (leukaemia.org.au)
  • DLBCL may develop independently or in some instances may develop in people who have been diagnosed with a low-grade lymphoma in the past (i.e. low-grade lymphoma can transform to DLBCL). (leukaemia.org.au)
  • The paracaspase MALT1 plays an essential role in activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) downstream of B cell and TLR pathway genes mutated in these tumors. (jci.org)
  • We confirmed that MALT1 targeting with compound 3 is effective at suppressing ABC DLBCL cells in vitro and in vivo. (jci.org)
  • Compound 3 revealed insights into the biology of MALT1 in ABC DLBCL, such as the role of MALT1 in driving JAK/STAT signaling and suppressing the type I IFN response and MHC class II expression, suggesting that MALT1 inhibition could prime lymphomas for immune recognition by cytotoxic immune cells. (jci.org)
  • Dr. Melnick's group showed that the BCL6 inhibitor was specific for BCL6 and did not block other master regulators, and that the experimental drug could powerfully kill DLBCL cells derived from human patients with this disease. (scienceblog.com)
  • In some cases, white blood cells are removed during a bone marrow biopsy . (medlineplus.gov)
  • Higher doses can't be used, even if they might kill more cancer cells, because they would severely damage the bone marrow, where new blood cells are made. (cancer.org)
  • This is because after getting high-dose chemo, the patient receives a transplant of blood-forming stem cells to rebuild the bone marrow. (cancer.org)
  • The blood-forming stem cells used for a transplant can come either from the blood or from the bone marrow. (cancer.org)
  • If you're considering allogeneic stem cell transplantation, you'll need a bone marrow donor. (lls.org)
  • Although the white blood cell count is usually elevated in leukemias, the hallmark of this disease is the appearance of atypical/ abnormal white blood cells in blood and bone marrow smears. (medhelp.org)
  • Stem cell transplantation - Abnormal cells in the blood and bone marrow are replaced with healthy new stem cells. (moffitt.org)
  • Your doctor may also request a bone marrow biopsy or spinal tap to determine if lymphoma cells are present in the brain or spinal cord. (healthcentral.com)
  • Stage 4 means that and the lymphoma is widespread through organs and tissues, such as the liver, lung, or bone marrow. (healthcentral.com)
  • In addition to the lymph nodes, the lymphatic system includes the spleen, which filters worn-out red blood cells and produces lymphocytes, and bone marrow, which is the spongy tissue inside the cavities of bones that manufactures blood cells. (rarediseases.org)
  • Stiff is chair of the SWOG Bone Marrow and Stem Cell Transplantation Committee. (newswise.com)
  • So prior to treatment, stem cells are removed from the patient's blood or bone marrow. (newswise.com)
  • bone marrow and/or peripheral blood progenitor cell (PBPC) infusion on day 0). (nature.com)
  • Lymphoma is a blood cell cancer - a condition where abnormal lymphocytes (a type of white blood cell) expand in number forming tumors often in lymph nodes but also in other regions, such as the bone marrow. (lymphomation.org)
  • On the other hand, a negative FDG-PET/CT result could rule out the presence of bone marrow involvement in 90% of peripheral T-cell lymphoma cases ( Clin Lymphoma Myeloma Leuk , October 2018, Vol. 18:10, pp. 687-691). (auntminnie.com)
  • There is also some question as to whether bone marrow biopsies add any value when assessing peripheral T-cell lymphoma cases. (auntminnie.com)
  • Stem cell transplant, also known as bone marrow transplant, allows our team to bring healthy new cells to your bone marrow to enhance the production of new cells. (uhhospitals.org)
  • In some aggressive subtypes of CTCLs, such as primary cutaneous gamma/delta T-cell lymphoma and primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma, more aggressive treatment including bone marrow transplantation should be considered early. (frontiersin.org)
  • Chen YP, Jones D, Chen TY, Chang KC (2014) Epstein-Barr virus present in T cells or B cells shows differential effects on hemophagocytic symptoms associated with outcome in T-cell lymphomas. (springer.com)
  • What Are the Symptoms of Non-Hodgkin's Lymphoma? (reference.com)
  • The symptoms of non-Hodgkin's lymphoma include swollen lymph nodes, abdominal pain, fatigue, fever and weight loss, according to the Mayo Clinic. (reference.com)
  • What Are The Symptoms of Pulmonary Lymphoma? (lymphomainfo.net)
  • The symptoms of cutaneous T-cell lymphoma (CTCL) can vary depending on its stage and what form of cutaneous T-cell lymphoma is present. (moffitt.org)
  • While most skin changes are not due to cutaneous T-cell lymphoma, it's vital to rule out malignant causes and receive appropriate treatment before symptoms progress. (moffitt.org)
  • If you are experiencing possible symptoms of cutaneous T-cell lymphoma and would like to consult with a Moffitt oncologist, call us at 1-888-663-3488 or complete a new patient registration form online. (moffitt.org)
  • Lymphoma itching symptoms can range from. (lymphomainfo.net)
  • We have more information about signs and symptoms of lymphoma . (macmillan.org.uk)
  • Diffuse large B-cell lymphoma can have general NHL symptoms such as night sweats, fevers, weight loss, fatigue, loss of appetite, or shortness of breath. (healthcentral.com)
  • This painless but complex procedure treats your white blood cells and returns them to your body - which helps improve your symptoms. (rush.edu)
  • The labeling carries a boxed warning for cytokine release syndrome (CRS), which is a systemic response to the activation and proliferation of CAR T cells, causing high fever and flu-like symptoms and neurologic toxicities. (prnewswire.com)
  • We now have guidelines on how to recognize and grade these side effects and how to manage the symptoms, and we were able to implement those across multiple institutions with no prior experience with CAR T-cell therapy," said Dr. Neelapu. (eurekalert.org)
  • These symptoms are a result of the impact of the lymphoma on the nervous system. (leukaemia.org.au)
  • At UH Seidman Cancer Center, we integrate all aspects of care, including supportive care that is intended to prevent or treat infections, low blood cell counts and several symptoms caused by lymphoma. (uhhospitals.org)
  • Skin directed therapies (SDTs) serve important roles in the treatment of early stage cutaneous T-cell lymphoma (CTCL)/mycosis fungoides (MF), as well as managing symptoms and improving quality of life of all stages. (frontiersin.org)
  • Skin directed therapies (SDTs) in cutaneous T-cell lymphoma (CTCL)/mycosis fungoides (MF) serve important roles in treating disease, but also in treating symptoms. (frontiersin.org)
  • The inhibition of this pathway can be induced by a drug known as NEMO Binding Domain, or NBD, a peptide causing increased cell death of malignant lymphocytes. (wikipedia.org)
  • Primary central nervous system lymphoma is a rare, malignant non-Hodgkin lymphoma that can arise in the brain, spinal cord, eye, leptomeninges, or cranial nerves. (medscape.com)
  • Our nationally renowned Malignant Hematology Program and Cutaneous Oncology Program are led by medical oncologists, radiation oncologists, hematologists, pathologists and other experts who focus exclusively on lymphomas and other hematologic diseases. (moffitt.org)
  • In T cell lymphoma, T lymphocytes, which are an essential part of the body's immune response, become malignant. (lymphomainfo.net)
  • Ibrutinib targets the BTK molecule, causing cell death and decreasing cellular migration and adhesion in malignant B-cells. (eurekalert.org)
  • AITL is characterized by the transformation of a T-cell into a malignant cell. (rarediseases.org)
  • 1. Any of various malignant tumors that arise from the lymphocytic cells of the immune system. (thefreedictionary.com)
  • long-term antigen stimulation is thought, through cytokine networks, to induce an inflammatory response with T-cell proliferation, leading to a clonal malignant T-cell with continuous expansion. (frontiersin.org)
  • Of the large-cell T-cell lymphomas , it has the best prognosis. (wikipedia.org)
  • American Cancer Society: "Survival Rates and Factors That Affect Prognosis (Outlook) for Non-Hodgkin Lymphoma," "Tests for Non-Hodgkin Lymphoma," "Treating B-Cell Non-Hodgkin Lymphoma," "Types of B-Cell Lymphoma," "Types of T-Cell Lymphoma," "What is Non-Hodgkin Lymphoma? (webmd.com)
  • Primary cutaneous lymphomas require distinction from histologically similar primary nodal ones because their clinical behavior, prognosis, and therapy are often different. (medscape.com)
  • Where Can You Find Information on the Prognosis for Non-Hodgkins Lymphoma? (reference.com)
  • Information on the prognosis, or outlook, of non-Hodgkin's lymphoma is available on the website of the American Cancer Foundation. (reference.com)
  • Lymphoma in Dogs: What Is The Prognosis and Treatment? (lymphomainfo.net)
  • Patients with good prognosis potential include those under 60 years of age, those with stage 1 or 2 lymphoma, and ones whose lymphoma has not metastasized outside of the lymph nodes or has spread to only one area outside of the lymph nodes, says the American Cancer Society. (reference.com)
  • With bad prognosis factors, the patient is over age 60 and has stage 3 or 4 lymphoma, says the American Cancer Society. (reference.com)
  • Prognosis and treatment depends on the specific type of lymphoma as well as the stage and grade. (wikipedia.org)
  • When a person appears to have a B-cell lymphoma, the main components of a workup (for determining the appropriate therapy and the person's prognosis) are: Establishing the precise subtype: Initially, an incisional or excisional biopsy is preferred. (wikipedia.org)
  • A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA ("Groupe d'Etude des Lymphomes de l'Adulte") study. (springer.com)
  • BCL6 causes the majority of diffuse large B cell lymphomas, the most common form of non-Hodgkin lymphoma. (redorbit.com)
  • Currently, about 60 percent of diffuse large B cell lymphomas can be cured with chemo-immunotherapy, said Dr. Melnick. (redorbit.com)
  • Cancer.Net: "Lymphoma - Non-Hodgkin: Subtypes. (webmd.com)
  • A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy. (medscape.com)
  • Cutaneous T cell lymphoma (CTCL) is a non-Hodgkin lymphoma of skin-homing T lymphocytes. (nih.gov)
  • We performed exome and whole-genome DNA sequencing and RNA sequencing on purified CTCL and matched normal cells. (nih.gov)
  • The results implicate mutations in 17 genes in CTCL pathogenesis, including genes involved in T cell activation and apoptosis, NF-κB signaling, chromatin remodeling and DNA damage response. (nih.gov)
  • Cutaneous T-cell lymphoma (CTCL) is an uncommon type of non-Hodgkin lymphoma (NHL). (cancer.ca)
  • CTCL is a cancer that starts in mature T cells in the skin. (cancer.ca)
  • Other types of B-cell and T-cell lymphoma can affect the skin, but they are different from CTCL. (cancer.ca)
  • In this article, we report that cutaneous T cell lymphoma (CTCL) cells and tissues ubiquitously express the immunosuppressive cell surface protein CD80 (B7-1). (mendeley.com)
  • CD80 expression in CTCL cells is strictly dependent on the expression of both members of the STAT5 family, STAT5a and STAT5b, as well as their joint ability to transcriptionally activate the CD80 gene. (mendeley.com)
  • In IL-2-dependent CTCL cells, CD80 expression is induced by the cytokine in a Jak1/3- and STAT5a/b-dependent manner, whereas in the CTCL cells with constitutive STAT5 activation, CD80 expression is also STAT5a/b dependent but is independent of Jak activity. (mendeley.com)
  • Although depletion of CD80 expression does not affect the proliferation rate and viability of CTCL cells, induced expression of the cell-inhibitory receptor of CD80, CD152 (CTLA-4), impairs growth of the cells. (mendeley.com)
  • Coculture of CTCL cells with normal T lymphocytes consisting of both CD4(+) and CD8(+) populations or the CD4(+) subset alone, transfected with CD152 mRNA, inhibits proliferation of normal T cells in a CD152- and CD80-dependent manner. (mendeley.com)
  • These data identify a new mechanism of immune evasion in CTCL and suggest that the CD80-CD152 axis may become a therapeutic target in this type of lymphoma. (mendeley.com)
  • When you have a rare cancer like cutaneous T-cell lymphoma (CTCL), our experienced team has the expertise you need. (rush.edu)
  • Dermatology and cancer experts at Rush specialize in diagnosing and treating cutaneous T-cell lymphoma (CTCL) - a group of rare, non-Hodgkin lymphomas that start on your skin. (rush.edu)
  • A small group of patients (10) with cutaneous T-cell lymphoma lesions (CTCL), who had tried anywhere from two to 10 medications unsuccessfully, experienced lesion healing with a low incidence of side effects from 0.03% topical resiquimod gel in a phase I open-label clinical trial , according to Alain H. Rook, MD , of the Abramson Cancer Center at the University of Pennsylvania, in Philadelphia, and colleagues. (medpagetoday.com)
  • This intracellular signaling pathway involved in B-cell activation and proliferation stays constantly activated, driving lymphocytes to proliferate continuously. (wikipedia.org)
  • It is a type of non-Hodgkin lymphoma involving aberrant T cells or null lymphocytes . (wikipedia.org)
  • B-cell leukemia/lymphoma panel is a blood test that looks for certain proteins on the surface of white blood cells called B-lymphocytes. (medlineplus.gov)
  • A type of lymphoma (cancer of the lymphatic system) that starts in the B lymphocytes (B cells). (nih.gov)
  • One goal of allogeneic stem cell transplant is to cause the T lymphocytes in the donor's blood or marrow to take hold (engraft) and grow in the patient's marrow. (lls.org)
  • Sometimes the T lymphocytes attack the cancer cells. (lls.org)
  • Unfortunately, T lymphocytes are the same cells that cause graft versus host disease (GVHD) . (lls.org)
  • Because of this serious and sometimes life-threatening side effect, doctors in certain cases want to decrease the number of T lymphocytes to be infused with the stem cells. (lls.org)
  • The technique involves treating the stem cells collected for transplant with agents that reduce the number of T lymphocytes. (lls.org)
  • Stem cell selection is another technique being studied in clinical trials that can reduce the number of T lymphocytes that a patient receives. (lls.org)
  • This technique produces a large number of stem cells and fewer other cells, including T lymphocytes. (lls.org)
  • This type of cancer develops in the white blood cells called "T-lymphocytes. (moffitt.org)
  • Natural killer cells are beneficial specialized lymphocytes that attack viruses and tumor cells. (lymphomainfo.net)
  • Lymphoma is a cancer affecting the white blood cells (lymphocytes) of the body's immune system. (lymphomainfo.net)
  • It develops when B-cells (also called B-lymphocytes) become abnormal. (macmillan.org.uk)
  • Lymphomas are cancer of white blood cells (lymphocytes) and can be divided depending on the type of cells, B-lymphocytes (B-cells) or T-lymphocytes (T-cells), AITL is a T-cell lymphoma. (rarediseases.org)
  • Lymph accumulates in the tiny spaces between tissue cells and contains proteins, fats, and certain white blood cells known as lymphocytes. (rarediseases.org)
  • There are two main types of lymphocytes: B-lymphocytes (B-cells), which may produce specific antibodies to "neutralize" certain invading microorganisms, and T-lymphocytes (T-cells), which may directly destroy microorganisms or assist in the activities of other lymphocytes. (rarediseases.org)
  • Further genetic modification allowed the use of ALLO-647 to selectively prolong lymphodepletion, which is the process of reducing the number of normal lymphocytes before infusing patients with CAR T cells. (mdanderson.org)
  • Natural killer T (NKT) cells are a unique subset of CD1d-restricted T lymphocytes that express characteristics of both T cells and natural killer cells. (mdpi.com)
  • Seeking to ignite the next major breakthroughs to treat blood cancers, The Leukemia & Lymphoma Society (LLS), The Mark Foundation, and The Paul G. Allen Frontiers Group today announced more than $6.75 million awarded to nine of the most exceptional scientists in the field. (news-medical.net)
  • As is the case with most all cancers, early detection of lymphomas leads to better outcomes and a positive quality of life. (moffitt.org)
  • B cell lymphoma is not one disease but a few dozen heterogeneous diseases, or individual cancers, that affect the b. (lymphomainfo.net)
  • Non-Hodgkin lymphomas are cancers that begin in certain cells of the immune system and can be either fast-growing (aggressive) or slow-growing. (prnewswire.com)
  • P eripheral T-cell lymphomas describes a diverse group of blood cancers that originate from T-cells, which may be at various stages of development. (lymphomation.org)
  • Kite is committed to bringing the promise of CAR T therapy to patients with hematological cancers, and as such, we are proud to launch our second cell therapy. (drugdiscoverynews.com)
  • 2. Any of various cancers characterized by the development of such tumors, especially Hodgkin lymphoma and non-Hodgkin lymphoma. (thefreedictionary.com)
  • Lymphomas are "blood cancers" in the lymph nodes. (wikipedia.org)
  • A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group," Blood , vol. 84, no. 5, pp. 1361-1392, 1994. (hindawi.com)
  • It then became evident that the majority of these tumors are derived from lymphoid cells of T or null immunophenotype. (bloodjournal.org)
  • In an autologous stem cell transplant , a patient's own blood stem cells are collected several times in the weeks before treatment. (cancer.org)
  • The cells are frozen and stored while the person gets treatment (high-dose chemo and/or radiation) and then are given back into the patient's blood by an IV. (cancer.org)
  • The immune reaction, or GVHD, is treated by administering drugs to the patient after the transplant that reduce the ability of the donated immune cells to attack and injure the patient's tissues. (lls.org)
  • Immunotherapy - Genetically modified cells or man-made antibodies are introduced to the body to help the patient's immune system destroy cancer cells or slow their growth. (moffitt.org)
  • When using the international prognostic index, the factors are the patient's age, the stage of the lymphoma, whether it has metastasized beyond the lymphatic system, how well the patient is able to perform day to day activities, and the blood levels of lactate dehydrogenase, or LDH, states the American Cancer Society. (reference.com)
  • Each dose of Breyanzi is a customized treatment created using a patient's own T-cells, a type of white blood cell, to help fight the lymphoma. (prnewswire.com)
  • The patient's T-cells are collected and genetically modified to include a new gene that facilitates targeting and killing of the lymphoma cells. (prnewswire.com)
  • The infusions of T-APCs are intended to make the patient's reprogrammed cancer-fighting T cells last longer. (seattlechildrens.org)
  • The experimental therapy, KTE-C19, is designed to equip a patient's own immune cells with weapons to find and destroy cancer cells. (eurekalert.org)
  • In addition to killing cancer cells, this high-dose treatment also destroys the patient's immune system cells. (newswise.com)
  • Autologous CAR T cell therapy, in which CAR T cells are engineered from a patient's own T cells, is effective against advanced non-Hodgkin lymphomas, but often, creating the therapy can be logistically challenging. (mdanderson.org)
  • The researchers also collected data on each patient's peripheral T-cell lymphoma subtype, disease status, lactate dehydrogenase and albumin levels, and blood counts. (auntminnie.com)
  • They are typically divided into low and high grade, typically corresponding to indolent (slow-growing) lymphomas and aggressive lymphomas, respectively. (wikipedia.org)
  • Aggressive lymphomas usually require intensive treatments, with some having a good prospect for a permanent cure. (wikipedia.org)
  • One classification system for lymphomas divides the diseases according to the size of the white blood cells that has turned cancerous. (wikipedia.org)
  • The classification acknowledges the recognition of large cells with pleomorphic nuclei and abundant cytoplasm. (wikipedia.org)
  • Several classification systems exist for NHL, including the Revised European American Lymphoma Classification, which is the foundation for the WHO lymphoma classification. (medicinenet.com)
  • Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. (medscape.com)
  • Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. (medscape.com)
  • WHO-EORTC classification for cutaneous lymphomas. (medscape.com)
  • Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). (medscape.com)
  • So biologically, these are two different disorders even though both of them are grouped together into the anaplastic large cell lymphoma classification. (lymphoma.org)
  • Micrograph of a primary mediastinal large B-cell lymphoma , a type of large-cell lymphoma. (wikipedia.org)
  • Macmillan Cancer Support: "Primary mediastinal large B-cell lymphoma. (webmd.com)
  • 1996). Primary mediastinal large B-cell lymphoma. (springer.com)
  • 2006). Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. (springer.com)
  • The molecular pathogenesis of primary mediastinal large B-cell lymphoma. (springer.com)
  • mediastinal (thymic) large B-cell lymphoma (C85.2-) mature T/NK-cell lymphomas (C84. (aapc.com)
  • MACOP-B and involved-field radiotherapy is an effective and safe therapy for primary mediastinal large B cell lymphoma," International Journal of Radiation Oncology Biology Physics , vol. 72, no. 4, pp. 1154-1160, 2008. (hindawi.com)
  • Primary mediastinal large B-cell lymphoma outcome may be significantly improved by the addition of rituximab to dose-adjusted (DA)-EPOCH and obviates the need for radiation: results from a prospective study for 44 patients," Blood , vol. 108, Abstract 209, 2006. (hindawi.com)
  • Primary mediastinal large B-cell lymphoma: accounts for 2-4% of all non-Hodgkin lymphomas. (leukaemia.org.au)
  • have coined a 'thoracic sandwich sign' in reference to anterior-mediastinal lymphadenopathy encompassing the brachiocephalic vein on chest CT in a patient with T-cell lymphoblastic lymphoma . (acronymfinder.com)
  • Primary central nervous system lymphoma is rare, accounting for 2-6% of all primary brain neoplasms and 1-2% of all non-Hodgkin lymphomas, and it usually presents as a solitary lesion. (medscape.com)
  • We present an unusual case of primary central nervous system lymphoma presenting as multiple lesions in the cerebellum in an immunocompetent host. (medscape.com)
  • Primary central nervous system lymphoma is rare, even more so in the cerebellum. (medscape.com)
  • However, the overall incidence of primary central nervous system lymphoma is rising in both immunocompromised and immunocompetent patients. (medscape.com)
  • In this report, we review the available literature for a better understanding of the pathophysiology and management of primary central nervous system lymphoma. (medscape.com)
  • To the best of our knowledge, this is the first reported case of a patient with primary central nervous system lymphoma presenting with multiple masses in the cerebellum. (medscape.com)
  • In addition, a difference often exists between primary cutaneous and nodal lymphomas in the presence of specific translocations. (medscape.com)
  • Cutaneous T-cell lymphomas (CTCLs) are a group of lymphomas where the skin is the primary site. (oncolink.org)
  • Breyanzi is not indicated for the treatment of patients with primary central nervous system lymphoma. (prnewswire.com)
  • The 2 primary immunodeficiency patients presented a T-cell lymphoblastic lymphoma and a diffuse large B-cell lymphoma. (acronymfinder.com)
  • Lymphoma Secondary to Congenital and Acquired Immunodeficiency Syndromes at a Turkish Pediatric Oncology Center. (medscape.com)
  • National Comprehensive Cancer Network, Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Hodgkin Lymphoma, Version I.2018 -- December 20, 2017. (cancer.org)
  • What is T-Cell Lymphoblastic Lymphoma? (lymphomainfo.net)
  • T-Cell Lymphoblastic Lymphoma (T-LBL) is a very rare subtype of non-Hodgkin's lymphoma . (lymphomainfo.net)
  • T-cell Lymphoblastic Lymphoma is very rare in adults and usually occurs in people under the age of 35. (patientslikeme.com)
  • Data from patients with T-cell lymphoblastic lymphoma, who reported starting treatments within the last 5 years. (patientslikeme.com)
  • Who has T-cell lymphoblastic lymphoma on PatientsLikeMe? (patientslikeme.com)
  • L-Asparaginase-associated hyperlipidemia with hyperviscosity syndrome in a patient with T-cell lymphoblastic lymphoma . (acronymfinder.com)
  • BCL-6 protein is expressed in precursor T-cell lymphoblastic lymphoma and in prenatal and postnatal thymus. (acronymfinder.com)
  • T-Cell Lymphoblastic Lymphoma With Coexisting Langerhans Cell Histiocytosis--Li & Borowitz) Answers to these questions will appear in the September 2001 issue. (acronymfinder.com)
  • Gene rearrangements in T-cell lymphoblastic lymphoma . (acronymfinder.com)
  • Researchers at The Wistar Institute and collaborators from the University of Notre Dame are developing anticancer compounds targeting a pathway of the endoplasmic reticulum (ER) stress response implicated in the development of multiple myeloma (MM), chronic lymphocytic leukemia (CLL) and lymphoma. (news-medical.net)
  • The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. (lls.org)
  • Longer follow-up is needed to determine durability of the responses," says lead author Sattva Neelapu, M.D. , professor of Lymphoma and Myeloma . (mdanderson.org)
  • Despite promising advances, there are still major gaps in treatment for patients with MCL who progress following initial therapy," said Michael Wang, M.D., professor of the Department of Lymphoma and Myeloma in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, and lead investigator of ZUMA-2. (drugdiscoverynews.com)
  • October 5, 2018 -- Don't expect much help from FDG-PET/CT results in predicting progression-free or overall survival among patients with peripheral T-cell lymphoma, according to a study published in the October issue of Clinical Lymphoma, Myeloma and Leukemia . (auntminnie.com)
  • CD4+CD56+ hematodermic neoplasm) is an extremely rare, aggressive form of lymphoma that affects the natural killer cells of the immune system. (lymphomainfo.net)
  • Intravascular large B-cell lymphoma: extremely rare form of lymphoma. (leukaemia.org.au)
  • MCL is a rare and aggressive B-cell subtype of non-Hodgkin lymphoma that, according to the Leukemia and Lymphoma Society, accounts for 6 percent of non-Hodgkin cases. (eurekalert.org)
  • Is there new research in clinical studies for this subtype of non-Hodgkin lymphoma? (lymphoma.org)
  • MCL is an aggressive B-cell type of non-Hodgkin's lymphoma , and the rare disease accounts for about 2%-10% of non-Hodgkin's lymphomas . (medicinenet.com)
  • Diffuse B-cell lymphoma is a type of non-Hodgkin's lymphoma. (webmd.com)
  • International Non-Hodgkin's Lymphoma Prognostic Factors Project. (medscape.com)
  • A predictive model for aggressive non-Hodgkin's lymphoma. (medscape.com)
  • Patient also has a hx of non-Hodgkin's lymphoma. (aapc.com)
  • October 19, 2012 - The U.S. Food and Drug Administration (FDA) approved a 90-minute infusion for rituximab (Rituxan) starting at Cycle 2 for patients with non-Hodgkin's lymphoma (NHL) who did not experience a grade 3 or 4 infusion-related adverse reaction during Cycle 1. (lymphoma.org)
  • SupportGroups.com builds awareness and support for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma . (lymphomainfo.net)
  • Also known as Hodgkin's disease , Hodgkin's lymphoma (HL) is a cancer of the white blood cells, or. (lymphomainfo.net)
  • In non-Hodgkin's lymphoma , you have your B-cell lymphomas and you have your T-cell lymphomas. (lymphomainfo.net)
  • It is the most common type of non-Hodgkin's lymphoma (NHL), comprising up to one-third of new NHL diagnoses in the United States. (healthcentral.com)
  • The purpose of this study is to evaluate inotuzumab ozogamicin in combination with rituximab prior to an autologous stem cell transplant (aSCT) in patients with relapsed/refractory diffuse large B-cell Non-Hodgkin's lymphoma. (pfizer.com)
  • The agency said that if Cell Therapeutics wants clearance to start marketing pixantrone (Pixuvri) in the U.S. for patients with non-Hodgkin's lymphoma, it will need to run another clinical trial to prove it is safe and effective. (xconomy.com)
  • I was disappointed that an agency charged with providing treatment hope for patients with life threatening diseases like relapsed/refractory non-Hodgkin's lymphoma would ignore clinically meaningful improvements in overall response rate and progression-free survival, let alone complete responses, something we all wish for our patients, but with existing treatments rarely achieve. (xconomy.com)
  • The American Cancer Society estimates that 66,000 people will be diagnosed with non-Hodgkin's lymphoma in 2008. (xconomy.com)
  • Newswise - MAYWOOD, Ill. - Performing early stem cell transplants in patients with aggressive non-Hodgkin's lymphoma does not improve overall survival in high-risk patients, according to a study published in the New England Journal of Medicine. (newswise.com)
  • One hundred and ten adult patients with non-Hodgkin's lymphoma (NHL) received an autologous hematopoietic cell transplant (ABMT) from 1988 to 1993. (nature.com)
  • Low incidence - approximately 10-15% of non-Hodgkin's lymphoma. (lymphomation.org)
  • Also, Wright has experience of cGMP manufacture of 25 ADC projects, including the manufacture of ADCETRIS (brentuximab vedotin), a CD30-targeting ADC for the treatment of relapsed or refractory Hodgkin's lymphoma and systemic anaplastic large cell lymphoma , which was one of the first ADCs approved. (thefreedictionary.com)
  • NEW YORK (April 13, 2010) - Researchers from the Sackler Center at Weill Cornell Medical College have designed a new class of drugs that targets BCL6, a master regulatory protein responsible for causing the most common type of non-Hodgkin's lymphoma. (scienceblog.com)
  • Since emerging data implicates BCL6 in other tumor types in addition to non-Hodgkin's lymphoma, it is possible that BCL6-targeted therapy could benefit many other cancer patients. (scienceblog.com)
  • They represent the commonest type of T-cell lymphomas in adults and the second most common form of extranodal non-Hodgkin's lymphoma. (frontiersin.org)
  • citation needed] Classic Hodgkin's lymphoma and nodular lymphocyte predominant Hodgkin's lymphoma are now considered forms of B-cell lymphoma. (wikipedia.org)
  • Lymphoma Research Foundation: "Peripheral T-Cell Lymphoma," "Understanding Non-Hodgkin Lymphoma. (webmd.com)
  • SEER Cancer Statistics Factsheets: Non-Hodgkin Lymphoma. (medscape.com)
  • Hepatitis B and C viruses and risk of non-Hodgkin lymphoma: a case-control study in Italy. (medscape.com)
  • Hodgkin lymphoma. (medlineplus.gov)
  • This is the most common type of transplant for Hodgkin lymphoma. (cancer.org)
  • Usually, in treating Hodgkin lymphoma, an allogeneic transplant is used only if an autologous transplant has already been tried without success. (cancer.org)
  • Chapter 105: Hodgkin lymphoma. (cancer.org)
  • Hodgkin lymphoma: A review and update on recent progress. (cancer.org)
  • Cutaneous T-cell lymphoma is a type of non-Hodgkin lymphoma that is also known as "cutaneous lymphoma" or "lymphoma of the skin. (moffitt.org)
  • Cutaneous T-cell lymphoma is a form of non-Hodgkin lymphoma that affects the skin. (moffitt.org)
  • Nodal marginal zone lymphoma (NMZL) is a slow growing, type of non-Hodgkin lymphoma (NHL) . (macmillan.org.uk)
  • We have more information about causes and risk factors for non-Hodgkin lymphoma . (macmillan.org.uk)
  • You can read more about further tests you may have in our information about non-Hodgkin lymphoma . (macmillan.org.uk)
  • We have more information about staging and grading of non-Hodgkin lymphoma . (macmillan.org.uk)
  • Three researchers who are recipients of a collaborative grant from the Samuel Waxman Cancer Research Foundation have developed a new type of drug designed to kill non-Hodgkin lymphoma tumor cells. (redorbit.com)
  • T-cell lymphoma describes several different types of Non-Hodgkin lymphoma which affect T cells . (bionity.com)
  • Adult T-cell leukaemia/lymphoma (ATLL) is a potentially aggressive type of mature T-cell non-Hodgkin lymphoma. (leukaemia.org.au)
  • San Diego, December 6, 2016) - A late-breaking abstract being presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego demonstrates that chimeric antigen receptor (CAR) T-cell therapy is a promising option for treating refractory non-Hodgkin lymphoma and practical to implement in a variety of real-world clinical settings. (eurekalert.org)
  • Patients with aggressive non-Hodgkin lymphoma have a major unmet need in terms of available therapies that can induce long-term remission, and there really has been no new treatment for these patients for over 20 years," said lead study author Sattva S. Neelapu, MD, of The University of Texas MD Anderson Cancer Center in Houston. (eurekalert.org)
  • Worldwide, B cell non-Hodgkin lymphoma is the most common hematological malignancy and represents a substantial clinical problem. (jci.org)
  • 1 The Ki-1 monoclonal antibody was originally described by the same group and was used to identify a novel antigen in the Hodgkin lymphoma cell line L428. (bloodjournal.org)
  • 2,3 Responses in B-cell non-Hodgkin lymphoma (B-NHL) were also favorable, though not as promising, with a response rate of 44 percent across a variety of different diseases. (hematology.org)
  • This report provides comprehensive information on the therapeutic development for B-Cell Non-Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. (mynewsdesk.com)
  • It also reviews key players involved in the therapeutic development for B-Cell Non-Hodgkin Lymphoma and special features on late-stage and discontinued projects. (mynewsdesk.com)
  • MCL is an aggressive form of non-Hodgkin lymphoma in which white blood cells known as B cells become cancerous and form tumors in the lymph nodes and other parts of the body. (newswise.com)
  • The type of cancer cell and its rate of growth will determine non-Hodgkin lymphoma treatment options. (uhhospitals.org)
  • Our multidisciplinary team approach, rapidly growing stem cell transplant program, wide range of clinical trials, personalized care and comforting environment ensure that patients with Hodgkin and non-Hodgkin lymphoma receive the highest quality of care. (uhhospitals.org)
  • For more information on Hodgkin and Non-Hodgkin lymphoma or to schedule an appointment with our team of lymphoma specialists, contact us today. (uhhospitals.org)
  • In MeSH, the phrase "mixed-cell lymphoma" is currently classified under non-Hodgkin lymphoma. (wikipedia.org)
  • After the lymph nodes shrink again or the disease gets less bulky, we typically offer patients an autologous stem cell transplantation procedure and can salvage probably about 50 percent of relapsed patients. (lymphoma.org)
  • The University of Pennsylvania group reported the outcomes for 38 patients with MCL aged ≥ 60 years who received R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) or R-Hyper-CVAD with or without autologous stem cell transplantation (ASCT). (lww.com)
  • Tecartus is an autologous, anti-CD19 CAR T cell therapy. (drugdiscoverynews.com)
  • ASCT stands for autologous stem cell transplantation. (newswise.com)
  • Successful use of allogeneic stem cell transplantation for treatment-refractory mycosis fungoides]. (medscape.com)
  • If your body can endure severe side effects, you may receive immunochemotherapy followed by a stem cell transplant. (nccn.org)
  • Am I a good candidate for a stem cell transplant? (healthline.com)
  • Which type of stem cell transplant should I consider? (healthline.com)
  • If you go through allogeneic SCT, your healthcare team will give you stem cells from another person. (healthline.com)
  • Allogeneic stem cell transplantation (infusion of donor stem cells into a patient) is the best-documented curative treatment for select patients with CML at this time. (lls.org)
  • A stem cell transplant lets doctors give higher doses of chemo (sometimes along with radiation therapy). (cancer.org)
  • Today, most transplants are done with cells that are taken out of the blood and are called peripheral stem cell transplants . (cancer.org)
  • There are 2 main types of stem cell transplants. (cancer.org)
  • They use different sources of blood-forming stem cells. (cancer.org)
  • In an allogeneic stem cell transplant , the blood stem cells come from someone else. (cancer.org)
  • A stem cell transplant is a complex treatment that can cause life-threatening side effects. (cancer.org)
  • Allogeneic stem cell transplantation can be a high-risk procedure. (lls.org)
  • Allogeneic stem cell transplants for patients who are older or have overall poor health are relatively uncommon. (lls.org)
  • However, reduced intensity allogeneic stem cell transplants may be an appropriate treatment for some older or sicker patients. (lls.org)
  • Because of specific features on the outer coat of stem cells, doctors can selectively remove stem cells from a cell mixture. (lls.org)
  • March 30, 2016 - The U.S. Food and Drug Administration approved defibrotide sodium (Defitelio) for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstructive syndrome, with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT). (lymphoma.org)
  • The Wnt pathway plays a role in embryonic development, stem cell growth and tumorigenesis. (ebi.ac.uk)
  • Stem cell transplants are intensive treatments, so it is not suitable for everyone. (macmillan.org.uk)
  • The study was designed to determine whether doing an early stem cell transplant - without first waiting to see whether a patient relapses -- would increase survival. (newswise.com)
  • This is probably because patients in the control group who relapsed were later offered stem cell transplants, Stiff and colleagues wrote. (newswise.com)
  • But while stem cell transplants did not improve overall survival among the entire group of high-risk and high-intermediate risk patients, the subset of high risk patients did appear to receive both a remission and survival benefit. (newswise.com)
  • The stem cells develop into new immune cells, replacing the immune cells destroyed by the treatment. (newswise.com)
  • Stem cell transplants may be offered if this type of lymphoma relapses. (leukaemia.org.au)
  • Stem cell transplantation may also be an option for some people. (leukaemia.org.au)
  • Patients whose disease progresses despite treatment with the standard therapy, Bruton's tyrosine kinase inhibitor (BTKi) agents, generally do not live past six months, and few patients qualify to proceed to an allogeneic stem cell transplant. (news-medical.net)
  • Guided by these preclinical results, we designed a phase I/II clinical trial ( NCT00490529 ) to evaluate the therapeutic potential of a similar vaccination approach as an additive to standard stem cell transplantation for patients with MCL," Levy says. (newswise.com)
  • The patients' immune cells were then collected and saved while the patients received a stem cell transplant. (newswise.com)
  • The vaccination regimen appeared to be safe, causing no side effects beyond those normally associated with stem cell transplants. (newswise.com)
  • About the Journal of Experimental Medicine The Journal of Experimental Medicine (JEM) features peer-reviewed research on immunology, cancer biology, stem cell biology, microbial pathogenesis, vascular biology, and neurobiology. (newswise.com)
  • Including access to lymphoma-specific clinical trials, we offer treatment solutions such as stem cell transplants that are not always available elsewhere. (uhhospitals.org)
  • A stem cell transplant may be the most viable option. (uhhospitals.org)
  • See lymphatic system and Lymphoma Simplified . (lymphomation.org)
  • Cutaneous T-cell lymphomas comprise a group of lymphatic malignancies that occur primarily in the skin. (frontiersin.org)
  • Rook AH, Yoo EK, Grossman DJ, Kao DM, Fox FE, Niu Z. Use of biological response modifiers in the treatment of cutaneous T-cell lymphoma. (medscape.com)
  • Novel treatment approaches for cutaneous T-cell lymphoma. (medscape.com)
  • Herrmann JJ, Roenigk HH Jr, Hönigsmann H. Ultraviolet radiation for treatment of cutaneous T-cell lymphoma. (medscape.com)
  • Cutaneous T cell lymphoma: update of treatment. (medscape.com)
  • Topical treatment of early cutaneous T-cell lymphoma. (medscape.com)
  • The US Food and Drug Administration (FDA) has approved Beleodaq (belinostat) for people with peripheral T-cell lymphoma who did not get better after treatment with other drugs, or whose cancer came back after treatment with other drugs. (cancer.org)
  • The approval was based on a study of 129 people with peripheral T-cell lymphoma that did not improve with treatment or came back after treatment. (cancer.org)
  • The B-Cell Lymphoma Moon Shot is revolutionizing the conventional medical research approach to rapidly translate findings into patient treatment options and develop personalized therapeutic strategies. (mdanderson.org)
  • This is the first CAR T cell therapy approved for the treatment of MCL. (lymphoma.org)
  • Moffitt Cancer Center provides a full spectrum of diagnostics and treatment to patients with cutaneous T-cell lymphoma and other skin malignancies. (moffitt.org)
  • Another factor that distinguishes Moffitt from other lymphoma treatment providers is our ambitious research initiatives and designation as a National Cancer Institute-designated Comprehensive Cancer Center. (moffitt.org)
  • For most people with NMZL, the aim of treatment is to get rid of as much of the lymphoma as possible. (macmillan.org.uk)
  • Novartis' Afinitor was granted FDA orphan designation as a treatment of diffuse large B-cell lymphoma, according to a post to the regulator's website. (yahoo.com)
  • Note that this phase I trial suggests that resiquimod, a TLR-7/8 agonist, may aid in the treatment of cutaneous T-cell lymphoma. (medpagetoday.com)
  • SILVER SPRING, Md. , Feb. 5, 2021 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Breyanzi (lisocabtagene maraleucel), a cell-based gene therapy to treat adult patients with certain types of large B-cell lymphoma who have not responded to, or who have relapsed after, at least two other types of systemic treatment. (prnewswire.com)
  • ene and cell therapies have evolved from promising concepts to practical cancer treatment regimens. (prnewswire.com)
  • T-cell immunotherapy is an experimental new cancer treatment that stimulates the immune system to fight disease. (seattlechildrens.org)
  • The study, which involved 22 institutions and tested a product called KTE-C19 (anti-CD19 CAR), is the first multicenter trial of this cellular immunotherapy-based treatment approach for lymphoma. (eurekalert.org)
  • He said the study, called ZUMA-1, bolsters evidence from previous trials that reported sustained remission after CAR T-cell therapy with KTE-C19, a treatment in which doctors extract T cells from a patient, genetically engineer the cells with CD19 receptors to seek out cancer cells, expand the population of the engineered cells, and then infuse them back into the patient. (eurekalert.org)
  • Researchers said the results are encouraging from an efficacy standpoint and also show that CAR T-cell manufacturing, treatment logistics, and the management of adverse events can be successfully implemented across multiple sites. (eurekalert.org)
  • During laboratory testing, scientists may test the treatment on cancer cells grown in petri dishes or test tubes. (healthline.com)
  • 4 Venetoclax has thus expanded the effective treatment options for patients with CLL and MCL who have exhausted other therapies including inhibition of the B-cell receptor pathway. (hematology.org)
  • C ) Cell-based reporter assay showing inhibition of cellular MALT1 activity in Raji MALT1-GloSensor cells following treatment with different inhibitors, as in Figure 1 . (jci.org)
  • Overall, our data demonstrate that the addition of a CpG-activated whole cell tumor vaccination followed by adoptive transfer of vaccine-primed immune cells to the treatment of MCL is feasible, safe, and can induce immune responses that are associated with a superior clinical outcome," Levy says. (newswise.com)
  • Therefore, Gurion and colleagues set out to evaluate the extent to which FDG avidity could predict treatment response in patients with peripheral T-cell lymphoma. (auntminnie.com)
  • The treatment of lymphoma depends on the type of lymphoma, stage of lymphoma, age and medical history of a patient. (uhhospitals.org)
  • As a generalisation, indolent lymphomas respond to treatment and are kept under control (in remission) with long-term survival of many years, but are not cured. (wikipedia.org)
  • Basically there are three large groups: the B cell, T cell, and natural killer cell tumors. (medicinenet.com)
  • In time, the cancerous cells turn into lymph node tumors. (reference.com)
  • It was first recognized by Stein et al 1 in 1985, who reported the consistent expression of the Ki-1 antigen (later designated CD30) in tumors with frequent cohesive proliferation of large pleomorphic cells. (bloodjournal.org)
  • Many hematologic malignancies express CD1d molecules and co-stimulatory proteins needed to induce anti-tumor immunity by NKT cells, yet most tumors are poorly immunogenic. (mdpi.com)
  • Over the following year, 89% of the patients remained free of minimal residual disease (MRD), meaning that their blood contained too few cancer cells to form any new tumors. (newswise.com)
  • It gets its name because the cancer cells spread out (diffuse) all over the lymph node. (webmd.com)
  • The sample may also be taken during a lymph node biopsy or other biopsy when lymphoma is suspected. (medlineplus.gov)
  • There are many types of peripheral T-cell lymphoma, a type of lymph node cancer. (cancer.org)
  • The most common test for this lymphoma is to remove part or all of an enlarged lymph node (a biopsy ). (macmillan.org.uk)
  • The blood sample is sent to a laboratory, where a specialist checks the cell type and characteristics. (medlineplus.gov)
  • Histopathology revealed diffuse large B-cell lymphoma, non-germinal center type. (medscape.com)
  • The giant cell-rich type is characterized by several multinucleated elements, often provided with Reed-Sternberg-like features and prominent intrasinusoidal diffusion [ 1 , 5 , 15 , 16 ]. (hindawi.com)
  • Cutaneous B-cell lymphoma is a rare type of skin cancer that may form as a nodule that appears the same color as your skin. (mayoclinic.org)
  • (e-f) Binding of CD86-Fc to 293T cells stably transduced with human wild-type (WT) CD28, (e) CD28 (p.Phe51Val), or (f) CD28 (p.Gln77Pro). (nih.gov)
  • A B cell is a type of lymphocyte that produces antibodies to fight infections. (lymphomainfo.net)
  • This type of lymphoma is more common in men than women and often diagnosed in people in their 60s and 70s, according to federal statistics. (aacr.org)
  • A lab technician examines the surface of the sample tissue cells to identify the proteins that give everyone his or her own unique tissue type, called human leukocyte antigens (HLAs). (lls.org)
  • This type of lymphoma affects mostly elderly patients, and only a few cases are documented each year. (lymphomainfo.net)
  • enteropathy associated T-Cell is a type of T-Cell Lymphoma that affects the small intestine arising from T-Cellc found between the cells that line the small intestine. (hubpages.com)
  • Subcutaneous panniculitis-like T-cell lymphoma is a type of skin cancer localized to the adipose tissue. (patientslikeme.com)
  • The Leukemia & Lymphoma Society (LLS) is the world's largest voluntary health agency dedicated to blood cancer. (lls.org)
  • The Leukemia & Lymphoma Society is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest extent allowed by tax laws. (lls.org)
  • The Leukemia & Lymphoma Society. (wikipedia.org)
  • Allogeneic CAR T cell therapy, in which CAR T cells are manufactured from a healthy donor, addresses these challenges. (mdanderson.org)
  • Although early, these findings will indicate that allogeneic CAR T cell therapy can be safe and induce significant responses in patients with relapsed or refractory B-cell non-Hodgkin lymphomas. (mdanderson.org)
  • Extracorporeal photopheresis (commonly known as ECP) is one of the most effective treatments for many people with advanced cutaneous T-cell lymphomas. (rush.edu)
  • Zolinza was evaluated in two clinical trials of 107 patients with cutaneous T-cell lymphoma who received Zolinza after their disease had recurred following other treatments. (medpagetoday.com)
  • Food and Drug Administration-authorized trials at Seattle Children's are testing T-cell therapy in children and young adults with relapsed or refractory acute leukemia or lymphoma who are not likely to survive with current treatments. (seattlechildrens.org)
  • Since 2005, LLS has funded research in Dr. Melnick's laboratory, much of which has been focused on developing better treatments for patients with B-cell lymphomas. (scienceblog.com)
  • Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell lymphoproliferative disorders involving the skin, the majority of which may be classified as Mycosis Fungoides (MF) or Sézary Syndrome (SS). (ingentaconnect.com)